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ABSTRACT 
 
DEVELOPING THE YEAST DISAGGREGASE HSP104 AS A TREATMENT FOR 
POLYGLUTAMINE DISEASE IN DROSOPHILA  
Mimi Cushman-Nick 
Dr. Nancy M. Bonini 
Dr. James Shorter 
There is currently no cure for neurodegenerative disease or the underlying burden of protein 
aggregation that is associated with symptom development.  A novel approach to combat this 
accumulation of misfolded protein species is surprisingly found in a protein disaggregase in yeast, 
the heat shock protein Hsp104.  To investigate whether Hsp104 can be introduced into an animal 
system and harnessed to attack disease-associated protein inclusions, we created a transgenic 
Drosophila model expressing Hsp104 and investigated whether this would mitigate toxicity and 
alter the load of protein accumulations.  We found that Hsp104 indeed suppressed toxicity of a 
disease-associated protein fragment containing an expanded polyglutamine tract.  However, we 
found that Hsp104 worsened toxicity of the full-length pathogenic polyglutamine protein, and this 
coincided with increased accumulation of amyloid inclusions.  This aberrant activity of Hsp104 
depended on intact domains in the non-polyglutamine stretches of the protein, and this negative 
interaction could be prevented by mutation to these neighboring domains.  These results indicate 
that knowing the precise protein state of a disease environment is critical in evaluating potential 
therapeutics.  Moreover, we sequentially activated Hsp104 after the onset of protein aggregation 
and start of tissue degeneration, to find that Hsp104, but not Hsp70, significantly suppressed 
progressive degeneration.  Thus, the unique ability of Hsp104 to tackle pre-existing amyloid 
conformers may offer a novel opportunity to reverse disease progression once underway. 
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CHAPTER 1 : INTRODUCTION 
 
HARNESSING THE MOLECULAR DISAGGREGASE HSP104 TO COMBAT THE 
AMYLOID ACCUMULATION THAT UNDERLIES NEURODEGENERATIVE DISEASE 
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Protein aggregation underlies neurodegenerative disease 
 
Proper protein folding is essential to life.  In order for a protein to perform its function, it 
must obtain its native state, but this is an extremely difficult task within the cell.  The 
cytosol is crowded (exceeding 200 mg/ml), with other molecules restricting protein 
movement as well as bombarding the nascent chain with potentially hazardous 
interactions (Ellis, 2001, 2007).  Moreover, because of aberrantly exposed hydrophobic 
sequences, misfolded protein is prone to accumulate into insoluble aggregates, thus 
compounding loss of function of the protein with potentially toxic gain of function due to 
accrual of these large, disruptive aggregates (Powers et al., 2009).  This problem is 
amplified in post-mitotic tissue, such as within the neurons of the central nervous 
system, where these species accumulate with time (Terman and Brunk, 2006).  
 
The collection of neurodegenerative diseases is comprised of distinct disorders, 
presenting with striking differences among the symptomatic impairments and affected 
systems (Taylor et al., 2002, Forman et al., 2004).  For example, Alzheimer’s disease 
(AD) causes cell loss in the cortex and hippocampus, with patients displaying dementia 
with loss of intellect and memory, while Parkinson’s disease (PD) presents with 
degeneration in the substantia nigra and is characterized by loss of motor control (Fahn, 
2003, Thies and Bleiler, 2011).  These and other neurodegenerative diseases are 
devastating to patients and their families, and also create a massive emotional and 
financial burden for society (Thies and Bleiler, 2011).  As the population rapidly ages, the 
prevalence of these diseases is increasing with no imminent cure (Fearnley and Lees, 
1991, Duncan, 2011, Lopez, 2011, Thies and Bleiler, 2011). 
4 
 
 
To combat this escalating problem, it would be ideal to target processes that are 
common to all neurodegenerative disease.  Interestingly, a remarkable feature of these 
disparate diseases is that many are characterized by underlying protein aggregation 
pathology (Forman et al., 2004, Chiti and Dobson, 2006).  AD patients develop 
extracellular plaques of amyloid-β peptide (Aβ) and intracellular tangles of tau, and PD 
has marked accumulation of α-synuclein (α-syn) in Lewy body inclusions (Forman et al., 
2004, Jellinger, 2012).  Not only do these pathological hallmarks define each disease, 
but the formation of these protein accumulations is associated with development of 
symptoms (Hardy and Selkoe, 2002, Ferrer et al., 2011, Chetelat et al., 2012, Masdeu et 
al., 2012). 
 
Interestingly, in some cases, symptomatically distinct disorders may have a common 
pathogenic mechanism.  For example, Huntington’s disease (HD), which has marked 
degeneration of the basal ganglia, and Spinocerebellar Ataxia Type 3/ Machado-Joseph 
disease (SCA3/MJD), which affects the hindbrain, share the mechanism by which 
degeneration is initiated (Zoghbi and Orr, 2000, Michalik and Van Broeckhoven, 2003, 
Orr and Zoghbi, 2007).  The pathogenic proteins associated with these diseases, 
huntingtin (htt) and Ataxin-3/ Machado Joseph disease protein (MJD), respectively, each 
contain a polyglutamine (PolyQ) tract within the protein that, when the repeat length 
exceeds a threshold, causes protein accumulation and disease (Norremolle et al., 1993, 
Kawaguchi et al., 1994).  In addition, this pathogenic PolyQ expansion has been 
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identified in other unrelated proteins that are collectively known as PolyQ diseases 
(Zoghbi and Orr, 2000).  
 
Despite markedly different primary sequences, Aβ, tau, α-syn, the PolyQ proteins, and 
other proteins implicated in neurodegenerative disease form protein accumulations by 
adopting a stereotypical fold called ‘amyloid’ (Kirschner et al., 1986, Forman et al., 
2004).  Amyloid is defined by the formation of β-sheet folds perpendicular to a fibril axis; 
Typically, these fibrils are 5-15 nm in width and up to several micrometers in length 
(Toyama and Weissman, 2011).  Because of the stable intermolecular contacts created 
by the extensive hydrogen bonds of the cross-β fold, the amyloid conformation is 
extremely stable and difficult to eradicate (Westermark et al., 2005, Chiti and Dobson, 
2006).  Indeed, amyloid fibrils are resistant to denaturation by detergents, boiling, and 
proteases (Westermark et al., 2005).  Once an amyloid fibril is formed, the conformation 
is self-templating; individual proteins adopt the existing fold upon joining the fibril (Nelson 
and Eisenberg, 2006, Jucker and Walker, 2011).  As such, certain fibrils with contacts 
that are susceptible to fragmentation may expose many templating ends, thus allowing 
the amyloid conformation to become transmissible, which is termed a ‘prion’ 
(proteinaceous infectious particle).  An example of this is the prion protein (PrP) in 
Creutzfeldt-Jakob disease (CJD), a variant of which is known as “mad cow” disease 
(Prusiner, 1982, Prusiner et al., 1983, Cushman et al., 2010). 
 
Also problematic are the soluble oligomers that form prior to fibrils, which also possess a 
generic conformation, distinct from fibers, which is shared by many amyloidogenic 
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proteins (Kayed et al., 2003). These oligomers may be even more cytotoxic than the 
fibrils themselves, and there are some lines of evidence to suggest that the 
sequestration of protein into fiber inclusions at the expense of oligomers may actually be 
protective (Dobson, 2003, Kayed et al., 2003, Douglas et al., 2008, Wolfe and Cyr, 
2011). These soluble oligomers may go on to promote polymerization of amyloid fibers 
(Shorter and Lindquist, 2004), or, like fibers, the soluble oligomeric assemblies can be 
persistent and SDS-stable (Walsh et al., 2002).  The existence of these amyloid 
precursors must be kept in mind when considering protein-aggregation disease and 
developing therapeutic interventions. 
 
Antagonizing amyloid fibrils and their soluble precursors are an attractive therapeutic 
target because these common protein conformations underlie so many 
neurodegenerative diseases.  However, because of the extreme stability of amyloid 
intermolecular contacts, the most promising current avenue of treatment is to prevent the 
contacts from forming prior to extensive protein aggregation and development of disease 
symptoms (Chiti and Dobson, 2006, Masdeu et al., 2012, Vanitallie, 2013).  While 
preventing amyloidogenesis is obviously desirable, it is likely impractical because 
symptoms often occur only after protein accumulation has advanced and become a 
heavy burden for the tissue (Hardy and Selkoe, 2002, Caughey and Lansbury, 2003).  
For example, accumulation of amyloid deposits precedes mild cognitive impairment, 
which is itself a precursor and predictor of AD (Masdeu et al., 2012).  Therefore, while 
preventative treatments may have some effect in deterring amyloid accumulation and 
7 
 
accompanying symptoms, a treatment is needed to reverse existing amyloidogenic 
conformers to truly combat the protein pathology associated with disease. 
 
Molecular chaperones: a natural defense against protein misfolding 
 
Because life requires proper protein folding, evolution has provided defenses against 
aberrant misfolding: molecular chaperones, which facilitate folding and prevent 
misfolding; protein disaggregases, which restore protein monomers from the aggregated 
state; and protein degradation machinery to eliminate proteins recalcitrant to rescue. 
 
Molecular chaperones comprise a variety of proteins that modulate protein homeostasis, 
and are essential in assisting nascent proteins to access their native fold within the 
crowded cellular environment (Hartl and Hayer-Hartl, 2002, Bukau et al., 2006).  In 
addition to facilitating proper protein folding, chaperones are critical in preventing 
misfolding, which may lead to protein aggregation (Hartl and Hayer-Hartl, 2002, 
Broadley and Hartl, 2009).  Because these chaperones are pivotal in counteracting the 
misfolded or unfolded protein conformations induced by stress, such as following heat 
shock, many are also known as heat shock proteins (HSPs) (Morimoto, 2008).  HSPs 
range in size from small HSPs (15-30 kDa) to the Hsp100 family (100+ kDa) and offer a 
variety of functional approaches to antagonize aberrant protein conformations: small 
HSPs block protein aggregation; Hsp60s (chaperonins) act as a folding chamber, thus 
competing with misfolding; Hsp70s facilitate access of proper tertiary structure and 
therefore suppress incorrect folding events; Hsp90s have modulatory and stabilizing 
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activity; and Hsp100s reverse protein misfolding and aggregation (Muchowski and 
Wacker, 2005, Broadley and Hartl, 2009, Garrido et al., 2012). 
 
Hsp70 has been of particular interest in countering protein aggregation.  A form of 
Hsp70 is found in most cellular compartments, and the chaperone acts to stabilize 
substrates and promote proper folding (Bukau and Horwich, 1998, Mayer and Bukau, 
2005).  The Hsp70 protein contains a C-terminal substrate-binding domain that interacts 
with the protein substrate and an N-terminal ATP binding site that hydrolyzes ATP to 
produce conformational shifts (Zhuravleva et al., 2012).  Hsp70 recognizes hydrophobic 
patches in nascent or transiently misfolded proteins and binds to the exposed sequence, 
which in turn induces ATP hydrolysis to clamp the chaperone closed around the 
substrate (Fig 1-1) (Hartl and Hayer-Hartl, 2002, Mayer and Bukau, 2005, Bukau et al., 
2006, Broadley and Hartl, 2009).  
This function is known as holdase 
activity, and repeated cycles of 
clamping may allow the substrate 
protein to access its native 
conformation upon release 
(Slepenkov and Witt, 2002, Mayer 
and Bukau, 2005).  The baseline 
ATPase rate of Hsp70 is quite slow, 
and requires regulation by co-factors 
such as nucleotide-exchange factors 
Figure 1-1  Hsp70 promotes proper folding 
As a nascent chain (green strand) is produced, 
the Hsp70 chaperone (red oval) binds to 
exposed regions to prevent aberrant misfolding 
and aggregation, thus allowing the protein to 
achieve its proper fold. 
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or coordinating chaperone Hsp40 to stimulate ATP hydrolysis (Ha and McKay, 1994, 
Russell et al., 1998, Laufen et al., 1999, Bukau et al., 2006).  The Hsp70 system is 
critical for routine protein homeostasis and perturbation of Hsp70 function can itself be 
associated with disease (Senderek et al., 2005, Kakkar et al., 2012). 
 
Hsp104, in contrast, is an HSP that, rather than preventing protein misfolding, actually 
reverses pre-existing protein aggregates.  The disaggregase is a member of the AAA+ 
(ATPases Associated with diverse cellular Activities) family and forms a functional unit 
by assembling into a ring-shaped homohexamer (Wendler et al., 2007).  Each monomer 
contains two nucleotide-binding domains (NBDs) that each couple to a substrate-binding 
loop with a conserved GYVG motif (KYKG in NBD1) responsible for engaging substrate 
(Lum et al., 2004, Lum et al., 2008).  ATP hydrolysis in each NBD confers large 
structural shifts to translocate substrates bound to the substrate-binding loops through 
the central pore of the ring (Wendler et al., 2007, Wendler et al., 2009).  This 
translocation mechanically pries substrate monomers from protein accumulations (Fig 1-
2).  The dissolution of stress-induced denatured protein aggregates confers protection 
and up to 10,000-fold increase in survival following heat shock (Sanchez and Lindquist, 
1990, Sanchez et al., 1992, Parsell et al., 1994, Glover and Lindquist, 1998).  These 
non-amyloid aggregates require the administration of coordinating chaperones Hsp70 
and Hsp40; the Hsp104 and its coordinating chaperone system is able to tackle 
substrates resistant to Hsp70/Hsp40 alone (Glover and Lindquist, 1998). 
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Moreover, Hsp104 can also disassemble highly stable amyloid fibrils.  The disaggregase 
employs different patterns of inter-subunit coordination for distinct substrates, with more 
subunits being recruited for the more obstinate amyloid substrates (DeSantis et al., 
2012).  This remarkable activity allows Hsp104 
to extract protein monomers from 
sequestration in amyloid fibrils in order to 
maintain the beneficial prion states observed 
in yeast (Fig 1-2) (Chernoff et al., 1995, 
Shorter and Lindquist, 2004).  In addition to 
phenotypic observations that Hsp104 
solubilizes amyloid fibrils in yeast, the effects 
have been reconstituted in a pure-protein 
system that demonstrates that Hsp104 is 
sufficient to reverse pre-formed amyloid fibrils 
(Shorter and Lindquist, 2004, 2006, Lo Bianco 
et al., 2008, DeSantis et al., 2012).  Further, 
Hsp104 also eliminates amyloidogenic 
oligomers, the soluble multimeric associations 
that serve as obligate intermediates preceding fibril formation (Shorter and Lindquist, 
2004, 2006, Lo Bianco et al., 2008, DeSantis et al., 2012).  Thus, Hsp104 has potent 
activity against the common structures required for amyloidogenesis, disassembling both 
fibril and oligomeric conformations that are shared by amyloidogenic proteins.   
 
Figure 1-2  Hsp104 resolubilizes 
aggregated proteins 
The Hsp104 hexamer (teal) is pictured 
with substrate-contacted loops (yellow 
Y) extending into the central channel.  
These channel loops bind to 
monomers within a disordered 
aggregate or an amyloid fibril and 
translocate it through the pore to 
resolubilize an individual protein. 
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Unlike Hsp70, Hsp104 has no known homologue or othologue in metazoan systems.  
The bacterial Hsp104 homologue ClpB is also able to provide thermotolerance and 
reverse disordered aggregates, but neither ClpB nor the mammalian Hsp110 share the 
remarkable ability to dismantle amyloid (Shorter, 2011, DeSantis et al., 2012).  Thus, the 
anti-amyloid function is unique to Hsp104 and, as such, might be harnessed by other 
systems if introduced exogenously. 
 
HSPs in treating neurodegenerative disease 
 
Because of the shared structural elements common to amyloid fibrils and pre-amyloid 
oligomers, molecular chaperones and HSPs might be able to target a mechanism 
common to many neurodegenerative diseases.  Targeting the more universal features of 
the amyloidogenesis pathway would be desirable because the precise properties of each 
amyloid fibril will be distinct on the molecular level, depending on the primary sequence 
of the disease-associated protein.  Further complicating the issue, identical primary 
sequences can form distinct intermolecular contacts to produce different strains of fibril 
with distinct properties (Tanaka et al., 2004, Toyama and Weissman, 2011).  To 
eliminate the diverse amyloid species associated with human disease, the prevention 
and even reversal of the stable cross-β conformation would be an enormous 
achievement.  Additionally, antagonizing pre-amyloid oligomers may be very important in 
attacking protein conformational disease because soluble oligomers have been 
suggested to be more toxic than insoluble fibrils.  While amyloid plaques/inclusions 
might offer some protection by sequestering the toxic soluble species, these amyloid 
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accumulations may also serve as a reservoir to release toxic oligomers (Koffie et al., 
2009, Jin et al., 2011, Shahnawaz and Soto, 2012).  Thus, a complete therapy would 
target both structures, and would interact broadly with diverse amyloidogenic proteins. 
 
Indeed, the molecular chaperone Hsp70 has been of great interest in application to 
protein aggregation disease because of its ability to mitigate endogenous protein 
misfolding, and has been shown to be a potent suppressor of neurodegenerative 
disease associated with protein aggregation (Muchowski and Wacker, 2005).  In cell 
culture, Hsp70 suppressed toxicity of Aβ, tau, and PolyQ proteins (Jana et al., 2000, 
Magrane et al., 2004, Shimura et al., 2004).  Additionally, the Hsp70 chaperone has 
been effective in dramatically suppressing degeneration in Drosophila models of PD and 
SCA3/MJD (Warrick et al., 1999, Auluck et al., 2002).  In mouse models of PolyQ 
disease, Hsp70 had minimal efficacy against mouse models of PolyQ diseases HD and 
SCA7 (Hansson et al., 2003, Helmlinger et al., 2004), but Hsp70 suppressed PolyQ 
pathology and severity of disease in a SCA1 model (Cummings et al., 2001).  A 
summary of the studies examining Hsp70 in disease models is presented in Table 1-1.  
Thus, initial studies indicate that Hsp70 may be a promising therapy in preventing 
neurodegenerative disease, but due to the nature of its function to avert protein 
misfolding, the outlook for treating existing disease is unclear. 
 
Table 1-1  Summary of disease models testing Hsp70 
Reference Animal system 
Disease 
model Effect of Hsp70 on disease 
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Cummings et 
al., 1998 
Cell culture 
HeLa 
SCA1 
(PolyQ) Decrease protein aggregation 
Warrick et 
al., 1999 Drosophila 
SCA3/MJD 
(PolyQ) 
Suppressed cell loss without preventing 
inclusion formation 
Jana et al., 
2000 
Cell culture: 
Neuro2a 
HD 
(PolyQ) Suppressed aggregates and cell death 
Cummings et 
al., 2001 Mouse 
SCA1 
(PolyQ) 
Improved motility, reduced pathology but 
not inclusions 
Auluck et al., 
2002 Drosophila PD Prevented dopaminergic cell loss 
Hansson et 
al., 2003 Mouse 
HD 
(PolyQ) 
No effect on inclusions, brain tissue loss, 
or behavioral phenotypes 
Helmlinger et 
al., 2004 Mouse 
SCA7 
(PolyQ) 
No effect on neuronal toxicity or 
aggregation 
Magrane et 
al., 2004 
Cell culture: 
N1 primary rat 
neurons 
AD: Aβ Prevented cell death 
Shimura et 
al., 2004 
Cell culture: 
Cos7 cells AD: Tau Prevented cell death 
 
Because of the unique capacity of Hsp104 to reverse pre-formed amyloid fibrils and pre-
amyloid oligomers, the disaggregase has also been tested in several models of 
amyloidogenic disease.  In general, Hsp104 was well tolerated in animal systems and 
even conferred thermotolerance to mammalian cells (Dandoy-Dron et al., 2006).  
However, Hsp104 has had variable efficacy in preventing disease.  On one end of the 
spectrum, mice transgenic for Hsp104 had no added protection against PrP infection, 
and at the other end, Hsp104 strongly suppressed α-syn aggregation and prevented 
neurodegeneration in a lentiviral rat model of PD (Dandoy-Dron et al., 2006, Lo Bianco 
et al., 2008).  However, the majority of these studies have focused on PolyQ disease.  
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Hsp104 mitigated formation of PolyQ-GFP aggregates in C. elegans, and this corrected 
a growth defect (Satyal et al., 2000).  Hsp104 reduced aggregation of htt in a transgenic 
mouse model, and offered a slight extension of lifespan, although behavioral 
impairments were not corrected (Vacher et al., 2005).  In a lentiviral rat model, Hsp104 
altered the distribution of htt inclusions and prevented brain pathology (Perrin et al., 
2007).  A summary of the studies examining Hsp104 in vivo is presented in Table 1-2.  
Thus, Hsp104 shows promise in a variety of disease settings and model organisms, but 
because the experimental paradigms require concomitant expression, its potential in 
treating pre-existing disease has not been fully evaluated. 
 
Table 1-2  Summary of in vivo models expressing Hsp104 
Reference Animal system 
Disease 
protein 
expressed 
Effect of 
Hsp104 on 
protein 
aggregation 
Effect of 
Hsp104 on 
disease 
phenotype 
Satyal et al., 
2000 C. elegans GFP-Q82 
Reduced 
aggregate 
formation 
Corrected 
growth rate 
defect 
Carmichael 
et al., 2000 
Mammalian cell 
transfection 
(PC12 and Cos7 
cell lines) 
EGFP-Htt-
Exon1-Q74 
Reduced 
proportion of 
cells with 
aggregates 
Reduced cell 
death and 
nuclear 
fragmentation 
Mosser et al., 
2004 
Human cell 
tranfection 
(PEER cell line) 
n/a n/a 
Increased 
survival 
following heat 
shock 
Vacher et al., 
2005 
Mouse 
(transgenic) Htt[n171]-Q82 
Reduced 
number of 
aggregates, 
not size or 
shape 
Did not correct 
motor defect, 
but did extend 
lifespan 
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Can chaperones reverse neurodegenerative disease? 
 
As previously highlighted, prevention of disease is potentially the most effective course 
of action, but patients often present with disease only after pathology has developed and 
the amyloid burden is high.  While Hsp70 has shown some efficacy in preventing 
disease, the ability to affect disease progression once the pathology has begun to 
accumulate remains unknown.  Although the technology exists to temporally control 
gene expression, all studies of Hsp70 as a modulator of disease have focused on 
concomitant co-expression or activation of the chaperone prior to disease initiation.  
Geldanamycin, a drug that boosts expression of endogenous Hsp70, was found to 
prevent neurodegeneration in mice when administered before a toxic insult of MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to chemically induce PD (Shen et al., 2005).  
Dandoy-Dron 
et al., 2006 
Mammalian cell 
transfection 
(CAD and HeLa 
cell lines) 
n/a n/a 
Increased 
survival 
following heat 
shock 
Mouse 
(transgenic) 
PrP 
(ME7 strain 
infection) 
No difference 
in PrPSc 
accumulation 
No difference 
in disease 
incubation time 
Perrin et al., 
2007 
E16 rat striatal 
neuron culture Htt[n171]-Q82 
Redirected into 
non-nuclear 
inclusions 
Prevented loss 
of neurons 
Rat 
(lentiviral) Htt[n171]-Q82 
Redistributed 
into more, 
smaller 
inclusions 
Prevented 
striatal 
pathology 
Lo Bianco et 
al, 2008 
Rat 
(lentiviral) α-syn-A30P 
Reduced 
formation of 
phosphorylated 
inclusions 
Reduced 
dopaminergic 
cell loss 
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However, the authors report that geldanamycin treatment was required before induction 
of the disease phenotype in order to have any beneficial effect (Shen et al., 2005).  It 
should also be noted that the MPTP model of PD does not result in α-syn aggregation, 
so these results may imply an indirect mechanism.  However, a protein-induced cell 
culture model of PD found similar results, determining that geldanamycin was required at 
least 24 hours prior to transfection with α-syn to prevent formation of pathological 
inclusions (McLean et al., 2004).  In Drosophila, pharmacological induction of Hsp70 
was found to suppress both PD and PolyQ disease, but, again, these were administered 
prior to disease onset (Auluck and Bonini, 2002, Wang et al., 2013).  A summary of the 
studies sequentially expressing Hsp70 is presented in Table 1-3.  Despite the existence 
of these experimental paradigms, sequential activation of chaperone expression 
following disease onset has not been examined. 
 
Table 1-3  Summary of models testing sequential activation of Hsp70 
Reference Animal system 
Hsp70 
selectively 
activated by: 
Disease 
model 
Effect of Hsp70 on 
disease 
Auluck and 
Bonini, 2002 Drosophila Geldanamycin PD 
Increased survival of 
dopaminergic neurons 
McLean et 
al., 2004 
Cell culture: 
H4 cells Geldanamycin PD 
Pretreatment prevented 
aggregation and 
toxicity 
Shen et al., 
2005 Mouse Geldanamycin 
MPTP 
induction 
of PD 
Prevented 
dopaminergic cell loss 
Note: no aggregates 
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Wang et al., 
2013 Drosophila 
HIP small 
molecule 
SBMA 
(PolyQ) 
Suppressed pupae 
toxicity, promoted  
protein degradation 
 
The potential to physically remodel the protein aggregation associated with 
neurodegenerative disease calls Hsp104 into focus.  In a pure protein system, Hsp70 
prevents fibrillization of PolyQ but cannot reverse it; Hsp104 strikingly reverses it 
(Muchowski et al., 2000, DeSantis et al., 2012).  Therefore, in vivo activation of Hsp70 
will likely be required prior to disease onset to have a strong modulatory effect, but 
Hsp104 might have the potential to tackle existing aggregates and halt disease 
progression that is already under way. 
 
This thesis seeks to examine the therapeutic potential of Hsp104 in a novel model 
system with the creation of transgenic Drosophila lines.  Here we show that, in 
Drosophila, Hsp70 is better at preventing onset of MJD/SCA3 toxicity, but that induction 
of Hsp104, but not Hsp70, has the remarkable ability to suppress disease progression 
once it has begun (Chapter 2).  However, despite no previous reports of deleterious 
effects following Hsp104 expression in animal systems, we encountered toxicity of 
Hsp104 when expressed at high levels in Drosophila.  This effect is explored further in 
Appendix I.  By lowering the protein expression level of Hsp104, we were able to 
minimize this effect and evaluate the efficacy of Hsp104 in combatting 
neurodegenerative disease.  A number of disease lines were screened (Appendix I), and 
an interesting interaction was observed between Hsp104 and the PolyQ protein MJD.  
The detailed analysis of Hsp104-mediated modulation of MJD amyloid formation and 
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toxicity is defined in Chapter 2.  Additionally, an evaluation of Hsp70 and Hsp104 
activated after onset of neurodegeneration is presented for the first time, with our results 
showing that Hsp104 halts the progression of pre-existing disease.  The implications of 
Hsp104 as a post-onset treatment for protein aggregation disease are discussed in 
Chapter 3. 
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INTRODUCTION 
 
Many neurodegenerative diseases, such as Alzheimerʼs Disease, Parkinsonʼs Disease 
(PD), prion disease, and the collection of polyglutamine (PolyQ) disorders, including 
Huntingtonʼs Disease (HD) and the Spinal Cerebellar Ataxias (SCAs), are characterized 
by the formation of protein inclusions in the nervous system (Forman et al., 2004, Chiti 
and Dobson, 2006, Cushman et al., 2010). Moreover, despite vastly different primary 
sequences, many of the proteins implicated in these diseases adopt the stereotypical 
amyloid conformation in the aggregated state (Forman et al., 2004). Amyloid is defined 
by a highly stable cross-β conformation, in which proteins polymerize via intermolecular 
contacts of β-strands that align orthogonal to the fiber axis. Amyloid is typically a stable 
structure that is resistant to denaturation by heat, detergents (up to 2% sodium dodecyl 
sulfate (SDS)), and proteases (Westermark et al., 2005, Chiti and Dobson, 2006).  
 
Despite the extraordinary structural stability of amyloid, a protein disaggregase from 
yeast, Hsp104, can rapidly solubilize amyloid. Hsp104 is a hexameric AAA+ (ATPases 
Associated with diverse cellular Activities) protein that couples ATP hydrolysis to 
translocation of substrate through a central pore, thus prying individual monomers from 
the amyloid fiber (Wendler et al., 2007, Tessarz et al., 2008, Wendler et al., 2009, 
DeSantis et al., 2012). In yeast, Hsp104 is a heat shock protein (HSP), promoting 
survival following stresses by resolubilizing denatured protein aggregates and restoring 
proteins to native form and function (Sanchez and Lindquist, 1990, Parsell et al., 1994). 
Hsp104 also maintains beneficial prion states by controlling the disassembly and 
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dissemination of amyloid aggregates (Shorter and Lindquist, 2004, 2006, Alberti et al., 
2009). 
 
Curiously, Hsp104 has no homologue in metazoa. Indeed, until recently it was unclear 
whether the metazoan proteostasis network possessed any coupled protein 
disaggregase and reactivation machinery. It is now clear that Hsp110, Hsp70, and 
Hsp40 collaborate to promote the dissolution and reactivation of disordered aggregates 
(Shorter, 2011, Rampelt et al., 2012), and can even slowly depolymerize amyloid fibrils 
from their ends (Duennwald et al., 2012). However, these disaggregase activities are 
slow and ineffective compared to Hsp104 (Shorter, 2011, Duennwald et al., 2012). In 
particular, amyloid depolymerization by Hsp110, Hsp70, and Hsp40 is many orders of 
magnitude slower (weeks versus minutes) than amyloid dissolution by Hsp104 
(Duennwald et al., 2012). Importantly, Hsp104 can synergize with metazoan Hsp110, 
Hsp70, and Hsp40 to promote dissolution of amyloid and nonamyloid aggregates 
(Shorter, 2011, Duennwald et al., 2012). Thus, introduction of Hsp104 into an animal 
system may provide an unprecedented opportunity to directly and rapidly target the 
intractable protein aggregates that underlie amyloid diseases (Shorter, 2008, Vashist et 
al., 2010). 
 
Spinocerebellar Ataxia Type 3 or Machado-Joseph Disease (MJD/SCA3) is the most 
prevalent dominantly inherited ataxia (Bettencourt and Lima, 2011, Paulson, 2012). The 
genetic basis of MJD/SCA3 is an expansion of the polyglutamine (PolyQ) tract of ataxin-
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3 (also known as Machado-Joseph Disease protein; MJD). When the PolyQ tract 
surpasses 50 consecutive Qs it is associated with the formation of amyloid aggregates 
and development of disease (Takiyama et al., 1993, Paulson et al., 1997). The normal 
physiological function of MJD is as a deubiquitylase (DUB) that catalyzes the cleavage of 
polyubiquitin (poly-ub) chains to promote proteostasis. It has a chain-editing function, 
preferentially cleaving certain poly-ub linkages to increase the presence of poly-ub 
chains that signal for degradation via the ubiquitin-proteasome system (UPS) (Winborn 
et al., 2008, Kuhlbrodt et al., 2011). MJD has DUB activity in the N-terminal Josephin 
domain, plus two ubiquitin-interacting motifs (UIMs) that present poly-ub chains to the 
Josephin domain, as well as the C-terminal PolyQ tract that is associated with disease 
(Masino et al., 2003). The PolyQ domain is known to form amyloid fibers, and 
interestingly, MJD aggregation occurs in a two-step process in vitro, with the Josephin 
domain forming SDS-soluble linear polymers that then convert into SDS-insoluble PolyQ-
driven amyloid fibers (Masino et al., 2004, Ellisdon et al., 2006, Ellisdon et al., 2007). As 
such, Hsp104 may be well suited to combating MJD protein aggregation because it 
antagonizes non-amyloid aggregates, pre-amyloid conformers, and amyloid fibers 
(Shorter and Lindquist, 2006, Lo Bianco et al., 2008, Shorter and Lindquist, 2008, 
DeSantis et al., 2012). 
 
Hsp104 has been introduced to combat protein-aggregation disease in metazoan 
systems with various levels of success (Satyal et al., 2000, Vacher et al., 2005, Dandoy-
Dron et al., 2006, Perrin et al., 2007, Lo Bianco et al., 2008). In C. elegans, Hsp104 
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prevented aggregation and toxicity of GFP-tagged PolyQ (Satyal et al., 2000). In a 
lentiviral rat model, co-expression of Hsp104 with a PolyQ fragment implicated in HD 
resulted in the accumulation of more but smaller aggregates and rescue of striatal 
dysfunction (Perrin et al., 2007). In mouse, animals transgenic for both an HD fragment 
and Hsp104 showed limited suppression of PolyQ inclusion formation but prolonged 
lifespan by ~20% (Vacher et al., 2005). While these studies suggest promise for Hsp104 
as a therapeutic against disease-associated protein aggregation, none has provided 
mechanistic insight into how Hsp104 interacts with amyloidogenic proteins in an animal 
system. Further, studies to date have looked only at prevention of aggregation by 
concomitant co-expression of Hsp104. There has not been an evaluation of the potential 
of Hsp104 to modulate disease phenotypes in vivo after aggregates have already formed 
and degeneration has begun; a situation likely to mimic an actual therapy. Therefore, we 
created novel Hsp104 Drosophila lines because of the well-characterized models of 
disease and the access to powerful genetic tools, such as the technology to temporally 
control the expression of Hsp104 after disease-associated aggregation and 
degeneration has begun. 
 
Our studies reveal surprisingly distinct interactions of Hsp104 with the full-length versus 
a truncated version of the MJD protein, and that Hsp104 indeed possesses the ability to 
suppress the progression of degeneration when activated subsequent to onset of 
expression of the disease protein. These data indicate that protein context is central in 
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Hsp104 interactions, and that Hsp104 displays in vivo the ability to halt the progression 
of pre-established disease. 
  
RESULTS 
 
Hsp104 mitigates toxicity of truncated MJD, but enhances toxicity of the full-
length MJD 
 
The disaggregase Hsp104 efficiently antagonizes protein aggregates in yeast, and while 
homologues are present in bacteria, plants, fungi, chromista, and protozoa, no functional 
homologue has been found in metazoa (Mosser et al., 2004, Vashist et al., 2010). We 
stably introduced Hsp104 into Drosophila to evaluate its ability to prevent and potentially 
reverse aggregation of disease-associated human proteins, readily available in various 
fly models of disease. To achieve strong expression of the Hsp104 protein in the fruit fly, 
we codon-optimized the transgene for Drosophila, and added a fly-optimal Kozak 
sequence (ACAAA) before the start codon (Trinh et al., 2008). The Hsp104 transgene 
was then expressed in Drosophila using the GAL4/UAS system (Brand and Perrimon, 
1993). Because we achieved high expression of Hsp104, expression by the gmr-GAL4 
driver in the eye had a mild disruptive effect (Fig 2-1A), which has also been observed 
for another AAA+ protein, p97 (Ritson et al., 2010). As the gmr-GAL4 driver line has 
multiple copies of the glass gene element for driving GAL4 expression, we instead used 
a driver line with reduced expression (Fig 2-1B) bearing only a single glass element, 
1×gr-GAL4. Using this driver, the effect of Hsp104 was minimized (Fig 2-1A and Fig 2-
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2A). Thus, we used the 1×gr-GAL4 driver line for our experiments evaluating the impact 
of Hsp104 on protein-aggregation disease in vivo. 
 (A) Expression of 
UAS-Hsp104 using 
gmr-GAL4 caused 
disruption of internal 
retinal structure by 
d7. A less strong 
driver, 1×gr-GAL4 
minimized this effect 
and prevented 
disruption to cellular 
organization within the retina. Arrows indicate the width of the retina to highlight changes in tissue 
integrity. 
(B) Immunoblots demonstrated that 1×gr-GAL4 drives lower Hsp104 expression than gmr-GAL4 
at d7. Actin served as a loading control. Quantitation of immunoblots determined that 1×gr-GAL4 
levels of Hsp104 were ~35% that of gmr-GAL4. Hsp104 levels were normalized to actin (n=3 
(mean ± SEM)). 
 
Hsp104 dissolves PolyQ amyloid in vitro (DeSantis et al., 2012, Duennwald et al., 2012) 
and has been expressed in various PolyQ animal models, with results ranging from 
minimal beneficial effect to strong abrogation of PolyQ aggregation (Satyal et al., 2000, 
Vacher et al., 2005, Perrin et al., 2007). However, a detailed analysis of the underlying 
protein interactions is lacking in vivo. We sought to dissect the ability of Hsp104 to 
antagonize PolyQ aggregation and toxicity using MJD as a model protein. Pathogenic 
MJD with expanded PolyQ has been previously established in fly models of MJD/SCA3, 
and induces progressive neurodegeneration with the formation of nuclear inclusions 
(Warrick et al., 1998, Warrick et al., 2005). We also examined a truncated C-terminal 
fragment of MJD that is predominantly comprised of the PolyQ tract because 
Figure 2-1  Tuning 
Hsp104 expression 
level for the fly eye. 
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fragmentation of the protein may be associated with MJD/SCA3 pathogenesis (Warrick 
et al., 1998, Haacke et al., 2007, Jung et al., 2009). 
 
We examined interactions of Hsp104 with the pathogenic, full-length MJD containing an 
expanded glutamine tract (MJDnQ78) and the truncated C-terminal region of the protein 
containing the expanded glutamine tract (MJDtrQ78) (Warrick et al., 1998). Hsp104 had 
no effect on non-pathogenic forms of MJD containing non-expanded PolyQ tracts (Fig 2-
2B), confirming that the interaction is PolyQ length-dependent. With expanded PolyQ 
domains, the pathogenic MJDtrQ78 and MJDnQ78 both caused degeneration of the 
external eye and disruption to internal retinal structure (Fig 2-2C, D). Unexpectedly, we 
found that Hsp104 had opposite effects on these two forms of MJD that have an identical 
PolyQ expansion: Hsp104 mitigated MJDtrQ78 degeneration (Fig 2-2C), yet enhanced 
degeneration associated with the full-length MJDnQ78 (Fig 2-2D). This effect is in 
contrast to human Hsp70, a molecular chaperone that suppresses PolyQ disease in 
multiple systems (Cummings et al., 1998, Warrick et al., 1999, Chan et al., 2000, 
Muchowski et al., 2000). Despite more severe degeneration due to stronger expression 
by the gmr-GAL4 driver, Hsp70 suppressed the toxicity of both MJDtrQ78 and MJDnQ78 
(Fig 2-2E). 
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(A) With the 1×gr-GAL4 driver at 
d7, Hsp104 alone had minimal 
disruption to external eye and 
internal retinal structure. Arrows 
indicate the width of the retina to 
highlight changes in tissue 
integrity. 
(B) With the 1×gr-GAL4 driver at 
d7, Hsp104 had no effect on MJD 
with non-expanded PolyQ tract. 
Non-pathogenic truncated protein 
MJDtrQ27 and full-length 
MJDnQ27 had no toxicity alone, 
and Hsp104 did not alter this lack 
of toxicity. The slight disruption to 
the retina in Hsp104-containing 
flies is consistent with Hsp104 
alone effect. Arrows indicate the 
width of the retina to highlight 
changes in tissue integrity. 
(C) With the 1×gr-GAL4 driver at 
d7, MJDtrQ78 showed moderate 
toxicity, and co-expression of 
Hsp104 mitigated the disrupted 
eye pigmentation and prevented 
disorganization of internal retinal structure. Arrows indicate the width of the retina to highlight 
changes in tissue integrity. 
(D) With the 1×gr-GAL4 driver at d7, Hsp104 enhanced toxicity of MJDnQ78, causing loss of 
pigmentation and dramatic tissue degeneration within the retina. Arrows indicate the width of the 
retina to highlight changes in tissue integrity. 
(E) With the gmr-GAL4 driver at d7, both MJDtrQ78 and MJDnQ78 displayed severe toxicity, with 
loss of pigmentation and necrotic patches on the eye (note that severity of degeneration is 
increased due to the use of the stronger gmr-GAL4 driver). Co-expression of Hsp70 strongly 
suppressed the toxicity of both full length and truncated pathogenic MJD proteins. Arrows indicate 
the width of the retina to highlight changes in tissue integrity. 
 
The opposite effects of Hsp104 on MJDtrQ78 and MJDnQ78 correspond to distinct 
modulation of underlying protein accumulations 
 
To probe the mechanism underlying the dichotomous results found for the Hsp104 
interaction with MJDtrQ78 and MJDnQ78, an in-depth investigation of the protein 
Figure 2-2  Hsp104 mitigates 
toxicity of Truncated MJD but 
enhances toxicity of Full-
length MJD. 
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aggregates was performed. To slow protein aggregation such that we could analyze 
underlying protein accumulations in detail, we expressed the transgenes in the eye with 
an adult-onset driver rhodopsin1(rh1)-GAL4. Analysis of the PolyQ protein 
accumulations showed that Hsp104 altered the kinetics of inclusion formation for both 
MJD protein isoforms. By cryosectioning and subsequent immunohistochemistry (IHC), 
MJDtrQ78 formed compact inclusions that increased in size over time (Fig 2-3A, top 
row). Quantification of inclusion size over time (Fig 2-3A, gray bars in graph) reveals 
distinct inclusion size populations (small <2.5 µm, medium 2.5-5 µm, large >5 µm in 
optical diameter), demonstrating that inclusions became larger and more numerous with 
time. Consistent with previous studies, co-expression of Hsp70 delayed the kinetics and 
significantly reduced MJDtrQ78 protein aggregation (Fig 2-3A, bottom row; green bars in 
graph, p=0.03). By contrast, Hsp104 initially delayed inclusion formation (p=0.004, but 
then significantly enhanced the formation of small inclusions (p=0.04), eventually 
reaching accumulation levels similar to that with MJDtrQ78 alone (Fig 2-3A, center row; 
red bars in graph, n.s. p=0.5). 
 
To examine protein accumulation by biochemical methods, we used SDD-AGE (Semi-
Denaturing Detergent–Agarose Gel Electrophoresis), a protein agarose gel technique 
that can resolve amyloid aggregates (Halfmann and Lindquist, 2008). This technique is 
useful for resolving high molecular weight polymer assemblies that maintain stable 
contacts in 2% SDS (a feature of highly stable amyloid). SDD-AGE revealed that the 
truncated MJDtrQ78 protein formed SDS-resistant amyloid structures that accrue with 
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time (Fig 2-3C). Unlike Hsp70, which significantly suppressed amyloid formation 
(p=0.003), Hsp104 did not change the overall kinetics of MJDtrQ78 amyloid formation or 
the overall level of aggregation (Fig 2-3C). Confirming that insoluble amyloid material 
was increased, the reduction of SDS-soluble levels of protein by immunoblot matched 
the concomitant increase in amyloid formation observed by SDD-AGE (Fig 2-3C). Thus, 
Hsp104 rescues MJDtrQ78 toxicity, but the relationship to MJDtrQ78 aggregation is 
complex. IHC revealed that Hsp104 initially delays MJDtrQ78 inclusion formation, but 
then significantly enhances the formation of small inclusions (Fig 2-3A). However, when 
amyloidogenesis was tracked by SDD-AGE, Hsp104 affected neither the rate nor the 
extent of amyloid formation (Fig 2-3C). This finding indicates that to rescue toxicity 
Hsp104 might reduce formation of soluble and toxic oligomeric MJDtrQ78 species that 
are populated during amyloidogenesis, just as it does with the yeast prion proteins 
Sup35 and Ure2 (Shorter and Lindquist, 2004, 2006). 
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(A and B) With 
the rh1-GAL4 
driver at 
indicated time 
points, cryo-
sections and 
IHC demon-
strate accum-
ulations of 
MJDtrQ78 and 
MJDnQ78 (red) 
over time, 
using anti-HA 
and anti-myc 
antibodies, 
respectively. 
Sections were 
co-stained with 
anti-Hsp104 or 
anti-Hsp70 
(green) as 
indicated, and 
nuclei were 
labeled by 
Hoechst (blue). 
Hsp104 
delayed but did 
not suppress 
aggregation of 
MJDtrQ78, but 
Hsp104 enhan-
ced accum-
ulation form-
ation of 
MJDnQ78. 
Hsp70 suppressed aggregation of both MJD proteins. The size of the aggregates was quantified 
using ImageJ, with delineations for large inclusions (>5 µm across), medium inclusions (2.5–5 
µm), or small inclusions (<2.5 µm) (n=3 (mean ± SEM)). Scale bar = 20 µm. *p<0.05, **p=0.001-
0.01, ***p<0.001; Statistics indicate comparison to the disease protein alone for total number of 
inclusions at each timepoint (black asterisks). Additional statistical comparisons for inclusion size 
Figure 2-3  
Hsp104 
delays 
aggregation 
of truncated 
MJD, but 
enhances 
aggregation 
of full-length 
MJD. 
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divisions are indicated by color, e.g., dark red asterisk indicates significant change in large 
inclusions. 
(C and D) With the rh1-GAL4 driver at indicated time points, SDD-AGE and immunoblot analysis 
show the progression of amyloid formation of MJDtrQ78 and MJDnQ78 proteins over time. 
Hsp104 did not greatly affect the aggregation profile of MJDtrQ78 but enhanced formation of 
SDS-insoluble amyloid aggregates of MJDnQ78. Hsp70 suppressed aggregation of both MJD 
proteins. The formation of large, SDS-insoluble aggregates by SDD-AGE corresponded with the 
disappearance of SDS-soluble soluble protein from immunoblots. MJDtrQ78 and MJDnQ78 were 
detected using anti-HA and anti-myc, respectively, with anti-tubulin as a loading control. Band 
density for both amyloid smears (SDD-AGE) and soluble bands (Western blot) were quantified 
using ImageJ (n=3 (mean ± SEM)). *p<0.05, **p=0.001-0.01, ***p<0.001; Statistics indicate 
comparison to the disease protein alone at each timepoint. 
 
Next, we assessed MJDnQ78 misfolding. In contrast to the truncated MJDtrQ78 isoform, 
the pathogenic full-length MJDnQ78 initially formed amorphous inclusions that did not 
become more numerous after day 1 (Fig 2-3B, top row; gray bars in graph). These 
MJDnQ78 amorphous aggregates appeared early by IHC, and insoluble amyloid 
aggregates developed later as observed by SDD-AGE (Fig 2-3B and D). Thus, the early 
MJDnQ78 aggregates are non-amyloid in nature but later convert into the insoluble 
amyloid structure, closely resembling the two-step aggregation kinetics observed in vitro 
(Masino et al., 2004, Ellisdon et al., 2006, Ellisdon et al., 2007). As with MJDtrQ78, co-
expression of Hsp70 delayed the kinetics of aggregation and significantly suppressed 
inclusion formation (Fig 2-3B, bottom row; green bars in graph, p=0.02). However, in 
marked contrast, co-expression of Hsp104 significantly increased the formation of large 
aggregates at early time points (p=0.002), and then significantly increased the number of 
small inclusions over time (Fig 2-3B, center row; red bars in graph, p<0.001). Consistent 
with IHC results, SDD-AGE analysis demonstrated that Hsp104 significantly promoted 
the early formation of insoluble MJDnQ78 amyloid aggregates (Fig 2-3D, p<0.001), 
whereas Hsp70 delayed kinetics of amyloid formation (Fig 2-3D, p=0.01). Hsp70, but not 
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Hsp104, stably colocalized with both MJDtrQ78 and MJDnQ78 inclusions (Fig 2-3A and 
B; see Fig 4 for channel breakdown). The striking contrast between the effects of 
Hsp104 and Hsp70 on inclusion formation 
reinforces their functional differences 
(Sanchez et al., 1993).  
 
(A) Split channels from the MJDtrQ78 treatment 
set at the Day 7 time point (from Fig. 3A). Note 
that Hsp104 (green, middle row) had minimal 
overlap with MJDtrQ78 inclusions (red, middle 
row), but some colocalization was observed. In 
contrast, Hsp70 (green, bottom row) strongly 
colocalized with MJDtrQ78 inclusions (red, 
bottom row). 
(B) Split channels from the MJDnQ78 treatment 
set at the Day 7 time point (from Fig. 3B). 
Hsp104 (green, middle row) had no observable 
colocalization with MJDnQ78 inclusions (red, 
middle row), while Hsp70 (green, bottom row) 
did colocalize with MJDnQ78 inclusions (red, 
bottom row). 
 
Domains neighboring the expanded PolyQ tract hinder protective Hsp104 
activities 
 
While it is known that in select conditions, Hsp104 promotes amyloid formation of 
specific yeast prions (Shorter and Lindquist, 2004, 2006, 2008), we did not anticipate 
that Hsp104 would have opposite actions on two constructs of the same PolyQ protein. 
Thus, we assessed which domains of the full-length MJD protein prevented rescue by 
Hsp104 by employing a series of expression-matched MJD variants with disruptions to 
Figure 2-4  Hsp70, but not Hsp104, 
colocalizes with both MJDtrQ78 and 
MJDnQ78 inclusions. 
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specific motifs (summarized in Fig 2-7A). Because the PolyQ domains are pure CAG 
repeats, they are subject to instability. Given this, the repeat lengths have been matched 
as closely as possible with matching protein expression levels (see (Warrick et al., 
2005)). Because of the reduced expression level by the 1×gr-GAL4 driver used for these 
experiments, MJDnQ84 (the pathogenic protein for this set of expression matched 
proteins) now showed mild degeneration. However, as before, analysis of retinal integrity 
demonstrated that the toxicity of MJDnQ84 was enhanced upon co-expression of 
Hsp104 (Fig 2-5A). In contrast, an MJD variant in which both UIMs were mutated and 
unable to engage poly-ub, MJD-Q80-UIM*, exhibited mild toxicity that was suppressed 
by Hsp104 (Fig 2-5A). Thus, the ability of the UIM domains to engage poly-ub hinders 
protective Hsp104 activity. 
 
We also examined variants lacking DUB activity through mutation of the active site in the 
Josephin domain, MJD-Q88-C14A, which causes more severe toxicity than MJDnQ84 
due to the loss of the physiological UPS function (Warrick et al., 2005). This occurs 
because DUB activity of MJD can suppress its own PolyQ toxicity; the C14A mutation is 
innocuous when MJD has a normal length, non-expanded Q repeat (Fig 2-6A) (Warrick 
et al., 2005). Co-expression of Hsp104 did not affect the severe MJD-Q88-C14A toxicity 
(Fig 2-5A). However, when the active site mutation was combined with the UIM 
mutations, in MJD-Q80-C14A-UIM*, Hsp104 now suppressed toxicity (Fig 2-5A). This 
result reiterates that functional UIMs hinder rescue by Hsp104. We further examined a 
separate splice variant lacking DUB activity through an exon deletion that includes the 
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active site, MJD-Q79-Δexon2 (missing amino acids 9-63) (Fig 2-6B) (Bettencourt et al., 
2010, Harris et al., 2010), which, like MJD-Q88-C14A, conferred severe toxicity. Co-
expression of Hsp104 with MJD-Q79-Δexon2 strongly suppressed degeneration (Fig 2-
5A). Thus, Hsp104 mitigated MJD toxicity when the exon containing the active site was 
deleted (MJD-Q79-Δexon2) but had no effect when the active site was inactivated by a 
single point mutation (MJD-Q88-C14A). Taken together, these data indicate that 
functional UIMs and an intact Josephin domain both prohibit Hsp104 from rescuing full-
length MJDnQ84 toxicity. 
 
To uncover additional mechanistic insight into the interactions with Hsp104, we 
examined inclusion formation and kinetics with adult-onset rh1-GAL4 expression. By 
IHC, the MJD variants formed accumulations in a manner roughly consistent with 
severity of eye degeneration (Fig 2-5B, top row; gray bars in graph). Those variants with 
mutated UIMs, MJD-Q80-UIM* and MJD-Q80-C14A-UIM*, showed significantly reduced 
levels of aggregate formation with Hsp104 (Fig 2-5B, bottom row; red bars in graph, 
p=0.003 for both). SDD-AGE analysis revealed that Hsp104 significantly enhanced the 
conversion of soluble protein to SDS-resistant polymers for variants with intact UIMs: 
MJDnQ84 and MJD-Q88-C14A (Fig 2-5C, p=0.002 and p=0.005, respectively). 
Moreover, Hsp104 significantly reduced the formation of amyloid material by MJD-Q80-
C14A-UIM* (Fig 2-5C, p=0.01). The MJD-Q79-Δexon2 protein was not detectable by 
immunoblot (but was confirmed by genotyping, Fig 2-6C, D), precluding aggregate 
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analysis of this variant. These findings underscore the role of active ubiquitin binding in 
obstructing productive remodeling by Hsp104.  
 
(A) With the 
1×gr-GAL4 
driver at d7, 
external eye 
and internal 
retinal structure 
showed 
suppression of 
toxicity by 
Hsp104 for 
MJD variants 
with mutated 
UIMs (MJD-
Q80-UIM* and 
MJD-Q80-
C14A-UIM*). 
Hsp104 
strongly 
suppressed the 
external eye 
degeneration 
and loss of 
internal retinal 
structure of 
MJD lacking a region spanning the Josephin domain (amino acids 9-63 (Δ exon 2)). The 
MJDnQ84 and MJD-Q80-UIM* crosses were performed at 29ºC to enhance the severity of 
degeneration. Arrows indicate the width of the retina to highlight changes in tissue integrity. 
(B) With the rh1-GAL4 driver at d3, Hsp104 suppressed inclusion formation in MJD variants with 
UIM mutations, as seen by IHC (d3). Accumulations of the MJD variant proteins were detected by 
anti-myc (red) and nuclei are labeled by Hoechst stain (blue). Scale bar = 20 µm. Size of 
inclusions was quantified using ImageJ, with delineations for large inclusions (> 5 µm across), 
Figure 2-5  A 
portion of the 
Josephin 
domain and 
the Ubiquitin-
Interacting 
Motifs prevent 
Hsp104 from 
rescuing full-
length MJD 
pathogenicity. 
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medium inclusions (2.5–5 µm), or small inclusions (< 2.5 µm) (n=3 (mean ± SEM)). Scale bar = 
20 µm. **p=0.001-0.01. 
(C) With the rh1-GAL4 driver at d3, SDD-AGE and Western immunoblot showed that by d3, 
Hsp104 enhanced aggregation of MJD variants with wild-type UIMs, but reduced formation of 
amyloid of MJD variants with UIM mutations. MJD variants were detected using anti-myc with 
anti-tubulin as a loading control. Band density for both amyloid smears (SDD-AGE) and soluble 
bands (Western blot) were quantified using ImageJ (n=3 (mean ± SEM)). **p=0.001-0.01. 
 
(A) Driven by 1xgr-GAL4 
at d7, MJD with non-
expanded Q has no 
toxicity. Loss of DUB 
activity through point 
mutation, MJD-Q27-
C14A, or through exon 
deletion, MJD-Q27-
Δexon2, did not confer 
toxicity. 
(B) The structure of the 
Josephin domain, from 
PDB file 1YZB. The 
amino acids lost in the 
exon 2 deletion are 
highlighted in gray and 
the catalytic residue 
mutated in the C14A 
variant is highlighted in 
red. 
(C) Genomic DNA from Drosophila was amplified for the UAS insert and was resolved on an 
agarose gel. We confirmed that MJD-Q79-Δexon2 was missing the appropriate size of DNA 
contained within exon 2. 
(D) Sequencing of the Josephin domain confirmed that MJD-Q79-Δexon2 lacked the bases 
encoding amino acids 9-63, but was otherwise identical to MJDnQ78. 
 
A summary of the effect of Hsp104 on MJD variants is presented in Fig 2-7B. In the two 
cases in which Hsp104 enhanced aggregation (MJDnQ84, MJD-Q88-C14A), the MJD 
protein has both functional UIMs and an intact Josephin domain. By contrast, protein 
variants whose toxicity and underlying protein accumulations were suppressed by 
Hsp104 (MJD-Q80-UIM*, MJD-Q80-C14A-UIM*, MJD-Q70-Δexon2) each lack UIM 
Figure 2-6  Character-
ization of DUB-deficient 
MJD variants. 
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binding or a portion of the Josephin domain. This supports a model in which an inflexible 
or “closed” loop is formed, possibly through associations with a poly-ub chain, between 
the functional 
UIMs and the 
intact Josephin 
domain (Fig 2-
7B, red circle). 
Our hypothesis 
is that Hsp104 
is able to 
effectively 
remodel a more 
flexible or “open” conformation of select protein variants (e.g., MJD-Q80-UIM*, MJD-
Q80-C14A-UIM*, MJD-Q70-Δexon2, or the truncated MJDtrQ78), but that the 
inflexible/closed conformation of other proteins (e.g., MJDnQ78, MJDnQ84, or MJD-
Q88-C14A) obstructs protective Hsp104 activities. 
 
Active remodeling by Hsp104 is required for modulation of protein pathogenicity 
 
To verify the critical role of active remodeling by Hsp104, we created an ATPase-Dead 
and substrate-binding defective Hsp104 transgenic fly. We introduced four mutations 
(Y257A:E285Q:Y662A:E687Q) into Hsp104 to ensure that Hsp104 could not engage 
Figure 2-7  Model of MJD domain contribution to the interaction with 
Hsp104. 
(A) Schematic of MJD variants with functional deficiencies.  
(B) Model of MJD protein conformation as it affects accessibility to Hsp104 
treatment. Hsp104 worsens the pathogenicity and enhances aggregation of 
MJD variants with functional UIMs and an intact Josephin domain. A closed 
loop may be formed between these domains, potentially through mutual 
association with a poly-ub chain, which inhibits productive remodeling by 
Hsp104. MJD variants with a more flexible conformation are receptive to 
successful remodeling by Hsp104. 
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substrate or hydrolyze ATP, creating the mutant known as Double Pore Loop Double 
Walker B (Hsp104DPLDWB), which is structurally identical to wild-type but functionally 
inactive (DeSantis et al., 2012). Unlike wild-type Hsp104, which caused mild retinal 
disruption by the gmr-GAL4 driver, similar expression levels of Hsp104DPLDWB were 
innocuous (Fig 2-8A, B). Moreover, Hsp104DPLDWB did not modulate the toxicity of either 
MJDtrQ78 or MJDnQ78 (Fig 2-8A), underscoring the importance of substrate 
translocation for Hsp104 to mitigate MJDtrQ78 or worsen MJDnQ78-associated 
degeneration. Thus, ATPase activity and substrate binding are required in vivo for 
modulatory effects of Hsp104.  
 
(A) With the gmr-GAL4 driver 
at d7, expression of the 
inactive mutant UAS-
Hsp104DPLDWB, which is unable 
to bind substrate or hydrolyze 
ATP, caused no effect on its 
own when expressed by gmr-
GAL4. Additionally, the 
inactive Hsp104DPLDWB did not 
modulate the toxicity of 
MJDtrQ78 or MJDnQ78. Eye 
images and retinal sections 
showed moderate 
degeneration upon expression 
of MJDtrQ78 or MJDnQ78, but 
unlike wild-type Hsp104 (see 
Fig. 2), Hsp104DPDLWB did not 
mitigate the degeneration caused by MJDtrQ78 nor did it enhance the toxicity of MJDnQ78. 
Arrows indicate the width of the retina to highlight changes in tissue integrity. 
(B) Western immunoblot demonstrated that WT Hsp104 and Hsp104DPLDWB had similar 
expression levels. Tubulin served as a loading control. Quantification of Western immunoblots 
confirmed that protein expression levels were similar, but that Hsp104DPLDWB was expressed at 
levels slightly higher than WT Hsp104. Hsp104 signal was normalized to tubulin (n=3 (mean ± 
SEM)). 
Figure 2-8  ATPase activity 
and substrate binding are 
required for Hsp104 to 
modulate disease. 
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Hsp104 suppresses progression of pre-existing degenerative disease in vivo 
 
Hsp104 is unique in its capacity to reverse pre-existing amyloids in yeast and in vitro. 
However, the potential of Hsp104 to affect pre-existing protein-aggregation disease in a 
metazoan, i.e., a genuine in vivo treatment situation, has never been addressed. To do 
so, we constructed fly lines containing three elements: (1) the toxic MJDtrQ78 protein 
driven directly by a gmr element such that the disease-associated protein was 
constitutively expressed in the eye; (2) a drug-inducible gmr-GAL4 driver known as 
“GeneSwitch” (gmr-GS) to activate GAL4 expression only in the presence of the drug 
RU486 (mifepristone) (Osterwalder et al., 2001, Roman and Davis, 2002); and (3) the 
UAS-HSP treatment molecule (here, Hsp104 or Hsp70), such that the HSP will be 
expressed conditionally only when RU486 is present in the fly food (Fig 2-9A). This 
system allows the activation of HSP expression sequential to disease-associated protein 
onset. In this manner, we could test the ability of exogenous HSPs to mitigate the toxicity 
of the pathogenic PolyQ protein after the pathogenic protein was already accumulating in 
aggregated forms and causing degeneration. We hypothesized that, due to its 
disaggregation rather than chaperone activity, Hsp104 may have the potential to 
markedly mitigate degeneration associated with pre-existing PolyQ protein aggregates. 
 
 
40 
 
(A) Western immunoblot 
demonstrated that the gmr-GS-
GAL4 line specifically drove 
Hsp104 expression in the 
presence of RU486 (gmr-GS 
ON), but there was no 
expression of Hsp104 in the 
absence of the drug (gmr-GS 
OFF) at d7. The level of 
expression by gmr-GS was 
lower than with the other eye-
specific drivers gmr-GAL4 and 
1×gr-GAL4.  Tubulin served as 
a loading control. 
Quantification of Western 
immunoblots confirmed that 
gmr-GS expressed at a lower 
level than the other drivers, 
with the amount of Hsp104 
expressed by gmr-GS reaching about 33% of that expressed by 1×gr-GAL4. Hsp104 levels were 
normalized to tubulin (n=3 (mean ± SEM)).  
(B) Paraffin sections demonstrate that the retinal tissue loss associated with gmr-MJDtrQ78 is 
apparent at d0, and progresses through d7. In comparison, control flies (7d) display no such loss 
of retinal integrity. For each example shown here, a 7,000 µm2 rectangular selection (used for 
quantification in Fig. 2-10) of a retinal section from three independent animals is presented. Each 
region was converted to a black and white image to show the area covered by tissue and 
quantitated by ImageJ analysis (see Methods). For the analysis in Fig. 2-10, regions from 6 
independent animals were used for quantitation; all experiments were repeated at least three 
times with similar results. 
 
We established that retinal degeneration associated with gmr-MJDtrQ78 had begun at 
the time of adult fly emergence (d0) and progressed in severity to d7 (Fig 2-9B, Fig 2-
10).  We then activated Hsp104 or Hsp70 expression at an early time point (d1), or a 
later time point (d3), and examined the pathogenic impact of the MJDtrQ78 protein at d7 
by retinal section. When activated at d1, Hsp104 was able to significantly mitigate retinal 
degeneration associated with MJDtrQ78 (p=0.001), while Hsp70 did not have a 
significant effect (Fig 2-10A, n.s. p=0.06). These data show that Hsp104 is significantly 
Figure 2-9  Establishing the 
GeneSwitch paradigm. 
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more effective than Hsp70 at mitigating toxicity once disease progression has begun (Fig 
2-10A, p=0.01). Importantly, inactive Hsp104DPLDWB had no effect (Fig 2-10A). Hsp104 
significantly improved tissue structure even when expression was induced at a later time 
point of d3 when degeneration was even more severe (Fig 2-10B, p=0.003). Moreover, 
while MJDtrQ78 treated with Hsp70 continued to degenerate with time, induction of 
Hsp104 arrested disease progression (Fig 2-10A, d7 vs d1; Fig 2-10B, d7 vs d3). We 
also examined the underlying protein aggregates by SDD-AGE and Western 
immunoblot. We observed that gmr-MJDtrQ78 had high levels of amyloid, and this was 
lessened with time (potentially due to tissue loss) (Fig 2-11). When turned on at d1, 
Hsp104 did not reverse MJDtrQ78 amyloid formation, but rather significantly increased 
the amyloid present by d7 (p=0.02), while Hsp70 had no effect (Fig 2-11A). Neither 
molecule significantly altered amyloid load when turned on at d3 (Fig 2-11B). These 
results imply that Hsp104 is not acting as a MJDtrQ78-amyloid disaggregase, but rather 
is mitigating toxicity in a distinct manner, which is also consistent with our results for 
MJDtrQ78 (see Fig 2-2, 2-3). Intriguingly, representative densitometry traces for the 
amyloid smears for each treatment condition turned on at d1 suggest that the peak of 
MJDtrQ78 amyloid species shift downward to indicate smaller amyloid accumulations by 
d3 following Hsp104 activation (Fig 2-11C). No shift in the densitometry trace is 
observed for the control or Hsp70 treatment (Fig 2-11C), suggesting that Hsp104 is 
indeed altering the character of amyloid species although not eliminating these fibrils 
completely. In summary, this novel system of temporally controlled HSP expression 
demonstrates that although concomitant expression of Hsp70 is more successful than 
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Hsp104 at preventing degeneration (see Fig 2-2), inducible expression of Hsp104 is 
more effective than Hsp70 at suppressing disease progression once protein aggregation 
and degeneration are already established (Fig 2-10). 
 
(A) External eye 
and internal retinal 
sections demon-
strate the effect of 
sequential onset of 
chaperone treat-
ment. The adult 
animals emerged 
from the pupal 
case with a 
disrupted eye (d0); 
chaperone activity 
was initiated at d1. 
Disruption caused 
by MJDtrQ78 was 
significantly sup-
pressed by 
activation of 
Hsp104 at d1. In contrast, Hsp70 or the inactive Hsp104DPLDWB did not significantly impact the 
progression of pathology. To quantify degeneration within the retina, the percentage of a standard 
area covered by tissue was measured by ImageJ (n=6 (mean ± SD)) (see also Fig 2-9). *p<0.05, 
**p=0.001-0.01. 
(B) The progression of toxicity of MJDtrQ78 was also significantly altered by sequential activation 
of Hsp104 later in the degenerative process, on d3. Quantification of tissue as above (n=6 (mean 
± SD)). **p=0.001-0.01.  
 
 
 
Figure 2-10  
Progressive 
MJDtrQ78 
pathogenicity can 
be suppressed by 
expression of 
Hsp104 after 
onset of 
degeneration. 
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(A and B) SDD-AGE 
and immunoblot 
analysis show the 
progression of amyloid 
formation of gmr-
MJDtrQ78 over time. 
Drug activation of 
disaggregase or 
chaperone at the early 
time point of d1 (A) 
shows that induced 
Hsp104 expression 
significantly increased 
amyloid load by d7. 
Hsp70 had no 
significant impact on 
amyloid levels. 
Activation of the 
molecules at later time 
point d3 (B) 
demonstrated that 
neither Hsp104 nor 
Hsp70 affected 
amyloid load. 
MJDtrQ78 was 
detected using anti-HA 
antibody with anti-
tubulin as a loading 
control. Band density 
for both amyloid 
smears (SDD-AGE) and soluble bands (Western blot) were quantified using ImageJ (n=3 (mean 
± SEM)). *p<0.05; Statistics indicate comparison to the disease protein alone at each timepoint. 
(C) Representative densitometry traces of the SDD-AGE amyloid immunoblots, as in A, show the 
distribution of amyloid species resolved by size. After HSP activation at d1, the distribution of 
MJDtrQ78 amyloid accumulations exposed to Hsp104 shifts downward by d3 (red trace), 
compared to the control (black) and Hsp70 (green) profiles. The densitometry analysis was 
performed in ImageJ and the effect was reproducible among three independent replicates. 
 
 
Figure 2-11  Hsp104 
does not mitigate 
disease progres-
sion by clearing 
MJDtrQ78 amyloid 
fibrils. 
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DISCUSSION  
 
Here, we reveal key novel insights into the efficacy and interactions of Hsp104 with the 
pathogenic PolyQ protein MJD. Our studies reveal the surprising finding that Hsp104 
interacts differentially with different forms of the MJD protein. Hsp104 is a potent 
suppressor of toxicity of the truncated protein, but an enhancer of toxicity of the full-
length protein. These differences are determined by specific domains of MJD that are 
not directly implicated in aggregation. Our findings have also uncovered a heretofore 
unrecognized and important application of Hsp104 in vivo, which is its ability to mitigate 
the course of protein-aggregation disease even after it has already initiated. Indeed, our 
studies show that Hsp104 is able to mitigate disease progression once it has begun, 
unlike the classical metazoan chaperone Hsp70. These studies provide new insight into 
the in vivo effects of Hsp104 in the context of a therapeutic agent. 
 
Hsp104 has opposite effects on two constructs of the same disease protein 
 
Our detailed investigations of the effects of Hsp104 on the MJD protein led to the 
unexpected result that Hsp104 has opposite effects on the toxicity of different versions of 
the MJD protein (MJDtrQ78 and MJDnQ78), despite the fact that these proteins contain 
the same pathogenic PolyQ stretch. These disparate actions indicate that Hsp104 might 
be a useful probe to understand the nature of aggregates and the toxicity imposed by 
them. Hsp70 suppressed both MJDtrQ78 aggregation and toxicity (Fig 2-2E, 2-3C). By 
contrast, Hsp104 mitigated toxicity of MJDtrQ78 without suppressing the extent of 
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MJDtrQ78 aggregation (Fig 2-2C, 2-3C). This result suggests that MJDtrQ78 
aggregation per se need not be deleterious. Uncoupling of aggregation and toxicity has 
also been observed in other settings. For example, numerous genetic suppressors of 
FUS and TDP-43 toxicity, which are connected with amyotrophic lateral sclerosis and 
frontotemporal dementia, rescue toxicity without affecting FUS or TDP-43 aggregation in 
yeast (Ju et al., 2011, Sun et al., 2011, Armakola et al., 2012). We suggest that Hsp104 
likely mitigates toxicity of MJDtrQ78 accumulations via subtle biochemical changes 
rather than gross changes in aggregation levels. 
 
What might these biochemical changes be? Hsp104 can disrupt toxic soluble oligomers 
of various proteins, including Sup35, which may help explain why Sup35 prion formation 
is not intrinsically toxic to yeast (Shorter and Lindquist, 2004, 2005, 2006, Lo Bianco et 
al., 2008, DeSantis et al., 2012). Thus, Hsp104 might eliminate toxic soluble oligomers 
formed by MJDtrQ78 just as it does for Sup35 and alpha-synuclein. Furthermore, the 
amyloid-remodeling activity of Hsp104 can selectively amplify some amyloid strains (i.e. 
different cross-β structures formed by the same polypeptide) at the expense of others 
(DeSantis and Shorter, 2012). Given that PolyQ can access both toxic and benign 
amyloid strains (Nekooki-Machida et al., 2009), it is plausible that the presence of 
Hsp104 might amplify benign amyloid strains of MJDtrQ78 at the expense of toxic 
strains (Nekooki-Machida et al., 2009, DeSantis and Shorter, 2012). Indeed, we 
observed that Hsp104 activity visibly altered the distribution of MJDtrQ78 amyloid 
species (Fig 2-11C), suggesting that Hsp104 may be selectively eliminating certain fibril 
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strains. Finally, to promote toxicity amyloid structures typically sequester large 
metastable proteins with unstructured regions, which occupy key nodes in functional 
networks linked to transcription, translation, chromatin organization, cell structure, and 
proteostasis (Olzscha et al., 2011, Vabulas and Hartl, 2011). Hsp104 might disaggregate 
and rescue these proteins sequestered by MJDtrQ78 amyloid or promote the formation 
of MJDtrQ78 amyloid strains that do not deplete such an essential constellation of 
proteins. Further studies are needed to distinguish these non-mutually exclusive 
possibilities. 
 
In other settings, it has been suggested that chaperone-initiated formation of large, 
insoluble amyloid aggregates can actually be protective by sequestering potentially toxic 
pre-fibrillar conformers (Dobson, 2003, Douglas et al., 2008, Wolfe and Cyr, 2011). Our 
results, however, indicate that, at least for Hsp104-driven enhancement of MJDnQ78, 
increased and accelerated aggregation is more toxic than MJDnQ78 aggregation that 
occurs in the absence of Hsp104. Our findings illustrate the complex relationship 
between aggregation and toxicity, which likely extends to other neurodegenerative 
disease models (Wolfe and Cyr, 2011). Moreover, our studies suggest that cautious 
interpretation is required when translating findings from cell culture experiments to 
neurodegeneration in animal models (Carmichael et al., 2000, Vacher et al., 2005). 
Although Hsp104 is not found in the metazoan proteostasis network, our observations 
could help inform how to manipulate existing components of the metazoan proteostasis 
network for therapeutic purposes. Thus, components that suppress MJDnQ78 
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aggregation are likely beneficial, whereas MJDtrQ78 toxicity can be mitigated without 
having to suppress MJDtrQ78 aggregation. 
 
Moreover, our findings demonstrate that an agent with a mitigating effect on the 
truncated version of the MJD protein may act in a different manner against the full-length 
MJD protein. Thus, what is good for one may not be beneficial to the other. In 
MJD/SCA3, as well as other neurodegenerative diseases, fragmentation of the disease 
protein may initiate aggregation and this process is critical for disease progression 
(Wellington et al., 1998, Graham et al., 2006, Haacke et al., 2007, Jung et al., 2009). 
Therefore, agents that effectively eliminate one specific sub-population of toxic protein 
accumulation but enhances another toxic sub-population may not be therapeutically 
viable in the complicated mixed populations that occur in disease. Our results highlight 
the complexity in developing therapeutic agents for neurodegenerative disorders. 
 
Protein context is critical in evaluating disease-associated proteins 
 
Although Hsp104 enhances MJDnQ78 amyloidogenesis and toxicity, we found that 
elimination of functional domains not implicated in PolyQ aggregation facilitated the 
ability of Hsp104 to suppress MJD-associated degeneration. Elimination of UIM 
functionality or removal of a component of the Josephin domain (exon 2) restored the 
remodeling capacity of Hsp104. This suggests that MJDnQ78 pathogenicity is not 
intrinsically intractable, but is capable of being suppressed by Hsp104 if other domains 
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of the protein are inactivated (e.g., the UIMs). Alternatively, potentiated or MJDnQ78-
optimized Hsp104 variants might be developed that are able to overcome these 
hindrances via increased unfolding power (Vashist et al., 2010, DeSantis et al., 2012).  
 
Our studies underscore the importance of protein context in studying protein-misfolding 
diseases. Within the protein itself, neighboring domains not thought to be involved in 
aggregation may be impacting accumulation kinetics and the biochemical properties of 
inclusions, as well as accessibility of the aggregation domain to potential disaggregase 
therapeutics. That Hsp104 efficiently mitigates toxicity of MJD variants with ubiquitin-
binding defects also demonstrates that, in addition to protein context, the cellular context 
of the protein is critical to consider; for example, the interaction between poly-ub chains 
and MJD may hinder Hsp104. 
 
Previous studies in vitro have characterized aggregation of the full-length, pathogenic 
MJD protein as a two-step process in which the protein assembles first into SDS-soluble 
fibrillar polymers associating via the Josephin domain, and then converts to SDS-
insoluble amyloid fibers driven by the PolyQ domain (Masino et al., 2004, Ellisdon et al., 
2006, Ellisdon et al., 2007, Masino et al., 2011). We propose that this two-step process 
occurs in vivo as well. Indeed, it is consistent with our observation that full-length 
MJDnQ78 forms amorphous accumulations that appear visually by IHC before they can 
be observed as SDS-insoluble amyloid aggregates by SDD-AGE (see Fig 2-3B and D). 
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We suspect that full-length MJD initially forms SDS-soluble, Josephin-driven non-
amyloid accumulations that initiate Hsp104 remodeling.  
 
The initial formation of non-amyloid polymers is also compatible with our model of 
Hsp104 interacting differentially with the “open” and “closed” conformations of the protein 
discussed above (see Fig 2-7B). We hypothesize that a poly-ub chain creates the closed 
loop by mutually interacting with the UIMs and the flexible helical hairpin encoded by 
exon 2 in the Josephin domain (Fig 2-6B), as this arm is thought to be important for 
interacting with substrates (Nicastro et al., 2005). Further experiments are required to 
confirm a poly-ub-mediated interaction between the two domains. According to our 
model, Hsp104 is able to efficiently translocate and release proteins that are more 
flexible (e.g., MJD-Q80-UIM*), resulting in fewer aggregates (see Fig 2-5B). But due to 
an inflexible conformation imposed by the UIMs and the Josephin domain, Hsp104 is 
unable to efficiently remodel proteins containing the closed loop (e.g., MJDnQ84). This 
incomplete or slow translocation may expose or “prime” the PolyQ region to drive the 
formation SDS-insoluble amyloid inclusions (see Fig 2-3D, Fig 2-5C).  
 
Our model suggests that the UIMs and the Josephin domain act together to obstruct 
Hsp104 remodeling, but we cannot rule out a separate function of the Josephin domain 
outside of poly-ub interactions. For example, removal of 55 amino acids might 
destabilize the Josephin domain such that it gets proteolytically cleaved and Hsp104 
would then encounter a protein similar to MJDtrQ78 and rescue toxicity. Alternatively, 
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because the MJD-Q79-Δexon2 protein could not be detected by biochemical methods, 
we cannot exclude the possibility that the deletion within the Josephin domain disrupts 
the proposed process of Josephin-domain-driven polymerization. In this case, toxicity of 
this variant may be dependent on highly soluble, possibly oligomeric species, which are 
effectively targeted by Hsp104. 
 
These findings indicate that there is an opportunity to tailor therapies that are optimized 
for a specific disease scenario. In the case of full-length MJD, if inefficient translocation 
by Hsp104 does indeed drive the switch from less toxic SDS-soluble aggregates to 
highly toxic SDS-insoluble amyloid inclusions, then the development of substrate-
optimized Hsp104 mutants (or Hsp104 mutants with altered ATPase rates or unfolding 
power) may increase efficiency of such interactions and enable Hsp104 to rescue 
disease phenotypes. Moreover, if UIM binding to poly-ub chains is impairing access of 
Hsp104 to MJD, this suggests that co-administering an agent to modulate function of a 
neighboring domain may affect the access of a treatment to the aggregation-prone 
domain. Indeed, increasing global DUB activity coupled with Hsp104 induction could 
overcome antagonism due to poly-ub chains. 
 
Implications for Hsp104 as a therapeutic agent 
 
Chaperone treatment, and examination of Hsp70 in particular, has been an exciting 
avenue of research in the battle to combat and contain neurodegenerative disease 
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(Muchowski and Wacker, 2005, Broadley and Hartl, 2009). However, all studies 
investigating Hsp70 as a modulator of disease have looked only at the chaperone 
transgenically co-expressed or activated prior to the disease insult. In a study seeking to 
activate existing Hsp70 rather than introducing exogenic expression, researchers sought 
to evaluate the chaperone in a mouse model of PD by boosting endogenous Hsp70 
expression by treating animals with geldanamycin (Shen et al., 2005). While this 
procedure has the potential to test true reversal of disease course, the authors found 
that beneficial effects were only observed if upregulation of Hsp70 was initiated prior to 
pharmacological induction of the PD phenotype (Shen et al., 2005). In fact, in a cell 
culture PD model, geldanamycin was required at least 24 hours prior to disease protein 
transfection to provide any protection against inclusion formation (McLean et al., 2004). 
In addition, pharmacologic activation of Hsp70 has been shown to suppress both PD 
and PolyQ disease in Drosophila (Auluck and Bonini, 2002, Wang et al., 2012), but 
again, these manipulations were performed prior to disease onset. Despite the existing 
pharmacological paradigms, and other genetic tools available, such as the tetracycline-
inducible system in mouse, no group has evaluated specific chaperone or disaggregase 
expression induced subsequent to expression of a disease-associated protein. 
  
An inducible system is particularly well suited for Hsp104 because of its unique ability to 
rapidly dismantle pre-existing amyloid aggregates. Since metazoan chaperones can only 
very slowly depolymerize amyloid (Duennwald et al., 2012), Hsp104 may be more 
effective in an environment with pre-existing aggregation than a chaperone such as 
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Hsp70, which is more adapted to prevent the initial aggregation. Here, we address the 
value of temporally controlled induction of disaggregase function after the initiation of 
PolyQ protein aggregation and the beginning of disease progression. To our knowledge, 
previous research has been performed with concomitant expression of a therapeutic 
gene, and thus does not distinguish prevention of disease from halting the progression of 
the disease state. Neurodegenerative diseases are not detected until later in life, and 
symptoms may not be apparent until pathological damage has accumulated beyond a 
tolerable point (Davies et al., 1997, Naslund et al., 2000, Braak et al., 2003). Thus, an 
agent that can rapidly impact the existing trajectory would be more valuable than one 
that can only prevent the development of the disease. 
 
Our experimental paradigm offers the exciting possibility to address the efficacy of 
Hsp104 (or other molecules) in a more genuine therapeutic setting. Indeed, we found 
that turning on Hsp104 was able to significantly suppress disease-associated 
degeneration. Interestingly, however, Hsp104 did not disaggregate MJDtrQ78 amyloid in 
these experiments (Fig 2-11A, B). Thus, Hsp104 might mitigate disease progression in 
this setting by: (a) eradicating toxic soluble MJDtrQ78 oligomers, (b) amplifying benign 
amyloid forms of MJDtrQ78 at the expense of toxic MJDtrQ78 amyloid, (c) by 
disaggregating and rescuing essential metastable proteins sequestered by MJDtrQ78 
aggregates. Our observation that activation of Hsp104 shifted the MJDtrQ78 amyloid 
smears resolved by SDD-AGE toward smaller species without eliminating the total 
amyloid population (Fig 2-11C) suggests that Hsp104 may indeed have strain selectivity. 
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Further studies are required to define precisely how Hsp104 mitigates disease 
progression. Our data show that Hsp70 induction after MJD-associated degeneration 
has already initiated was unable to significantly mitigate disease progression. 
Optimization of Hsp70 expression, or administration of the suite of chaperones (for 
example, Hsp70 with Hsp110 and Hsp40), may improve the outcome, but our findings 
are consistent with other reports that Hsp70 must be administered before disease 
initiation to have a positive effect (McLean et al., 2004, Shen et al., 2005). Our 
observation that even a later-onset induced expression of Hsp104 is able to significantly 
suppress progressive PolyQ degeneration suggests that it is possible to mitigate disease 
phenotypes even after aggregates have begun accumulating and marked pathological 
degeneration is underway. 
 
Naturally, several barriers must be surmounted to translate Hsp104 into a therapeutic 
agent for human neurodegenerative disease (Shorter, 2008, Vashist et al., 2010). Not 
least is the issue that gene therapy might be required to introduce Hsp104 (or any other 
genetic modifier) as a therapeutic agent. Gene therapy has yielded encouraging 
preclinical results for several disorders including congenital blindness (Hacein-Bey-Abina 
et al., 2002, Bainbridge et al., 2008, Maguire et al., 2008). However, technical and safety 
issues restrict facile translation to the clinic. Indeed, gene therapy for neurodegenerative 
diseases remains in early developmental stages and considerable caution is essential at 
this time. However, initial studies have generated cautious optimism that gene therapy in 
the adult brain might be safe for various neurodegenerative disorders, including 
Parkinson’s disease (Feigin et al., 2007, Kaplitt et al., 2007, Stoessl, 2007, San 
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Sebastian et al., 2013, Simonato et al., 2013). Thus, even though we await several key 
advances before any Hsp104 gene therapy (or any other gene therapy) becomes truly 
viable it is, nonetheless, important to develop solutions to protein misfolding and to test 
these solutions both in vitro and in the most appropriate animal models. Moreover, the 
fact that Hsp104 is well tolerated by mammalian systems is encouraging (Carmichael et 
al., 2000, Mosser et al., 2004, Vacher et al., 2005, Dandoy-Dron et al., 2006, Perrin et 
al., 2007, Lo Bianco et al., 2008). Ultimately, we envision that only transient expression 
of Hsp104 (or a substrate-optimized variant) would be required to provide therapeutic 
benefit. In this way, long-term expression of an exogenous agent and potential off-target 
side effects would be minimized. Alternatively, methods could be developed to deliver 
pure Hsp104 (or a substrate-optimized variant) to targeted areas in a single or multiple 
doses, and thereby avoid issues connected with long-term expression. These various 
issues and others highlight the complexities of designing therapeutics to treat human 
neurodegenerative disease. 
 
Finally, the concept of using a yeast protein as the basis for a therapeutic agent might at 
first glance seem implausible. However, it must also have seemed equally implausible to 
use a lethal protein toxin from the bacterium, Clostridium botulinum, as a therapeutic 
agent. Despite being a deadly toxin, botulinum toxin variants have found key clinical 
applications due to their highly potent and selective ability to cleave SNARE proteins and 
prevent secretion (Schiavo et al., 1992). Importantly, they are used to treat a variety of 
neuromuscular disorders including: blepharospasm, strabismus, muscle spasms, upper 
motor neuron syndrome, cervical dystonia and chronic migraine (Bentivoglio and 
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Albanese, 1999, Hallett, 1999, Osborne et al., 2007, Elia et al., 2009, Esquenazi et al., 
2009, Yeh et al., 2011). Indeed, the massive clinical success of botulinum toxin variants 
suggests it is critical to identify potentially therapeutic biological activities that originate in 
the microbial world and utilize and develop them to treat human disease. 
 
MATERIALS AND METHODS 
 
Drosophila transgenic lines and crosses 
Transgenic flies expressing UAS-Hsp104 and UAS-Hsp104DPLDWB were generated by 
standard techniques using the pUAST vector (Brand and Perrimon, 1993). In order to 
boost expression of the transgene, pUAST-Hsp104 was codon-optimized for expression 
in Drosophila and a Kozak sequence (ACAAA) was added prior to the start codon (Trinh 
et al., 2008).  
 
The full sequence of codon-optimized Hsp104 is: 
ATGAACGATCAGACCCAGTTCACCGAGCGCGCCCTGACCATCCTGACCCTGGCCCA
GAAGCTGGCCAGCGATCACCAGCACCCCCAGCTGCAGCCCATCCACATCCTGGCC
GCCTTCATCGAGACCCCCGAGGATGGCAGCGTGCCCTACCTGCAGAACCTGATCG
AGAAGGGCCGCTACGATTACGATCTGTTCAAGAAGGTGGTGAACCGCAACCTGGTG
CGCATCCCCCAGCAGCAGCCAGCCCCAGCCGAGATCACCCCAAGCTACGCCCTGG
GCAAGGTGCTGCAGGATGCCGCCAAGATCCAGAAGCAGCAGAAGGATAGCTTCAT
CGCCCAGGATCACATCCTGTTCGCCCTGTTCAACGATAGCAGCATCCAGCAAATCTT
CAAGGAGGCCCAGGTGGATATCGAGGCCATCAAGCAGCAGGCCCTGGAGCTGCGC
GGAAACACCCGCATCGATAGCCGCGGAGCCGATACCAACACCCCCCTGGAGTACC
TGAGCAAGTACGCCATCGATATGACCGAGCAGGCCCGCCAGGGAAAGCTGGACCC
AGTGATCGGACGCGAGGAGGAGATCCGCAGCACCATCCGCGTGCTGGCCCGCCG
CATCAAGAGCAACCCATGCCTGATCGGAGAGCCAGGAATCGGCAAGACCGCCATC
ATCGAGGGAGTGGCCCAGCGCATCATCGATGATGATGTGCCAACCATCCTGCAGG
GAGCCAAGCTGTTCAGCCTGGATCTGGCCGCCCTGACCGCCGGCGCCAAGTACAA
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GGGCGATTTCGAGGAGCGCTTCAAGGGCGTGCTGAAGGAGATCGAGGAGAGCAAG
ACCCTGATCGTGCTGTTCATCGATGAGATCCACATGCTGATGGGCAACGGCAAGGA
TGATGCCGCCAACATCCTGAAGCCAGCCCTGAGCCGCGGACAGCTGAAGGTCATC
GGAGCCACCACCAACAACGAGTACCGCAGCATCGTGGAGAAGGATGGAGCCTTCG
AGCGCCGCTTCCAGAAGATCGAGGTGGCCGAGCCAAGCGTGCGCCAGACCGTGGC
CATCCTGCGCGGACTGCAGCCCAAGTACGAGATCCACCACGGCGTGCGCATCCTG
GATAGCGCCCTGGTGACCGCCGCCCAGCTGGCCAAGCGCTACCTGCCATACCGCC
GCCTGCCAGATAGCGCCCTGGATCTGGTGGATATCAGCTGCGCCGGAGTGGCCGT
GGCCCGCGATAGCAAGCCAGAGGAGCTGGATAGCAAGGAGCGCCAGCTGCAGCTG
ATCCAGGTGGAGATCAAGGCCCTGGAGCGCGATGAGGATGCCGATAGCACCACCA
AGGATCGCCTGAAGCTGGCCCGCCAGAAGGAGGCCAGCCTGCAGGAGGAGCTGG
AGCCACTGCGCCAGCGCTACAACGAGGAGAAGCACGGCCACGAGGAGCTGACCCA
GGCTAAGAAAAAGCTGGATGAGCTGGAGAACAAGGCCCTGGATGCCGAGCGCCGC
TACGATACCGCCACCGCCGCCGATCTGCGCTACTTCGCCATCCCCGATATCAAGAA
GCAGATCGAGAAGCTGGAGGATCAGGTGGCCGAGGAGGAGCGCCGCGCCGGCGC
CAACAGCATGATCCAGAACGTGGTGGATAGCGATACCATCAGCGAGACCGCCGCC
CGCCTGACCGGCATCCCCGTGAAGAAGCTGAGCGAGAGCGAGAACGAGAAGCTGA
TCCACATGGAGCGCGATCTGAGCAGCGAGGTGGTGGGCCAGATGGATGCCATCAA
GGCCGTGAGCAACGCCGTGCGCCTGAGCCGCAGCGGACTGGCCAACCCACGCCA
GCCAGCCAGCTTCCTGTTCCTGGGCCTGAGCGGCAGCGGCAAGACCGAGCTGGCC
AAGAAGGTGGCCGGCTTCCTGTTCAACGATGAGGATATGATGATCCGCGTGGATTG
CAGCGAGCTGAGCGAGAAGTACGCCGTGAGCAAGCTGCTGGGCACCACCGCCGG
CTACGTGGGCTACGATGAGGGCGGCTTCCTGACCAACCAGCTGCAGTACAAGCCC
TACAGCGTGCTGCTGTTCGATGAGGTGGAGAAGGCCCACCCCGATGTGCTGACCG
TGATGCTGCAGATGCTGGATGATGGCCGCATCACCAGCGGCCAGGGCAAGACCAT
CGATTGCAGCAACTGCATCGTGATCATGACCAGCAACCTGGGCGCCGAGTTCATCA
ACAGCCAGCAGGGCAGCAAGATCCAGGAGAGCACCAAGAACCTGGTCATGGGCGC
CGTGCGCCAGCACTTCCGCCCCGAGTTCCTGAACCGCATCAGCAGCATCGTGATCT
TCAACAAGCTGAGCCGCAAGGCCATCCACAAGATCGTGGATATCCGCCTGAAGGAG
ATTGAGGAGCGCTTCGAGCAGAACGATAAGCACTACAAGCTGAACCTGACCCAGGA
GGCCAAGGATTTCCTGGCCAAGTACGGCTACAGCGATGATATGGGCGCCCGCCCC
CTGAACCGCCTGATCCAGAACGAGATCCTGAACAAGCTGGCCCTGCGCATCCTGAA
GAACGAGATCAAGGATAAGGAGACCGTGAACGTGGTGCTGAAGAAGGGCAAGAGC
CGCGATGAGAACGTGCCAGAGGAGGCCGAGGAGTGCCTGGAGGTGCTGCCAAACC
ACGAGGCCACCATCGGAGCCGATACCCTGGGCGATGATGATAACGAGGATAGCAT
GGAGATCGATGATGATCTGGATTAA 
 
Multiple insertion lines were characterized for each transgene. To create the 1×gr-GAL4 
driver line, the pGMR (glass multimer reporter) vector (Hay et al., 1994) was digested by 
XhoI/Acc651 to remove the insert containing five glass-binding sites.  Complementary 
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oligonucleotides (5ʼ-TCGAACCCAGTGGAAACCCTTGAAATGCCTTTAACTCGAGACG 
G-3ʼ and 5ʼ-GTACCCGTCTCGAGTTAAAGGCATTTCAAGGGTTTCCACTGGGT-
3ʼ), with a single copy of the 31 bp glass-binding site from the Rh1 proximal enhancer, 
were duplexed and ligated into the vector, producing p1×GR (1 copy of glass 
reporter).  This plasmid was then modified to introduce the GAL4 coding sequence, 
excised from pGaTN (Brand and Perrimon, 1993) with HindIII, to create p1×gr-GAL4. 
MJD lines are from (Warrick et al., 2005). Experiments were performed at 25ºC except 
for a select few 
conducted at 29ºC 
as indicated. All 
results were 
confirmed with 
multiple UAS-
Hsp104 insertion 
lines (Fig 2-12). 
 
Key genetic 
interactions were 
confirmed with the 
1xgr-Gal4 driver and 
two independent 
Hsp104 transgenic 
lines with similar expression levels, 2.1 (3) and 4.1 (X). Both Hsp104 lines suppressed toxicity of 
truncated MJD (MJDtrQ78 and MJDtrQ92) and MJD-Q79Δexon2, worsened toxicity of MJDnQ78, 
and had no effect on MJD-Q88.C14A.  Images from 1xgr-Gal4 and 1xgr-Gal4; Hsp104 2.1 rows 
are also used in previous figures. 
 
Figure 2-12  
Confirmation of 
Hsp104 interaction 
with key MJD lines. 
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Evaluation of eye degeneration 
Eye images were obtained on day 7 of adulthood using a Leica Z-16 apo zoom 
microscope. To view internal retinal structure, heads were embedded in paraffin 
according to standard protocols, sectioned at 8 µm, and autofluorescence was viewed 
with a Leica fluorescence microscope. To quantify tissue loss, a standard area (3×15 
rectangle; 7,000 µm2) (see also Fig 2-9) was selected within the paraffin retinal section 
and the percentage of area covered by tissue was measured in ImageJ. Statistical 
analysis was performed using one-way ANOVA and unpaired t-test. 
 
Cryosections and immunohistochemistry 
Heads were frozen in Tissue Freezing Medium (Electron Microscopy Sciences) and 
sectioned at 12 µm by cryotome, and the tissue sections were then fixed with 4% 
paraformaldehyde. Immunohistochemistry was performed according to standard 
procedures using primary antibodies anti-HA 5B1D10 (1:100, Invitrogen 32-6700) or 
anti-myc 9E10 (1:100, Santa Cruz sc-40) (both mouse) alongside either anti-Hsp104 
(1:100, Enzo Life Sciences ADI-SPA-1040) or anti-Hsp70 (1:100, Enzo Life Sciences 
ADI-SPA-812) (both rabbit). Hsp70 staining was confirmed with human-specific anti-
Hsp70 (1:100, Santa Cruz sc-24) (mouse) alongside anti-HA Y11 (1:100, Santa Cruz sc-
805) or anti-myc A14 (1:100, Santa Cruz sc-789) (both rabbit). Rabbit primary antibodies 
were preadsorbed at 1:25 with fixed, dissected wild-type larvae. Secondary antibodies 
were Alexa Fluor 594 Goat-anti-Mouse IgG (1:100, Life Technologies A-11032), Alexa 
Fluor 488 Goat-anti-Rabbit IgG (1:100, Life Technologies A-11008), Alexa Fluor 594 
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Goat-anti-Rabbit IgG (1:100, Life Technologies A-11037), and Alexa Fluor 488 Goat-
anti-Mouse IgG (1:100, Life Technologies A-11029). Sections were co-stained with 
Hoechst nuclear dye (1:1000, Molecular Probes 33342) and viewed with a Leica 
fluorescence microscope. A 75 µm × 75 µm square (5625 µm2) area was selected; 
particle analysis was performed with ImageJ and statistics performed with one-way 
ANOVA and unpaired t-test. 
 
Immunoblots and SDD-AGE  
For Hsp104 expression level characterization, heads were ground with a pestle in 
NuPage LDS Sample Buffer, boiled for 3 min, run on NuPage 4-12% Bis-Tris gel, and 
semi-dry transferred onto nitrocellulose membrane. Antibodies used were anti-Hsp104 
(1:2000, Enzo Life Sciences ADI-SPA-1040) and anti-actin (1:2000, Abcam ab8227) with 
secondary antibody Goat-anti-Rabbit-HRP (1:5000, Chemicon AP307P). For MJD 
aggregation analysis through SDD-AGE (Semi-Denaturing Detergent Agarose Gel 
Electrophoresis) and accompanying Western immunoblots, heads were ground in lysis 
buffer (100 mM Tris pH 7.5, 50 mM NaCl, 10 mM β-Mercaptoethanol, and Roche 
complete mini EDTA-free protease inhibitor cocktail tablets) (Halfmann and Lindquist, 
2008) and an aliquot was taken for evaluation of soluble material by Western 
immunoblot, as above. To the remaining sample, 4X Sample Buffer (2X TAE, 20% 
glycerol, 8% SDS, bromophenol blue) was added to final concentration 1X. The samples 
were run on a 1.5% agarose gel with 0.1% SDS in a running buffer of 1X TAE (40 mM 
Tris, 20 mM Acetic acid, 1 mM EDTA, pH 8.3) containing 0.1% SDS, and then 
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transferred overnight onto nitrocellulose membrane using downward capillary transfer 
(Halfmann and Lindquist, 2008). Antibodies used were anti-HA-conj-HRP 3F10 (1:500, 
Roche 12013819001), anti-myc 9E10 (1:500, Santa Cruz sc-40) followed by Goat-anti-
Mouse-HRP (1:2000, Jackson ImmunoResearch 115-035-146), and anti-tubulin-conj-
HRP (1:1000, Cell Signaling 11H10). All immunoblots were imaged using a FujiFilm 
LAS-3000 imaging system and quantification was performed in ImageJ and statistically 
analyzed by one-way ANOVA and unpaired t-test. 
 
Gene switch protocol 
A 4.0 mg/ml stock solution of RU486 (Sigma M8046) was prepared in 100% ethanol, and 
then 50 µl (200 µg) was added to pre-prepared food vials containing ~12 ml of food and 
gently shaken overnight (Shen et al., 2009). For control conditions, 50 µl of 100% 
ethanol was added to vials. Adult flies were aged in food treated with either RU486 or 
ethanol for the time periods indicated. 
 
ADDENDUM 
 
To begin, clarification of the term “amyloid” is required.  In this manuscript, the term is 
used to describe accumulated protein material that is resistant to 2% SDS and therefore 
resolves as a high molecular weight smear by SDD-AGE.  However, to define this 
aggregated material as amyloid rigorously by biochemical and other criteria, further 
techniques are needed to confirm the presence of the cross-β conformation.  The 
diagnostic amyloid-binding dyes Congo Red (CR) and Thioflavin-S (ThS) would be 
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useful in making this distinction.  Amyloid material stained with CR shows apple-green 
birefringence under polarized light, while ThS increases fluorescence when bound to 
amyloid in tissue (Kelenyi, 1967, Klunk et al., 1989, LeVine, 1993).  Additionally, tissue 
containing amyloid material exhibits inherent birefringence (Sipe and Cohen, 2000).  The 
technique of X-ray diffraction is also instructive, as amyloid fibrils give a characteristic 
diffraction pattern consistent with β-sheets running perpendicular to the fibril axis (Sunde 
et al., 1997).  Visual examination of the tissue by EM may also be informative, as 
amyloid fibrils appear as a non-branching linear structure (Cohen and Calkins, 1959).  
Moreover, even without the detection equipment required to analyze the previous 
techniques, sequential extraction of the protein inclusions can inform on the stability of 
the aggregates.  Thus, following solubilization in 2% SDS used in our SDD-AGE 
experiments, further treatment of the eye tissue in increasing concentrations of formic 
acid could be used to determine the properties of existing amyloid species by these 
additional criteria (Rostagno and Ghiso, 2009). Thus, our usage of the term applies 
specifically to the properties of the protein material in response to SDS; additional 
characterization as outlined above is needed to extend these initial findings to confirm 
that the protein inclusions are truly amyloid in nature.  
 
Next, because we used the general eye-specific 1xgr-Gal4 driver to evaluate eye toxicity 
in the retina and the photoreceptor-specific driver rh1-Gal4 to examine protein 
aggregation in the adult in a subset of retinal cells, we wanted to confirm that the finding 
regarding the distinct interactions of Hsp104 with MJDtrQ78 and MJDnQ78 were 
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applicable to both situations.  As such, we determined toxicity with the rh1-Gal4 system 
to accompany the protein aggregation data (see Fig 2-3), and evaluated protein 
aggregation in the 1xgr-Gal4 system to accompany the existing toxicity results (see Fig 
2-2). 
 
First, we evaluated toxicity of the disease proteins to the photoreceptor cells using the 
rh1-Gal4 driver.  Using the pseudopupil assay to shine light through the flyʼs eye, one 
can quantify the loss of rhabdomere structure because intact photoreceptor cells 
illuminate as red while disrupted cells do not. The photoreceptors cluster into 
stereotypical ommatidial patterns containing seven photoreceptors in each ommatidium.  
As such, 100% of ommatidia examined for control flies contain seven photoreceptors per 
cluster, indicating that there is no toxicity in this condition (Fig 2-13A).  Consistent with 
our 1xgr-Gal4 results, Hsp70 displayed no toxicity when expressed with rh1-Gal4 (Fig 2-
13A).  Similarly, Hsp104 on its own had no toxicity to the photoreceptor cells (Fig 2-13A); 
this is in contrast to our observations of Hsp104 toxicity upon expression with gmr-Gal4 
or 1xgr-Gal4 (Fig 2-1A).  Because rh1-Gal4 is an adult-onset driver, we interpret this to 
reflect that developing cells are more sensitive to disruption by expression of Hsp104.   
 
Expression of the disease protein MJDtrQ78 was very toxic to photoreceptor cells, with a 
mean number of 4.52 ± 0.28 photoreceptor cells per ommatidium (Fig 2-13B).  Co-
expression of Hsp104, with a mean of 3.90 ± 0.20, did not significantly impact toxicity 
(Fig 2-13B, p=0.09).  MJDnQ78 was less toxic, with a mean of 6.72 ± 0.07 
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photoreceptors per ommatidium (Fig 2-13C).  Hsp104 co-expression significantly 
enhanced toxicity, with now only 2.60 ± 0.17 photoreceptors per ommatidium (Fig 2-13C, 
p<0.001).  Hsp70 significantly suppressed toxicity of both disease proteins (Fig 2-13B, 
p<0.001, Fig 2-1C, p=0.002).  These results generally reflected the trends in toxicity we 
observed for the 1xgr-Gal4 driver, although we did not confirm the trend of Hsp104-
mediated suppression of MJDtrQ78 toxicity. 
 
The pseudopupil assay, performed 
by expressing disease protiens 
with the rh1-Gal4 driver and 
examining at d18, quantifies the 
number of intact photoreceptor 
neurons in each ommatidial 
cluster.  (A) Control flies and those 
expressing Hsp104 or Hsp70 
alone had no loss of photoreceptor 
rhabdomeres, indicating that these 
proteins have no toxicity.  (B)  
MJDtrQ78 showed strong toxicity 
and Hsp104 co-expression did not 
significantly alter photoreceptor 
loss.  However, Hsp70 strongly 
suppressed MJDtrQ78 toxicity.  (C)  
MJDnQ78 had milder toxicity, but 
Hsp104 co-expression significantly 
enhanced degeneration of 
photoreceptor cells.  Again, Hsp70 
suppressed toxicity.  The number 
of photoreceptors in each 
ommatidial cluster was evaluated 
by ANOVA (n=10 (mean ± SEM)). 
**p=0.001-0.01, ***p<0.001; 
Statistics compare HSP co-
expression conditions to disease 
protein alone. 
 
Figure 2-13  MJD toxicity to 
photoreceptor neurons 
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Next, we also performed the complementary investigation, evaluating protein 
aggregation in the 1xgr-Gal4 system.  Due to technical limitations, it was not possible to 
perform IHC on these retinas, so we conducted SDD-AGE and Western immunoblot 
analysis.  Our results show that Hsp104 does not alter the overall kinetics of MJDtrQ78 
amyloid aggregation (Fig 2-14A).  We observed that Hsp104 increased the total 
MJDtrQ78 amyloid 
load, but 
hypothesized that 
this may be due to 
increased tissue 
integrity.  To 
address this, we 
normalized to the 
rhodopsin signal as 
an indicator of total 
amount of eye 
tissue and saw that 
there was no 
significant change 
between untreated 
and Hsp104-treated 
MJDtrQ78 amyloid 
Figure 2-14  Aggregate analysis using 1xgr-Gal4 
With the rh1-GAL4 driver at indicated time points, SDD-AGE and 
Western immunoblot analysis show the progression of amyloid formation 
of MJDtrQ78 (A) and MJDnQ78 (B) proteins over time. Hsp104 did not 
greatly affect the aggregation profile of MJDtrQ78 but enhanced 
formation of SDS-insoluble amyloid aggregates of MJDnQ78. The 
formation of large, SDS-insoluble aggregates by SDD-AGE 
corresponded with the disappearance of SDS-soluble soluble protein 
from immunoblots. MJDtrQ78 and MJDnQ78 were detected using anti-
HA and anti-myc, respectively, with anti-rhodopsin as a tissue level 
control and anti-tubulin as a loading control. Band density for both 
amyloid smears (SDD-AGE) and soluble bands (Western blot) were 
quantified using ImageJ; presented both as raw values and as adjusted 
to rhodopsin signal to normalize for tissue level (n=3 (mean ± SEM)). 
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accumulation (Fig 2-14A).  This is consistent with our conclusions presented in the 
Chapter 2, but rh1-Gal4 evaluation of aggregation allows more sensitive observations 
using IHC.   
 
 Our results also show that Hsp104 co-expression greatly increases the rate and extent 
of MJDnQ78 amyloid aggregation (Fig 2-14B).  Again, analysis of rhodopsin levels 
confirms that eye tissue is lost in the Hsp104 condition; however the adjusted MJDnQ78 
amyloid load is still greatly increased upon Hsp104 co-expression (Fig 2-14B).  This is 
consistent with the aggregation pattern as analyzed using the rh1-Gal4 driver.  In 
summary, these data confirm that the conclusions (presented in Chapter 2) drawn from 
1xgr-Gal4-driven eye tissue toxicity and rh1-Gal4-driven protein accumulation analysis 
appear appropriate. 
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CHAPTER 3 : CONCLUSIONS 
 
CONCLUSIONS AND IMPLICATIONS OF HSP104 AS A THERAPEUTIC AGENT. 
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Hsp104 is influenced by the flanking sequence surrounding the PolyQ domain 
 
We have established that Hsp104 and MJD have a profound genetic interaction in 
Drosophila, and that the resulting impact of Hsp104 treatment on the severity of MJD-
driven degeneration may be either ameliorative or detrimental.  Surprisingly, it was not 
the aggregation-prone PolyQ domain that determined the outcome of Hsp104 treatment, 
but, rather, successful remodeling by Hsp104 was dictated by the surrounding domains 
within the MJD protein.  An expansion in the PolyQ region was required for the 
development of MJD toxicity, but Hsp104 could either mitigate or exacerbate MJD-
associated degeneration, depending on protein context.  
 
It is well established that PolyQ flanking sequence is able to influence PolyQ 
aggregation rate (Wetzel, 2012).  For exon 1 of Htt, inclusion of the polyproline 
sequence C-terminal to the PolyQ domain slows amyloid growth and prevents β-sheet 
formation (Richardson and Richardson, 1989, Bhattacharyya et al., 2006, Lakhani et al., 
2010, Dlugosz and Trylska, 2011).  Conversely, the N-terminal region forms α-helical 
conformations that associate into tetramers, which may nucleate PolyQ-mediated 
amyloidogenesis (Thakur et al., 2009, Atwal et al., 2011, Jayaraman et al., 2012, Wetzel, 
2012).  Despite the changes to kinetics conferred by these complex flanking sequences, 
the resulting Htt-exon1 amyloid core has similar biochemical properties to a pure PolyQ 
sequence of same repeat length that is minimally flanked by lysines, K2QNK2 (Thakur et 
al., 2009, Sivanandam et al., 2011).  Therefore, we did not anticipate that flanking 
sequence would impact an agent that disrupts the PolyQ aggregation core. 
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To examine the role of flanking sequence in our studies of the MJD protein, we must 
consider the distinct modulatory outcomes resulting from Hsp104 coexpression.  The 
truncated C-terminal MJD fragment comprised mainly of the expanded PolyQ region 
(MJDtrQ78) caused severe eye toxicity, and co-expression of Hsp104 ameliorated the 
associated retinal degeneration (Fig 2-2).  Hsp104 therefore suppressed toxicity, but did 
not do so by altering the amount of SDS-resistant aggregates formed by MJDtrQ78 (Fig 
2-3).  In contrast, the full-length MJD protein with expanded PolyQ (MJDnQ78) also 
conferred toxicity to the fly eye, but co-expression of Hsp104 strikingly increased the 
severity of the retinal degeneration (Fig 2-2), which corresponded to a dramatic 
acceleration in the formation of MJDnQ78 amyloid-like inclusions (Fig 2-3).  Our results 
reveal that the presence or absence of the N-terminal Josephin domain and UIMs 
dramatically impacted the interaction between MJD and Hsp104.  Because these 
specific experiments were performed with concomitant expression, it is not possible to 
conclude whether Hsp104 is altering early oligomerization stages or differentially 
approaching the PolyQ aggregation core. 
 
Hsp104 efficacy depends on precise protein context 
 
It was unexpected that two variants of the same protein that contain identical 
aggregation domains would have such distinct outcomes following Hsp104 treatment.  
We therefore studied a collection of MJD variants with various functional and structural 
deficiencies to the domains neighboring the PolyQ domain to determine which portions 
of the full-length MJD protein caused Hsp104 to not only fail to suppress toxicity but to 
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enhance it.  Because this set of variants contains domains inactivated through point 
mutations, the role of each domain’s function can be separated from its contribution as a 
flanking sequence. 
 
Because MJD has deubiquitylase (DUB) activity in the N-terminal Josephin domain and 
this is known to contribute to proteostasis, elimination of DUB function confers a more 
severe toxicity than is caused by pathogenic MJD with intact DUB activity (Warrick et al., 
2005).  We examined two separate MJD variants that lack DUB function, through either 
point mutation or exon deletion.  The severe degeneration caused by the MJD variant 
with mutation of the catalytic residue, MJD-Q88-C14A, was not suppressed by co-
expression of Hsp104.  However, the toxicity of MJD with a deletion of exon 2 (a.a. 9-
63), MJD-Q79-Δexon2, which is missing the catalytic residue as well as a large 
structural component of the Josephin domain, was strongly suppressed by Hsp104 (Fig 
2-5).   
 
The distinct outcomes of Hsp104 treatment on DUB-deficient MJD variants inactivated 
by either C14A or Δexon2 modifications indicate that some feature contained within exon 
2 is hindering proper Hsp104 function.  The α-helices α1, α2, and α3 are a large 
structural component of the Josephin domain and are noticeably absent in the Δexon2 
construct (Fig 3-1, gray).  Thus, these helices could be inhibiting Hsp104 due to the 
structural stability conferred by these α-helices.  We think this is unlikely due to Hsp104’s 
ability to remodel an abundance of diverse substrates, but it is possible that the 
presence of these highly stable structures could slow down the Hsp104 enzymatic 
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activity so the remodeling kinetics 
favor increased amyloid-like 
polymerization rather than 
resolubilization.  We think it more 
likely that Hsp104 is impeded by an 
interaction between the flexible 
helical hairpin formed by α2 and α3 
of MJD and a poly-ub chain, which 
may coordinate along this finger-like 
protrusion to enter the active site 
(Fig 3-1, magenta) (Nicastro et al., 
2005).  Thus, without this structural 
component to associate with poly-
ub chains, the MJD-Q79-Δexon2 would be more flexible and therefore amenable to 
Hsp104 remodeling, but MJD-Q88.C14A, with its Josephin domain tethered by a poly-ub 
chain, would not.  
 
It is also worth noting that the initial Josephin-driven oligomerization steps may be 
disrupted upon deletion of the structural component encoded by exon 2 of MJD.  It is 
difficult to interpret the results of this variant because the protein was undetectable by 
antibody; we do not know if inclusions were formed at all.  Immunohistochemistry with α-
Hsp70/Hsc70 to visualize the endogenous Hsp70 that colocalizes with aggregates 
demonstrated that neither MJD-Q79-Δexon2 nor MJD-Q79-Δexon2 co-expressed with 
Figure 3-1  Structure of Josephin domain 
Crystal structure of the Josephin domain, 1YZB in 
PDB.  The catalytic residue responsible for DUB 
activity is C14, highlighted in red, with the necessary 
coordinating amino acids in blue.  The amino acids 
contained in exon 2 (a.a. 9-63) are designated by gray.  
Notice that the Δexon2 MJD lacks α-helices α1, α2, 
and α3, which make a large structural component of 
the Josephin domain.  The poly-ub entry sites to the 
catalytic active site are located along α4 and are 
highlighted in magenta.  It is thought that poly-ub 
chains line up along the α2 and α3 coils to gain access 
to the entry sites 
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Hsp104 contained accumulations (data not shown).  It is possible that non-aggregated, 
monomeric protein is itself a toxic species (Zoghbi and Orr, 2000, Wetzel, 2012), and if 
the MJD protein cannot oligomerize via the Josephin domain, this may be conferring the 
observed toxicity.  The PolyQ domains contained within soluble monomers is known to 
collapse in on itself in solution (Crick et al., 2006), so if this is occurring for MJD, 
remodeling by Hsp104 might be able alleviate the protein toxicity without the 
involvement of large protein aggregates.  This is purely speculative at this point, but in 
vitro experiments could be helpful in determining the oligomerization capacity of MJD-
Q79-Δexon2 and therefore refine our model of its interaction with Hsp104. 
 
The Ubiquitin-Interacting Motifs (UIMs) are also important for the DUB function of MJD, 
as they bind the poly-ub chain and direct it toward the Josephin domain active site.  
Consistent with our hypothesis of poly-ub involvement, we additionally found the UIMs to 
be critical in modulating MJD disease suppression by Hsp104.  Pathogenic MJD with 
mutations to the ubiquitin-binding residues of the UIMs, MJD-Q80-UIM*, conferred mild 
toxicity, and co-expression of Hsp104 did not worsen the degeneration, as it did for 
expression-matched full-length MJD with competent UIMs, MJDnQ84 (Fig 2-5).  More 
strikingly, the combination of the Josephin active site mutation C14A to abolish DUB 
activity combined with UIM mutations, MJD-Q80-C14A-UIM*, caused much stronger 
degeneration, and co-expression of Hsp104 provided a strong suppression of toxicity.  
Hsp104 was not able to suppress toxicity of MJD with the Josephin mutation alone, 
MJD-Q88-C14A (Fig 2-5).  We also observed that Hsp104 again promoted aggregation 
of MJD variants with intact UIMs, but solubilized SDS-resistant aggregates of MJD 
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variants with mutated UIMs (Fig 2-5).  Thus, we conclude that regardless of DUB 
functionality, active UIMs that are capable of binding poly-ub chains block the 
accessibility of MJD to Hsp104 remodeling. 
 
Other features of MJD were determined to be unrelated to the negative interaction 
between MJD and Hsp104 (see Table I-4).  We therefore constructed a model in which 
the Josephin domain and the UIMs are both required to induce the adverse outcome of 
Hsp104 treatment (Fig 3-2).  We propose that an interaction between the two domains, 
potentially mediated through mutual binding of a poly-ub chain, creates a structural 
hindrance that Hsp104 is unable to effectively process, thus driving an enhancement of 
protein aggregation and associated toxicity. 
 
We have created a model of 
how the MJD protein may look 
based on the organization of 
domains:  Josephin domain 
(gray), UIMs (blue), and PolyQ 
(purple), with a poly-ub chain 
(green) added to demonstrate 
functional binding of the UIMs.  
With these representations, it 
is easy to see the formation of 
a structural connection 
between the Josephin domain 
and the UIMs, potentially 
mediated by reciprocal binding of a poly-ub chain.  This connection is designated with red circles 
to highlight the closed loop formed between the domains.  We hypothesize that Hsp104 is unable 
to process MJD due to this connection and thus worsens aggregation and toxicity.  In contrast, 
this inflexible conformation is not present if the UIMs are mutated (UIM*) or if a portion of the 
Josephin domain is removed (Δexon2), thus facilitating productive interactions with Hsp104. 
 
Figure 3-2  Model of Hsp104 
effect on MJD variants 
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How does Hsp104 drive aggregation of Full-length MJD? 
 
To expand upon the actual mechanism by which the closed loop formed by intact MJD 
domains obstructs Hsp104 remodeling, we have incorporated other biochemical data 
about MJD amyloidogenesis into a more detailed mechanistic model.  Previous in vitro 
experiments have established that MJD forms aggregates in a two-step process, first 
forming SDS-soluble 
linear polymers by 
associating via the 
Josephin domain and 
then converting to SDS-
insoluble amyloid fibrils 
driven by the expanded 
PolyQ domain (Fig 3-3) 
(Masino et al., 2004, Ellisdon et al., 2006, Ellisdon et al., 2007).  We therefore propose 
that these SDS-soluble Josephin-driven polymers are also formed by MJD in vivo and 
initiate remodeling by Hsp104.  This fits well with our observations regarding aggregation 
kinetics in vivo, with amorphous, SDS-soluble MJDnQ78 accumulations appearing by 
IHC before the SDS-insoluble amyloid-like material by SDD-AGE (Fig 2-3).  In fact, this 
Josephin association may actually initiate Hsp104 remodeling, as the disaggregase does 
not remodel natively folded substrates (Doyle et al., 2007). 
 
We speculate that MJD is affected by Hsp104 translocation differently depending on the 
presence of the connection between the Josephin domain and the UIMs.  When a 
Figure 3-3  Model of two-step aggregation of MJD 
Summary of in vitro studies demonstrating that MJD aggregates in 
a two-step process.  MJD first forms SDS-soluble linear polymers 
by associating via the Josephin domain and then converts to SDS-
insoluble amyloid fibrils driven by the expanded PolyQ domain. 
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structural inflexibility is formed by this “closed loop” in intact MJD, Hsp104 is unable to 
fully translocate the protein and, in the process, exposes the PolyQ domain to accelerate 
the formation of toxic PolyQ-driven amyloid-like inclusions (Fig 3-4 A).  This would be 
akin to the in vitro finding that addition of a pure PolyQ fragment recruits full-length MJD 
to bypass Josephin-driven aggregation and immediately join the PolyQ-driven amyloid 
fibril (Haacke et al., 2006).  In contrast, we propose that when the closed loop is absent 
in the UIM* or Δexon2 variants, the MJD protein is successfully translocated and 
aggregates are resolved (Fig 3-4 B). 
 
A.  The closed loop between the Josephin 
domain and the UIMs in intact MJD hinders 
Hsp104 remodeling.  We propose that MJD 
starts as Josephin-driven aggregates in vivo, as 
observed in vitro, which initiates Hsp104 
remodeling.  The structural constraint between 
the Josephin domain and the UIMs prevents (or 
slows) successful Hsp104 translocation, which 
exposes the PolyQ domain to allow rapid 
accumulation of amyloid-like accumulations, 
causing severe toxicity. 
B.  MJD variants lacking the closed loop are 
successfully remodeled by Hsp104.  Again, we 
propose that MJD starts as Josephin-driven 
aggregates, but because there is no association 
between the Josephin domain and the UIMs, the 
MJD protein is efficiently translocated by 
Hsp104.  This results in fewer aggregates, which 
correspond to reduced toxicity. 
 
 
We have therefore constructed specific molecular models to describe the protein-protein 
interactions between Hsp104 and MJD using results from genetic interactions in 
Figure 3-4  Model of differential interaction 
between Hsp104 and MJD 
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Drosophila.  While this model is consistent with our observations (see Chapter 2), we 
have not directly tested it experimentally.  Pure protein disaggregation assays with MJD 
variants containing the UIM mutations would be an ideal approach to probe this 
interaction.  Specifically, it will be important to determine whether Hsp104 has distinct 
modes of action on MJDtrQ78 versus MJDnQ78 with purified components in vitro.  
Hsp104 has been shown to disaggregate pre-formed amyloid fibrils of a pure PolyQ 
repeat (DeSantis et al., 2012), so we anticipate that Hsp104 will effectively eliminate 
MJDtrQ78 fibrils with its minimal flaking sequence.  However, we suspect that outside of 
its cellular context, Hsp104 will not drive aggregation of MJDnQ78 in vitro due to the 
absence of poly-ub chains.  The addition of purified poly-ub chains to the reaction would 
allow us to investigate whether the formation of a closed loop through mutual poly-ub 
binding between specified domains of MJD is indeed driving Hsp104-mediated 
aggregation; introduction of UIM mutations would preclude this negative interaction. 
 
Further research is required to extend these findings to other disease proteims.  Note 
that co-expression of Hsp104 suppressed the toxicity of truncated MJD without 
eliminating the amount of SDS-insoluble aggregates (see Fig 2-2, 2-3).  Moreover, 
activation of Hsp104 subsequent to the appearance of MJDtrQ78 aggregates actually 
increased aggregate accumulation (see Fig 2-11), which was associated with greater 
tissue survival (see Fig 2-10).  The reason for this ameliorative effect is unknown, but 
may be due to interactions with soluble oligomers, among other possibilities (see 
Chapter 2 for full discussion).  Critically, this result demonstrates that increased load of 
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amyloid-like accumulations is not always deleterious, and that subtle biochemical 
changes can be sufficient to eliminate toxicity of aggregation-prone proteins. 
 
Implications of modulating protein inclusions 
 
It is generally thought that reducing the burden of amyloidogenic conformers might 
prevent the cascade of pathological insults that occur in protein-aggregation disease 
(Hardy and Selkoe, 2002).  Indeed, in a mouse model of AD, the rapid occurrence of 
large protein aggregates was toxic to neighboring cells (Meyer-Luehmann et al., 2008), 
indicating that this is a critical mediator of pathogenicity.  It is therefore intuitive that 
reversing large inclusions may alleviate pressure on cells.  Moreover, merely turning off 
expression of PolyQ-htt using the tet-inducible system in mice has reversed the nuclear 
and cytoplasmic aggregates, and this also alleviated behavioral symptoms (Yamamoto 
et al., 2000).  Therefore, eradicating amyloid-like accumulations might offer greater 
benefit than simply preventing further addition to the aggregate, suggesting that the 
disaggregase activity of Hsp104 may be more powerful than the chaperoning activity of 
Hsp70.  Critically, in targeting these aggregated species, any therapeutic must prevent 
the release of soluble, toxic oligomers from the fibrillar aggregate (Koffie et al., 2009).  
Therefore, an agent capable of dismantling both fibrils and oligomers would be ideal, 
again bringing focus onto Hsp104. 
 
Our staging experiments determined that Hsp104 prevented tissue degeneration when 
expressed subsequent to onset of expression of MJDtrQ78, effectively halting tissue loss 
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while actually promoting accumulation of SDS-insoluble protein accumulations.  It will be 
critical to understand the source of toxic species in vivo, because in this case, Hsp104 is 
not acting as a disaggregase.  We have considered alternate modes of action by 
Hsp104, such as interactions with soluble oligomers, but our results highlight that 
elimination of amyloid-like inclusions is not required to alleviate protein-associated 
toxicity.  Further detailed characterization of the mechanism by which Hsp104 prevents 
tissue degeneration would be insightful for further development of Hsp104 as a 
treatment tool.   
 
Moreover, additional limitations of Hsp104 must be considered.  Hsp104 has been 
shown to spontaneously promote oligomerization of a yeast prion, and low levels of 
Hsp104 generally stimulate amyloid fibril formation (Shorter and Lindquist, 2004, 2006).  
This occurs because high levels of Hsp104 efficiently resolubilize amyloid fibrils, but low 
levels break fibrils into smaller pieces.  This activity is critical in the physiological function 
of Hsp104 in maintaining yeast prion states, as it promotes heritability of the fibril into 
daughter cells (Wegrzyn et al., 2001, Shorter and Lindquist, 2006).  However, exposing 
more replicative ends might have catastrophic consequences in a disease state, and 
could seed unimpeded growth of protein inclusions.  Additionally, consistent with the 
model of our results in Drosophila (Chapter 2), inefficient or incomplete translocation of 
substrates might expose previously shielded aggregation domains and thus stimulate 
the protein aggregation cascade and accompanying toxicity.  A better understanding of 
mechanism will be critical in evaluating the interaction between Hsp104 and protein 
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inclusions in vivo and to evaluating its full and complete potential as a disruption agent to 
protein aggregation disease. 
 
Evaluating Hsp104 as a treatment for protein aggregation disease 
 
As discussed, Hsp104 presents limitiations in treating protein aggregation disease in 
vivo at this time; however, with further development, the potential issues surrounding 
Hsp104 treatment might be suppressed or minimized by optimizing the chaperone for a 
disease environment.  The chaperonin GroEL has been optimized by alterations to the 
folding chamber to maximize refolding of particular substrates (Tang et al., 2006).  
Similar tailoring of Hsp104 may allow it to preferentially contact particular disease-
associated substrates and avoid nonspecific remodeling of benign proteins.  Changes 
among subunit collaboration or to the ATPase rate of Hsp104 may also eliminate 
unintended negative interactions with obstinate substrates by increasing the unfolding 
power.  However, such an alteration might increase overall remodeling activity, and 
therefore enhance off-target effects; these modifications would likely need to be paired 
with substrate-optimization.  Further, the complication of amyloid fibril strains may pose 
a problem in a disease setting; certain fibril strains are more difficult to eradicate and, 
moreover, certain strains are associated with stronger toxicity (Tanaka et al., 2006, 
Nekooki-Machida et al., 2009, DeSantis and Shorter, 2012).  Promisingly, Hsp104 
coordinates subunits to tackle even difficult strain conformations (DeSantis et al., 2012), 
and identifying features of Hsp104 that result in optimized activity against these stubborn 
strains in screens of Hsp104 mutant libraries is ongoing. 
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A critical feature of Hsp104 function in yeast is that the remodeled substrate is able to 
regain its native conformation and resume physiological activity (Patino et al., 1996, 
Shorter and Lindquist, 2004).  However, it is less clear that this is a desirable outcome in 
neurodegenerative disease.  For example, in AD, tau is a microtubule-binding protein, so 
recovering protein monomers from an amyloid inclusion might restore lost function.  On 
the other hand, the Aβ peptide, which also accumulates in amyloid aggregates in AD, is 
an aberrant cleavage product with no known function, so elimination of the peptide may 
be preferable to release of monomer, which rapidly reassociates with existing 
assemblies (Cohen et al., 2013).  A variant of Hsp104, known as HAP, physically 
couples to the bacterial proteolytic chamber ClpP such that any substrates translocated 
by HAP are fed directly into ClpP and degraded (Tessarz et al., 2008).  Thus, an Hsp104 
variant optimized for tau might restore functional tau protein while an Aβ-optimized HAP 
variant might eliminate Aβ altogether.  Moreover, administration of the HAP/ClpP system 
in vivo might prevent unintended deleterious effects of Hsp104 treatment (e.g., 
promoting MJDnQ78 aggregation) by eliminating amyloid accumulations without 
stimulating any off-target seeding or inadvertent protein misfolding following 
translocation by Hsp104.  Thus, we envision that disease-specific treatments with 
Hsp104 are possible, and may in fact be preferable to the broad remodeling activity for 
which Hsp104 is known. 
 
Our results underscore that understanding the exact nature of the disease state will be 
critical in designing therapies.  For example, truncation of MJD is thought to initiate 
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pathogenesis in SCA3/MJD because it exposes the templating PolyQ region to drive 
amyloid formation (Haacke et al., 2006, Haacke et al., 2007).  In this case, application of 
Hsp104 may be very useful in the initiating phases of SCA3/MJD in which Truncated 
MJD prevails, as Hsp104 was found to suppress early MJDtrQ78 aggregation and 
impede toxicity, but Hsp104 application would be detrimental when Full-length MJD is 
recruited to the aggregates.  This may not be insurmountable, as addition of a co-agent 
to disrupt poly-ub binding could potentially unleash Hsp104 remodeling power, as 
observed for the UIM* variants.  Because of the complicated set of interactions within the 
cell and the diverse composition of aggregates in vivo, Hsp104 may need to be modified 
before it is able to tackle all components of the disease environment effectively. 
 
Our results indicate that Hsp104 expression should be controlled in an animal system. 
Previous studies have expressed Hsp104 in a variety of metazoan systems with no 
deleterious effects (Satyal et al., 2000, Vacher et al., 2005, Dandoy-Dron et al., 2006, 
Perrin et al., 2007, Lo Bianco et al., 2008), and moreover, Hsp104 was seen to confer 
beneficial stress resistance to mammalian cells (Dandoy-Dron et al., 2006).  Therefore, it 
has been perplexing that Hsp104 was not evolutionarily conserved to metazoans, and 
our result that sustained high levels of Hsp104 can cause cytotoxicity may provide a 
reason for this loss. In yeast, Hsp104 levels are tightly regulated; Hsp104 is not detected 
under normal growth conditions, but expression is rapidly induced upon heat stress 
(Sanchez and Lindquist, 1990), which is consistent with the notion that high basal levels 
are not desirable. In fact, even the inducible Hsp70 that is endogenous to Drosophila is 
tightly controlled when not needed, and forced high expression causes a growth defect 
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to Drosophila cells (Feder et al., 1992).  Therefore, careful control of expression, rather 
than indiscriminate upregulation, may be required to harness Hsp104 as a therapeutic. 
 
The administration of a foreign protein such as Hsp104 as a treatment to humans 
currently depends on gene therapy, a technique that still requires much optimization.  
Further, there are additional complexities as noted surrounding Hsp104 action, which 
must be addressed to present the protein as a potential therapeutic option.  We have 
presented ideas to circumvent some of these problems.  However, our results, which 
were unpredicted, suggest that introduction of Hsp104 into the complex disease 
environment requires caution.  We observed that Hsp104 suppressed the toxic effects of 
MJDtrQ78 when expressed concomitantly and in staged experiments, but we also 
discovered that Hsp104 was capable of enhancing degeneration induced by MJDnQ78.  
Further, the mechanism by which Hsp104 is alleviating toxicity is still unknown.  
Regardless, Hsp104 remains a powerful tool to examine the biological and biochemical 
effects of disrupting existing aggregates in animal models.  
 
Conclusions 
 
The use of molecular chaperones and heat shock proteins may be a valuable approach 
to combating protein aggregation diseases and intractable amyloid disorders.  In such 
diseases, patient presentation of symptoms often indicates advanced pathology. 
Therefore, a molecule such as Hsp104 that can target existing protein assemblies may 
be better suited to tackling pre-existing disease-associated protein aggregation than a 
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fold-promoting chaperone such as Hsp70 (Chapter 2).  Because of the nature of the 
disease environment, true reversal of the pathological amyloid-like inclusions might have 
multi-fold benefits: relief of mechanical burden on the cells, elimination of a reservoir 
able to release soluble oligomers, termination of the capture and conversion of native 
monomers, and containment of pathology to existing regions, to name a few.  Therefore, 
because of its ability to remodel pre-existing amyloidogenic conformers, Hsp104 
emerges as a unique potential treatment that warrants further characterization. 
 
Because of the issues surrounding protein resolubilization, concomitant expression of a 
therapeutic molecule is not sufficient to evaluate the potential medicinal application of 
molecular chaperones and heat shock proteins.  Prevention of disease by a treatment 
that coincides with pathogenicity is distinct from disease reversal by a treatment 
occurring after pathogenesis is underway.  While prevention of disease is likely the most 
effective way to preserve nervous system structure and function, it is not feasible without 
advances in biomarker identification and improved diagnostic capabilities.  Current 
limitations in identifying disease onset prior to symptom onset require an intervention to 
modulate existing disease pathology.  In animal models, gene expression technology 
that allows staged activation of specific molecules should be utilized to understand how 
controlled expression affects disease progression once it is underway.  Our results in 
Drosophila demonstrate for the first time that Hsp104 can indeed halt SCA3/MJD-
associated tissue degeneration once it has begun.  This serves as a first step in 
evaluating molecular modulators of disease in a true therapeutic setting, but the capacity 
to modulate pre-existing disease must be tested in other model systems and for other 
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protein aggregation diseases.  In particular, the existence of the tetracycline-inducible 
system in the mouse calls for detailed analysis of Hsp104 as a disease modulator in a 
mammalian system.  Coupled with the identification of Hsp104 features that enhance 
anti-amyloid activity, such studies may provide unique, tailored therapies for the distinct 
diseases of the nervous system. 
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APPENDIX I : ADDITIONAL FLY RESULTS 
 
EXPRESSING HSP104 IN THE FLY 
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In order to test the capacity of Hsp104 to modulate protein aggregation disease in vivo, 
we created an Hsp104 transgenic fly.  We unexpectedly observed that Hsp104 
expressed on its own had toxicity in the fly eye.  We therefore wanted to explore and 
characterize this effect, presented in Part 1.  After tuning Hsp104 expression for the fly, 
we conducted two genetic screens to see if Hsp104 had any impact on degeneration 
caused by proteins associated with human neurodegenerative disease.  Although the 
most intriguing interaction with MJD is defined in Chapter 2, we document the full results 
of the genetic screens here, in Part 2.  Finally, to gain further understanding of how 
Hsp104 functions in an animal system, we created two mutant Hsp104 transgenic lines.  
An inactive Hsp104, DPLDWB, and an increased activity mutant, A503V, are described 
and characterized in Part 3. 
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PART 1.  Creating an Hsp104 fly 
 
Background 
 
Previous attempts to create an Hsp104 transgenic fly were unsuccessful, with 
expression levels too low to detect.  Therefore, we modified the Hsp104 gene before 
creating the plasmid.  First, we added a Kozak sequence prior to the AUG start codon to 
enhance translation of the mRNA.  We selected the sequence ACAAA for optimal 
expression in Drosophila (Trinh et al., 2008). 
 
Next, we used GenScript to have the gene codon-optimized for expression in 
Drosophila.  Between species, there are differences in the relative abundancy of tRNAs 
that each correspond to a codon.  For example, the synonymous codons ACG, ACA, 
ACT, and ACC all 
encode the amino 
acid Threonine, but 
the tRNA associated 
with ACT is most 
common in yeast 
and ACC tRNA is 
more available in 
Drosophila.  Therefore, a gene such as Hsp104 that is adapted for expression in yeast 
might be limited by available tRNAs in Drosophila.  Accordingly, exchanging a rare 
codon for one more common in Drosophila can enhance translation speed and 
Figure I-1  Codon optimization of Hsp104 
The relative frequency specific to Drosophila for each codon is plotted 
against the relative position of the codon.  A higher frequency (more 
white) indicates that the codon corresponds to a tRNA that is more 
readily available in the fly.  Before optimization, the Codon Adaptation 
Index (CAI) was 0.56, suggesting that the sequence was only half of its 
potential optimum efficiency.  After optimization, the CAI of the gene 
was boosted to 0.98, which suggests it will be more efficiently translated 
in the fly. 
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efficiency.  Our initial Hsp104 sequence had a Codon Adaptation Index (CAI) of 0.56, 
indicating that the sequence has only 56% similarity to the most efficient sequence for 
the fly.  After optimization, the CAI jumped to 0.98, demonstrating that almost every 
codon was maximally available (Fig I-1).  Not all sites could be optimized to the 
maximum frequency in order to prevent introduction of restriction cleavage sites.  
 
We had the optimized gene synthesized by GenScript, with the ACAAA Kozak sequence 
prior to the start codon (the full sequence is listed in Chapter 2).  We used restriction 
sites XhoI and XbaI to insert the gene into the pUAST vector for injection into the fly, 
which was performed by Genetic Services. 
 
Multiple independent Hsp104 lines were obtained.  The transgenes were mapped and 
balanced: 
 
Table I-1  WT Hsp104 lines 
Line: Chromosome: Description 
1.1 X Possibly two transgenes [not used] 
2.1 3 Weak 
4.1 X Weak 
5.1 X Strong 
6.1 3 (/Sb) Strong; cannot go homozygous 
7.1  Floating transgene [not used] 
 
To characterize expression level, the Hsp104 gene was expressed in the eye by the 
gmr-Gal4 driver and analyzed by Western blot (Fig I-3).  In the course of characterizing 
these lines, we unexpectedly discovered that Hsp104 expression disrupts the fly eye.   
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High expression of Hsp104 may be harmful 
 
To determine relative levels of Hsp104 among the lines, the gene was expressed in the 
eye by the gmr-Gal4 driver.  In doing so, we discovered that Hsp104 expression caused 
a slight eye disruption to the 
weak lines, 2.1 and 4.1, and 
noticeable degeneration to the 
strong lines, 5.1 and 6.1 (Fig I-
2A).  Paraffin sections 
confirmed dramatic toxicity 
through loss of retinal integrity 
caused by Hsp104 expression 
by gmr-Gal4 (Fig I-2A).  
Because gmr-Gal4 has 
multiple copies of the glass 
element driving Gal4 
expression, we used a 
reduced driver with only one 
copy of the glass element, 
1xgr-Gal4.  This driver 
reduced the impact of Hsp104 
on eye morphology, with the 
strong lines, 5.1 and 6.1, impairing retinal structure but with minimal effect contributed by 
the weak lines, 2.1 and 4.1 (Fig I-2B).  As such, using the 1xgr-Gal4 driver with a weak 
Figure I-2  Hsp104 causes eye degeneration 
A. Hsp104 driven by gmr-Gal4 is toxic.  The weak Hsp104 
lines, 2.1 and 4.1, displayed slight disruption to the external 
eye and structural impairments to the retina.  The strong 
lines, 5.1 and 6.1, had visible degeneration with necrotic 
patches on the eye and severely disorganized retinal 
structure. 
B. Hsp104 driven by the reduced driver 1xgr-Gal4 is less 
disruptive to the eye.  Strong Hsp104 lines, 5.1 and 6.1, had 
much improved retinal organization.  The weak lines, 2.1 and 
4.1, had only minimal impact on the eye, with normal cellular 
organization within the retina and no disruption visible in the 
external eye. 
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line of Hsp104 were used to evaluate the efficacy of Hsp104 in mitigating disease (see 
Chapter 2). 
 
 
 
Because lowering Hsp104 expression with the reduced driver minimized the effect of 
Hsp104 on the eye, we wanted to thoroughly associate protein expression level with 
degree of disorganization in the retina.  Quantitative Western immunoblots were 
Figure I-3  Hsp104 expression level corresponds with severity of degeneration 
Western immunoblots were performed for each Hsp104 line driven by either gmr-Gal4 or 1xgr-
Gal4.  Quantification was performed in ImageJ and each Hsp104 band was normalized to actin as 
a loading control.  n=3, Mean±SEM.  The eye image and retinal section for each genotype 
presented in Fig I-2 was arranged to correspond with increasing expression level.  In this manner, 
it became very apparent that the correspondence between higher Hsp104 expression level and 
increased severity of eye defect. 
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performed to compare Hsp104 expression level among the different lines with both 1xgr-
Gal4 and gmr-Gal4 drivers (Fig I-3A).  To evaluate the impact of increased expression 
level, the eye images and retinal sections from Fig I-2 were arranged in order of 
increasing Hsp104 signal intensity.  It is very apparent that high expression level 
corresponded with increased severity of degeneration (Fig I-3B).  Thus, our attempts to 
boost expression by codon-optimizing the gene and adding a Kozak sequence may have 
been too successful; the high levels of expression must be dialed back using the 
reduced 1xgr-Gal4 driver to minimize the toxic effect of Hsp104. 
 
We were not anticipating any disruption caused by Hsp104.  Previous studies have 
examined Hsp104 expression in various model systems, including C. elegans, mouse, 
and rat (Satyal et al., 2000, Vacher et al., 2005, Dandoy-Dron et al., 2006, Perrin et al., 
2007, Lo Bianco et al., 2008).  Moreover, Hsp104 expression actually conferred 
beneficial protective effects in mammalian cell culture (Dandoy-Dron et al., 2006).  
Therefore, we had no indication that Hsp104 may be toxic in an animal system.  Further, 
we also examined an inactive Hsp104 that is unable to hydrolyze ATP and is incapable 
of binding substrate, Hsp104 DPLDWB.  This inactive Hsp104 had no negative impact 
on the retina (see Chapter 2 and Fig I-9), confirming that the toxic effect is dependent on 
Hsp104 activity.  We were unsure why we observed an activity-dependent deleterious 
effect of Hsp104 expression while others have not.  Is this toxicity due to the high 
expression levels we achieved?  Is this effect specific to the fly, or even more 
specifically, the fly eye? 
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To address this, we crossed a strong line, Hsp104 6.1, a weak line, Hsp104 2.1, and an 
inactive Hsp104 line, DPLDWB 2.1, to several driver lines to induce expression in 
multiple systems.  Amongst all drivers, a similar pattern emerged that Hsp104 6.1 was 
harmful and the effect of weak-expressing Hsp104 line, 2.1, was milder in degree, 
suggesting that the damage is dose-dependent.  Moreover, the inactive Hsp104 
DPLDWB had no effect on any system (Table I-2), confirming the necessity of active 
remodeling in conferring toxicity.  Strikingly, Hsp104 6.1 was lethal when expressed 
ubiquitously (da-Gal4), pan-neuronally (elav-Gal4), or in all muscle cells (24B-Gal4).  
Ubiquitous expression of the weaker Hsp104 2.1 was also lethal, but lethality was not 
complete when expressed in muscle cells (Table I-2).  Interestingly, Hsp104 2.1 
expressed pan-neuronally had no obvious toxicity; the flies eclosed, survived, and 
produced progeny (Table I-2).  This result indicates that further experiments could be 
performed using the elav-Gal4 neuronal driver, such as performing Kaplan-Meier 
survival curves to evaluate efficacy of Hsp104 as a therapeutic for disease toxicity. 
 
Table I-2  Toxicity of Hsp104 in multiple systems 
Driver name: Expression System: 
Effect of: 
WT Hsp104 2.1 
(Weak) 
WT Hsp104 6.1 
(Strong) 
DPLDWB 
Hsp104 2.1 
gmr-GAL4 eye Mild     degeneration 
Severe 
degeneration No effect 
da-GAL4 ubiquitous Lethal          (pupae) 
Lethal          
(larvae) No effect 
elav-GAL4 pan-neuronal No effect Lethal             (early larvae) No effect 
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24B-GAL4 pan-muscle Semi-lethal    (~10% escape) 
Lethal           
(larvae/pupae) No effect 
 
Hsp104 expression results in aggregation of protein 
 
We wanted to begin to characterize the mechanism of Hsp104 in causing degeneration 
on its own.  Because of Hsp104’s unique disaggregase activity, we hypothesized that 
Hsp104 may be indiscriminately remodeling endogenous proteins or protein complexes, 
thus disrupting the normal homeostasis of the eye.  To investigate this, we examined 
whether Hsp104 caused general protein 
aggregation by using 
immunohistochemistry (IHC) to probe for 
the existence of protein accumulations with 
an antibody against endogenous 
Drosophila Hsp70/Hsc70, which 
colocalizes with aggregates. 
Figure I-4  Hsp104 drives aggregation 
A. Retinal sections probed by IHC reveal protein 
aggregates in tissue expressing Hsp104.  An 
antibody against endogenous Hsp70/Hsc70 was 
used because it colocalizes with protein 
aggregates (red) and tissue was counterstained 
with Hoechst to identify nuclei (blue).  Hsp104 
expression by gmr-Gal4 or by 1xgr-Gal4 
resulted in protein aggregation. Hsp104 
expressed by gmr-GS does not result in 
aggregated protein.   
B. Western immunoblot demonstrates relative 
protein expression levels of Hsp104.  The gmr-
GS driver expresses at a much lower level than 
1xgr-Gal4, which is itself lower than gmr-Gal4.  
This immunoblot is also pictured in Fig 2-9. 
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As anticipated, protein aggregates were not observed in eyes containing just the gmr-
Gal4 driver with no transgene expressed (Fig I-4, top panel).  Expression of Hsp104 2.1 
driven by gmr-Gal4, however, did result in protein aggregation.  In addition to 
compromised retinal depth, consistent with that seen by paraffin sections (Fig I-2A), a 
number of protein accumulations were observed throughout the eye tissue (Fig I-4, 
second panel).  The reduced 1xgr-Gal4 driver expressing Hsp104 also showed the 
development of protein accumulations, to a lesser extent (Fig I-4, third panel).  
Therefore, the impaired retinal integrity caused by Hsp104 corresponds to the formation 
of protein aggregates.   
 
The mechanism by which Hsp104 causes protein aggregation remains speculation, but 
this finding may indicate that Hsp104 is remodeling crucial proteins or protein complexes 
to result in misfolding and accumulation of these endogenous proteins.  If this is indeed 
the mode of action, facilitating protein clearance pathways may counteract the effect. 
 
The damaging Hsp104 effect may be developmental 
 
We have established that expression of Hsp104 by gmr-Gal4 and 1xgr-Gal4 caused 
toxicity to the eye and this corresponded with the appearance of aggregated protein.  
However, we did not observe these features when examining other drivers that are 
adult-onset.  Therefore, we hypothesized that the Hsp104 effect may be specific to 
developing cells, which are potentially more sensitive to perturbation. 
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We examined a modified gmr-Gal4 driver that is activated only in the presence of a drug, 
a system called GeneSwitch (gmr-GS).  Unlike constant expression with gmr-Gal4, when 
Hsp104 was turned on in the eye in the adult fly using gmr-GS, no Hsp104-induced 
protein aggregation was observed (Fig I-4A).  However, we are unable to conclude 
definitively that the lack of aggregation is because Hsp104 was not expressed during 
development.  Western immunoblot demonstrated that the expression level using gmr-
GS was much lower than by the other two eye-specific drivers (Fig I-4B), so we cannot 
exclude the possibility that reduced protein levels may be responsible for the suppressed 
phenotype. 
 
In the course of our experiments, we also examined the adult-onset rhodopsin driver 
rh1-Gal4, which is specific to photoreceptor cells.  In this system, toxicity is measured 
not by tissue loss but by degeneration of individual photoreceptor cells.  By shining light 
through the eye, the surviving photoreceptor cells are illuminated, and one can count the 
number of photoreceptors in each ommatidium. In this assay, Hsp104 had no toxicity 
and the pattern of seven photoreceptors per ommatidium was preserved (Fig 2-13).  
Because rh1-Gal4 is adult-onset, this again points to a developmental process in the 
initiation of Hsp104 toxicity, but does not exclude other possibilities, such as expression 
level or another cellular factor in the tissue-specific environment.  
 
To fully test if the Hsp104 defect is developmental, further experiments are needed.  
Because protein levels are so different among the variants of the gmr-Gal4 driver, it is 
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difficult to compare differences in toxicity between the drivers.  Therefore, comparing a 
strong Hsp104 line, such as 6.1, driven by gmr-GS to a weak line, such as 2.1, driven by 
1xgr-Gal4, would result in similar expression levels.  Thus, the contribution of expression 
during development could be teased apart from differences in protein level.  To confirm 
the contribution of gene expression during development, raising gmr-GS larvae on the 
activating drug would turn on the Hsp104 gene during developmental stages and 
presumably resemble the toxicity of concomitant expression with gmr-Gal4. 
 
Can Hsp104 toxicity be modulated? 
 
Because we were not expecting to see any effect of Hsp104 expression, we wanted to 
examine whether other molecules could suppress the observed toxicity.  This would be 
useful in development of Hsp104 as a disease treatment, but might also provide insight 
into the processes by which Hsp104 exerts toxicity.  We observed two potential 
modifiers: 
 
1.  The molecular chaperone Hsp70 
 
The first molecule we wanted to co-express with Hsp104 was the chaperone Hsp70.  It 
is known to function as a coordinating chaperone with Hsp104, facilitating interactions 
with substrates.  Therefore, we reasoned that the entire chaperone network may be 
unbalanced by Hsp104 expression and that raising Hsp70 levels would restore harmony.  
In addition, Hsp70 is a strong suppressor of disease in multiple systems, and there are 
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numerous examples of strong suppression of protein aggregation disease in Drosophila 
provided by Hsp70 (see Fig 2-2, (Warrick et al., 1999, Chan et al., 2000, Auluck et al., 
2002)).  We were therefore extremely surprised that co-expression of Hsp70 and 
Hsp104 is lethal (Fig I-5).  With gmr-Gal4, we observed total lethality (Fig I-5A), and 
reduced expression by 1xgr-Gal4 was 
lethal in males but we did obtain 
females expressing both genes.  
Evaluation of these escapers 
confirmed that Hsp104 and Hsp70 
synergize to produce extreme toxicity, 
with complete loss of eye pigmentation 
and degeneration (Fig I-5B). 
 
The mechanism of toxicity resulting 
from the interaction between Hsp104 
and Hsp70 remains unknown.  The 
synergistic toxicity is undeniable, but 
follow-up experiments would be 
required to characterize how this arises.  These proteins are co-expressed in eye tissue, 
so the disruption must be extremely intolerable to cause death of the entire organism.  
Our hypothesis is that Hsp104 is indiscriminately driving aggregation of endogenous 
proteins and the addition of Hsp70 facilitates substrate interactions, thus worsening the 
magnitude of the effect.  If the introduced Hsp104 were itself misfolding, then it is likely 
Figure I-5  Hsp104 and Hsp70 synergize to 
induce lethality 
A. With the gmr-Gal4 driver, eye images show that 
Hsp70 has no effect on the eye.  However, when co-
expressed with Hsp104, animals are inviable and die 
before emerging from the pupal case. 
B. With the reduced 1xgr-Gal4, Hsp70 again has no 
impact on the eye.  Co-expression of Hsp104 is 
lethal in males, but females survive although with 
extreme degeneration of the eye.  These escapers 
demonstrate that the combination is toxic. 
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that Hsp70 expression would chaperone the protein and prevent its misfolding.  
Moreover, the Hsp104 toxicity was dependent on activity, as Hsp104 DPLDWB had no 
negative impact on any tissue.  Therefore, we interpret this finding to suggest that Hsp70 
facilitates an activity-dependent Hsp104 process that disrupts normal cellular function.   
 
2.  The deubiquitylase MJD 
 
In the course of evaluating Hsp104 as a disease-modulating agent, we noticed that non-
pathogenic MJDnQ27 may show a capacity to suppress the Hsp104 effect.  We were 
investigating the effect of Hsp104 on suppressing degeneration associated with 
expanded PolyQ in the MJD protein (Ataxin-3/ Machado-Joseph Disease protein), and 
examined non-expanded MJDnQ27 as a control.  The physiological role of MJD is as 
deubiquitylase (DUB) that contributes to proteostasis through the ubiquitin-proteasome 
system (UPS) (see Chapter 2).  Therefore, expression of MJDnQ27 would provide the 
physiological DUB activity without the accompanying PolyQ-initiated toxicity. 
 
Even with the reduced 1xgr-Gal4 driver, a slight disruption caused by Hsp104 is 
apparent, with some dark banding of the photoreceptor cells and a separation of the 
basal level of the retina (Fig I-6A).  Co-expression of Hsp104 with MJDnQ27 has no 
such disruption (Fig I-6A), indicating that MJD corrects the process the Hsp104 disturbs.   
 
To fully conclude that MJD is affecting the Hsp104 toxicity, we needed to look at 
conditions in which Hsp104 had a much stronger effect.  We therefore examined the 
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gmr-Gal4 driver with every Hsp104 line (Fig I-6B), and retinal degeneration was 
observable for each Hsp104 line.  For every Hsp104 line driven by gmr-Gal4, co-
expression of MJDnQ27 had no impact on severity of degeneration (Fig I-6B).  As such, 
we conclude that MJDnQ27 is able to correct mild disruptions caused by Hsp104 
expressed by 1xgr-Gal4, but MJDnQ27 is unable to impact the severe degeneration 
caused by Hsp104 expressed by gmr-Gal4. 
 
B 
 
 
These findings suggest that the physiological function of MJD is able to suppress mild 
disruptions caused by Hsp104.  This is consistent with our interpretation of Hsp104 
causing errant protein aggregation; enhanced UPS function stimulated by MJD would 
counteract the accumulation of aberrantly remodeled substrates.  However, the lack of 
Figure I-6  MJDnQ27 suppresses 
Hsp104 
A. Eye images and retinal sections 
demonstrate that Hsp104 2.1 expression 
by 1xgr-Gal4 causes a slight disruption to 
the cellular organization within the retina.  
MJDnQ27 has no toxicity on its own, and 
further, serves to suppress the toxicity of 
Hsp104.  Co-expression of both proteins 
prevents the eye impairment of Hsp104 
alone. 
B. Co-expression of MJDnQ27 has no 
impact on eye degeneration caused by 
Hsp104 expression by gmr-Gal4. 
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suppression for gmr-Gal4 driving Hsp104 suggests that the ability of MJDnQ27 to 
modulate this toxicity is very limited. 
 
Conclusions and Future Directions 
 
Our finding that expression of Hsp104 alone had any effect on the fly eye was 
unexpected.  We have characterized that increased Hsp104 expression level 
corresponds to more severe toxicity, indicating that high doses are not well tolerated in 
the fly.  Moreover, we discovered the toxic effect of Hsp104 coincided with the 
development of protein aggregates.  Further investigation will be required to determine 
the nature of these aggregates and which proteins comprise them.  Since Hsp104 
toxicity was enhanced rather than rescued by Hsp70, this implies a synergistic effect in 
active remodeling of endogenous substrates.  Consistent with this notion was the finding 
that MJDnQ27, a facilitator of the UPS, suppressed limited examples of Hsp104-driven 
degeneration. 
 
However, the significance of the toxic effect of Hsp104 remains unconfirmed and many 
details are lacking.  For example, the role of the observed Hsp104-driven protein 
aggregates in causing toxicity is unclear.  Our transgenic lines are poised to perform 
further experiments to characterize the association between aggregation and toxicity, for 
example, by detecting aggregate levels Hsp104 with Hsp70 (increased toxicity) or with 
MJD (decreased toxicity).  Moreover, we have some indication that Hsp104 may be 
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causing problems specifically during development, so controlled experiments to separate 
this contribution would greatly add to the characterization of Hsp104’s effect. 
 
Many questions remain surrounding the specific mechanism of Hsp104 cytotoxicity as 
well.  We have made the observation that Hsp104 expression results in protein 
aggregation, but we have not characterized the accumulations further.  We presume that 
Hsp104 is driving aggregation by causing aberrant remodeling of endogenous 
substrates, but this remains a hypothesis and requires further investigation.  In 
particular, examining whether this aggregation is enhanced by the combination of Hsp70 
with Hsp104 will be informative regarding our model of the chaperones’ synergistic off-
target effects.  Moreover, our finding that MJD suppresses mild Hsp104 toxicity should 
also be combined with an investigation into aggregation status, as enhanced UPS 
activity might alleviate toxicity by combating protein accumulation.  Use of MJD variants 
that lack DUB activity would be required to confirm that physiological activity of MJD is 
responsible for the suppression of Hsp104 toxicity. 
 
It is also possible that controlled expression may be required for any inducible 
chaperone.  Hsp104 is tightly regulated in yeast, and is undetectable at basal levels 
(Sanchez and Lindquist, 1990).  Thus, the expression is highly controlled except when 
specifically required to function during stress and recovery.  Consistent with this idea, 
even the inducible Hsp70 that is endogenous to Drosophila causes developmental 
defects to fly cells when basal levels are highly over-expressed (Feder et al., 1992).  As 
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such, our use of GeneSwitch technology may be the most appropriate application of 
Hsp104 induction. 
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PART 2.  Genetic screens: Does Hsp104 moduate toxicity of disease proteins? 
 
To determine if Hsp104 could be harnessed as a therapeutic, a broad variety of 
neurodegenerative disease-associated proteins were screened to see if Hsp104 could 
mitigate protein toxicity in the fly eye.  Because of the deleterious effect of Hsp104 
alone, we used the reduced eye driver 1xgr-Gal4 with the weak-expressing line Hsp104 
2.1.  We found interesting interactions between Hsp104 and different MJD isoforms, and 
followed up with a more targeted screen of MJD variants. 
 
We have defined the interaction between Hsp104 with MJD in detail in Chapter 2, but 
wanted to document the complete results of our genetic screens.  The full list of results 
is presented below; the complete collection of eye images and paraffin sections are 
available in the Bonini lab. 
 
Screen 1:  Does Hsp104 impact any protein aggregation disease? 
 
We screened a panel of proteins known to be associated with neurodegenerative 
disease to determine if Hsp104 had any capacity to modulate disease toxicity. 
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Table I-3  Screen: Does Hsp104 modulate neurodegenerative disease? 
Alzheimer’s Disease 
Disease protein: Line name: Interaction with Hsp104: 
Aβ42 – WT #11c39/TM3,Ser [K Iijima] 
Aβ did not cause eye degeneration; 
interaction not determined 
Aβ42 – Arctic #4b1 (3) [K Iijima] 
Aβ did not cause eye degeneration; 
interaction not determined 
Aβ42 – artificial #24c9/CyO [K Iijima] 
Aβ did not cause eye degeneration; 
interaction not determined 
Tau – WT Box 26-1c [M Feany] 
No observable Tau toxicity;  
interaction not determined 
Tau – R406W Box 26-1e [M Feany] 
No observable Tau toxicity; 
interaction not determined 
 
Amyotrophic Lateral Sclerosis 
Disease protein: Line name: Interaction with Hsp104: 
TDP-43–YFP (S) on 2 [Hyung-Jun Kim] No interaction 
TDP-43 + hAtx2-
32Q; gmr-Gal4 
(YHIII) 
TDP-43 (37M), hAtx2-
32Q (F26); gmr-YHIII 
[Hyung-Jun Kim] 
No interaction (does not appear that 
Hsp104 disruption is additive) 
 
PolyQ disorders 
Disease protein: Line name: Interaction with Hsp104: 
Atx1-Q82 M6 on 3 [P Taylor] No interaction 
Htt-exon1-Q93 exon1[174]-httQ93 (2) [L Thompson] 
No observable Htt toxicity; 
Interaction not determined 
dAtx2 Drosophila Atx2.4 Box 12-1c No interaction 
 
Machado-Joseph Disease (SCA3) 
Disease protein: Line name: Interaction with Hsp104: 
MJDnQ78 #24.1 (3) Hsp104 enhanced toxicity 
MJD-Q88.C14A #5.2 CyO/Sco; w+/Sb No interaction (severe degeneration) 
MJD-Q79-
Δexon2 #6.1 (2) Hsp104 suppressed toxicity 
MJDtrQ46 nos> c19.1 L15 No observable toxicity; interaction not determined 
MJDtrQ54 nos> c19.1 L16 No observable toxicity; interaction not determined 
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The disease proteins caused minimal degeneration in this screen because of the use of 
the reduced expression driver 1xgr-Gal4.  Therefore, it was difficult to determine if 
Hsp104 suppressed toxicity or interacted in any way with a number of these proteins. 
 
Of the various disease models tested, Hsp104 interactions with different variants of MJD 
looked the most interesting.  We looked at truncated fragments of the MJD protein that 
are comprised mainly of the expanded PolyQ tract and saw that Hsp104 suppressed the 
severity of truncated MJD toxicity.  We also looked at non-truncated MJD, which in 
addition to its PolyQ-dependent role in disease, the full-length MJD protein has a 
physiological role in proteostasis as a ubiquitin chain editing enzyme.  The MJD protein 
has deubiquitylase (DUB) activity carried out by the N-terminal Josephin domain, with 
residue C14 acting as the catalytic amino acid.  The interaction between Hsp104 and 
full-length MJD is more complex. 
 
We examined three variants the full-length MJD protein: the intact protein with functional 
DUB domain (MJDnQ78), a variant with a point mutation to inactivate the catalytic amino 
acid (MJD-Q88.C14A), and another non-functional variant that lacks a large portion of 
MJDtrQ64 nos> c19.1 L17 No observable toxicity; interaction not determined 
MJDtrQ70 nos> c19.1 W631 No observable toxicity; interaction not determined 
MJDtrQ78 nos> c19.1 L18 No observable toxicity; interaction not determined 
MJDtrQ92 nos> c19.1 L19 Hsp104 suppressed toxicity 
MJDtrQ78 c11.2 E11 /CyO Hsp104 suppressed toxicity 
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the Josephin domain (amino acids 9-63) that includes the active site (MJD-Q79-
Δexon2).  We found striking distinctions among the variants of the same MJD protein.  
The pathogenic MJDnQ78 had moderately severe toxicity when expressed by 1xgr-
Gal4, and Hsp104 had a very strong interaction, causing much stronger degeneration, 
including early lethality. 
 
Due to loss of physiological DUB activity, MJD-Q88.C14A was more toxic than 
MJDnQ78 and showed much stronger degeneration.  Co-expression of Hsp104 had little 
effect on this extreme toxicity, with both genotypes showing high lethality.  MJD-Q79-
Δexon2 also had increased toxicity due to loss of the catalytic activity.  However, we 
observed that Hsp104 had a strong interaction with MJD-Q79-Δexon2, and completely 
unlike the interaction with the other full-length MJD variants, provided strong 
suppression of disease-associated toxicity. 
 
These dramatically distinct interactions of Hsp104 with different forms of the same MJD 
protein warrant further investigation, which were examined in the next genetic screen in 
Screen 2.   
 
Screen 2:  Defining the interaction between MJD and Hsp104 
 
We saw surprising interactions between Hsp104 and different isoforms of the MJD 
protein (Screen I).  Hsp104 effectively suppressed the toxicity of truncated forms of MJD 
that are comprised mainly of an expanded PolyQ tract.  However, Hsp104 dramatically 
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enhanced the toxicity of full-length MJD despite the aggregation domain being an 
identical PolyQ expansion.  We also observed a surprising disparity between two MJD 
variants lacking deubiquitylase (DUB) activity, which were originally constructed to be 
redundant examples of inactive MJD.  However, the variants were demonstrated to be 
distinct, as Hsp104 strongly suppressed the variant lacking a portion of the Josephin 
domain that contains the active site but did not affect the variant with a point mutation to 
the active site. 
 
In order to probe which portions of full-length MJD hinder the suppression of toxicity that 
is observed for truncated MJD, we used a collection of MJD variants with various 
functional deficiencies.  In addition to variants lacking DUB activity, we also examined 
interaction mutants unable to coordinate with known functional partners in the cellular 
environment. 
 
Our conclusions and a detailed model of the interactions between Hsp104 and MJD are 
explored in depth in Chapter 2 (Fig 2-7), but the full results of the entire MJD screen are 
presented here for reference. 
 
In addition to MJD variants, we tested Huntingtin protein isoforms, as it was another 
PolyQ protein that may or may not have an interaction with Hsp104.  Additionally, we 
also examined the interaction between Hsp104 and other molecular chaperones.  The 
AAA+ chaperone p97 was of particular interest because of its structural homology to 
Hsp104 (Wendler et al., 2007) and its known ability to interact with MJD in its role as part 
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of the UPS (Kuhlbrodt et al., 2011).  Moreover, we were eager to test for an interaction 
between Hsp104 and Hsp70.  Hsp70 collaborates with Hsp104 during its disaggregation 
activity and Hsp70 is a known suppressor of degenerative phenotypes, so we wanted to 
see if co-expression of Hsp70 with Hsp104 would mitigate the deleterious effect of 
Hsp104 on its own. 
 
Table I-4  Screen: Defining the interaction between Hsp104 and MJD 
Expanded MJD screen 
Truncated MJD, non-expanded Q 
Disease protein: Line name: Interaction with Hsp104: 
MJDtrQ27 N18.3-d No interaction 
MJDtrQ46 nos> c19.1 L15 No interaction 
 
Truncated MJD, expanded Q 
Disease protein: Line name: Interaction with Hsp104: 
MJDtrQ92 nos> c19.1 L19 Hsp104 suppressed toxicity 
MJDtrQ78 c11.2 E11 /CyO Hsp104 suppressed toxicity 
Q71tr-257 #3.13 Hsp104 suppressed toxicity 
 
Truncated MJD with location tags 
Disease protein: Line name: Interaction with Hsp104: 
MJDtrQ27–NES A50.2 No interaction 
MJDtrQ77–NES #13.1 Hsp104 suppressed toxicity 
MJDtrQ27–NLS #28.1 No interaction 
MJDtrQ65-NLS #52a Hsp104 suppressed toxicity 
 
Full-length functional MJD, non-expanded Q 
Disease protein: Line name: Interaction with Hsp104: 
MJDnQ27 #46.2 MJDnQ27 suppressed the mild Hsp104 disruption 
MJDnQ27p #30.2 No visible interaction 
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Full-length functional MJD, expanded Q 
Disease protein: Line name: Interaction with Hsp104: 
MJDnQ78 #24.1 Hsp104 enhanced toxicity 
MJDnQ84p #7.2 (29ºC) Hsp104 enhanced toxicity 
Atx3-Q83-6M #3.1 Hsp104 enhanced toxicity 
 
Full-length non-functional MJD 
Disease protein: Line name: Interaction with Hsp104: 
MJD-Q27Δ #25 No interaction 
MJD-Q79Δ #6.1 Hsp104 suppressed toxicity 
MJD-Q27.C14A P1467 No interaction 
MJD-Q88.C14A #5.2 No interaction (severe degeneration) 
 
MJD interaction mutants 
Disease protein: Line name: Interaction with Hsp104: 
MJD-Q27-UIM* #11.1 No interaction 
MJD-Q80-UIM* #31.1 (29ºC) No interaction (mild degeneration) 
MJD-Q80-DM #1.2 Hsp104 suppressed toxicity 
MJD-Q71-HNHH 
(p97*) #3.11A No interaction 
 
MJD lacking RNA toxicity 
Disease protein: Line name: Interaction with Hsp104: 
MJDnQ81 CAA/G #69.1 (II) Hsp104 slightly enhanced toxicity 
MJDnQ82.C14A 
CAA/G #4.17B /CyO Hsp104 enhanced toxicity 
 
Josephin domain; MJD lacking PolyQ 
Disease protein: Line name: Interaction with Hsp104: 
MJD-ΔQ MJDΔ2 #44.2 /Tb No interaction 
Josephin – IR #3.3 /CyO No visible interaction 
dJosephin #2.3A (3) No interaction 
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Other interactions 
Huntingtin 
Disease protein: Line name: Interaction with Hsp104: 
Exon1-htt-Q20 exon1[174]-httQ20 (II) [L Thompson] No interaction 
Exon1-htt-Q93 exon1[174]-httQ93 (2) [L Thompson] No toxicity; no interaction 
Htt[1-676]-Q0 htt676-Q0#B [T Littleton] No interaction 
Htt[1-676]-Q138 htt676-Q138#C [T Littleton] Hsp104 enhanced toxicity 
 
Chaperone p97 
Protein: Line name: Interaction with Hsp104: 
ter94 FRT ter94 [26.8] #42B  [D Ruben] No interaction 
ter94 Box 31-1d [D Ruben] No interaction 
p97 #6.1/Tb No interaction 
 
Chaperone Hsp70 
Protein: Line name: Interaction with Hsp104: 
hHsp70 #53.1 /CyO Lethal in males; some females survived but with severe degeneration 
gmr-Gal4 + 
hHsp70 P1055-R4 /CyO Completely lethal  
 
Our screen yielded important insight into the portions of full-length MJD that hinder 
productive interactions with Hsp104.  These results are well summarized in Chapter 2.  
Additionally, we highlight three interesting findings: 
 
1.  Hsp104 is not modulating MJD toxicity by suppressing RNA toxicity 
 
In addition to protein-driven toxicity, full-length MJD is known to have a component of 
RNA toxicity (Li et al., 2008).  In PolyQ disease, the repeat of the CAG codon within the 
110 
 
RNA strand forms a hairpin structure and contributes toxicity to the PolyQ protein 
phenotype (de Mezer et al., 2011).  Previous work from our lab has demonstrated that 
mutating the sequence such that the pure CAG repeat is interrupted by alternating CAA 
and CAG (CAA/G) eliminates the toxic RNA structure while maintaining the same PolyQ 
protein sequence (Li et al., 2008).  Thus, examining CAA/G forms of MJD will define 
protein-only interactions.  Therefore, if we find that the Hsp104-driven enhancement of 
full-length MJD is no longer evident with the CAA/G mutations, then it may be that the 
negative interaction with Hsp104 is due to RNA toxicity rather than protein. 
 
Full-length MJD with CAA/G did not have strong eye toxicity and co-expression of 
Hsp104 slightly worsened retinal structure, but ultimately had little effect.  In order to 
evaluate the interaction more thoroughly, full-length MJD with CAA/G plus the Josephin-
inactivating C14A point mutation was used to confer more severe degeneration.  With 
this more severe phenotype, it was apparent that co-expression with Hsp104 enhanced 
degeneration.  This is consistent with previous full-length MJD results containing a pure 
CAG repeat, so these results indicate that Hsp104 is worsening toxicity through protein 
interactions rather than by affecting RNA toxicity.  Further experiments would be 
required to fully eliminate the possibility of an interaction between Hsp104 and RNA, but 
the observed effect on MJD is due to protein-protein interactions, which is consistent 
with our protein aggregation results (Fig 2-3B and D) and our model (Fig 2-7). 
 
2.  Subcellular location of MJD does not affect accessibility to Hsp104 
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Location variants of truncated MJD were examined to determine if subcellular 
localization affected Hsp104 performance.  We had found that Hsp104 suppressed 
toxicity of truncated MJD with expanded Q, and we wished to examine whether Hsp104 
could still access the protein when localized to either the nucleus or the cytoplasm. 
 
Truncated MJD with an added nuclear export signal (NES) was directed to the cytosol; it 
caused severe toxicity, which was suppressed by co-expression of Hsp104.  Similarly, 
nuclear-directed truncated MJD, by means of an added nuclear localization signal (NLS), 
caused more moderate toxicity, and this was also mitigated by co-expression of Hsp104.  
Thus, Hsp104 is able to localize to, and function within, either the cytosol or the nucleus, 
suggesting that it is promising to treat protein aggregates regardless of subcellular 
localization. 
 
3.  The Hsp104 interaction with PolyQ protein Huntingtin may mirror MJD 
 
Huntingtin (Htt) is the PolyQ protein implicated in development of Huntington’s Disease 
(Norremolle et al., 1993).  Like MJD, expanded PolyQ in Htt leads to the formation of 
inclusions and development of disease pathology (Davies et al., 1997).  The PolyQ 
domain is found in the N-terminus of the protein, and because Htt is very large (>3000 
amino acids), smaller fragments of Htt that contain the N-terminal aggregation domain 
are often examined to facilitate aggregation (Thakur et al., 2009).  We investigated Exon 
1, which contains 67 amino acids plus the variable-length PolyQ repeat, and also a 
larger fragment containing amino acids 1-676 plus PolyQ. 
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Htt, like MJD, required expanded PolyQ in order to cause toxicity.  Thus, no 
degeneration was observed for Exon1 Htt-Q20 or Htt[1-676]-Q0, and Hsp104 had no 
effect (Fig I-7).  Exon1 Htt-Q93 did not have visible toxicity when expressed by the 
reduced 1xgr-gal4 driver, and Hsp104 had 
minimal effect when co-expressed, appearing 
identical to the mild effect of Hsp104 alone 
(Fig I-7A).  Therefore, any interaction 
between the Exon1 Htt fragment and Hsp104 
cannot be determined.  Like Exon1, Htt[1-
676]-Q138 did not cause obvious 
degeneration with the 1xgr-Gal4 driver, but in 
marked contrast, Hsp104 co-expression 
caused strong toxicity with visible retinal 
degeneration (Fig I-7B).  Thus, Htt[1-676] 
does have an interaction with Hsp104, and 
this resulted in increased toxicity of the 
disease protein. 
 
Thus, we observed an Hsp104-driven worsening of toxicity for the longer fragment Htt[1-
676] but no such interaction with Exon1 Htt.  Superficially, this resembles our findings for 
MJD:  PolyQ domains with more protein flanking sequence are subject to negative 
interactions with Hsp104 but a more accessible PolyQ domain is effectively remodeled 
by Hsp104.  However, the mechanism of the Hsp104 interaction with Htt requires much 
Figure I-7  Hsp104 may have a negative 
interaction with Huntingtin 
Fragmented variants of Htt with non-
expanded Q demonstrated no toxicity. 
Because of the reduced expression by the 
1xgr-Gal4 driver, the expanded Q variants 
also displayed no degeneration.  However, 
we observed that while co-expression of 
Hsp104 with Exon1 Htt-Q93 did not 
synergistically induce degeneration (A), the 
combination of Hsp104 with Htt[1-676]-
Q138 caused enhanced toxicity (B). 
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further characterization to draw any conclusions.  For example, the expression levels of 
the two proteins may be very different and while Hsp104 is able to manage Exon1, Htt[1-
676] passes a critical level that Hsp104 cannot tackle.  Alternatively, because the 
difference between the PolyQ repeats in these two Htt variants is fairly substantial, it 
could be that Hsp104 is able to remodel PolyQ regions up to a certain point but the 
enzymatic activity is overwhelmed when the Q exceeds a threshold.  A panel of variants, 
such as those examined for MJD, would be required to fully understand the observed 
interaction. 
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PART 3.  Examining Hsp104 mutants 
 
Background 
 
In addition to developing wild-type (WT) Hsp104 to investigate its capacity in modulating 
protein-aggregation disease, we also sought to create Drosophila lines expressing 
Hsp104 mutants.  In addition to highlighting the deficiencies or enhancements of each 
mutant, these may also offer mechanistic insight into how WT Hsp104 functions. 
 
We were particularly interested to test an inactive mutant because this important control 
has never been performed in vivo.  We chose the inactive Double Pore Loop Double 
Walker B (DPLDWB) Hsp104 mutant, which has four mutations (Y257A: E285Q: Y662A: 
E687Q) to prevent ATP hydrolysis and substrate binding (DeSantis et al., 2012).  Thus, 
the Hsp104 molecule will be inactive in remodeling (Walker B mutations) but will also be 
unable to serve as a trap to substrates (pore loop mutations) (Bosl et al., 2005).  It is 
critical to compare DPLDWB to WT Hsp104 because it will truly distinguish active 
remodeling effects from passive effects that may occur as a result of novel protein 
expression. 
 
Additionally, we created an Hsp104 variant with a mutation to the middle domain, 
A503V.  Previous research in the Shorter lab has shown that A503V Hsp104 has 
enhanced anti-amyloid activity in vitro (unpublished data), so we were eager to test 
whether it may have improved efficacy when introduced in vivo.  Again, it is critical to 
compare A503V to WT Hsp104 to determine what effect the mutation has on activity. 
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ATPase Dead Hsp104 
 
To create the ATPase Dead Hsp104, we used site-directed mutagenesis to introduce the 
inactivating mutations (Y257A: E285Q: Y662A: E687Q) into our codon-optimized WT 
Hsp104 plasmid.  Multiple independent DPLDWB Hsp104 lines were obtained.  The 
transgenes were mapped and balanced: 
 
Table I-5  DPLDWB Hsp104 lines 
Line: Chromosome: Description 
2.1 3 Moderate 
5.4 X Moderate 
9.1 2 Moderate 
19.1 3 Moderate 
 
To characterize expression level, the Hsp104 gene was expressed in the eye by the 
1xgr-Gal4 driver.  We compared to levels of WT Hsp104 because it is critical to know 
whether the proteins are at similar levels to make accurate comparisons.  We found that 
all DPLDWB lines had very similar expression levels, and that these fell between the 
weak WT Hsp104 line 2.1 and the strong WT Hsp104 line 6.1 (Fig I-8B).  Therefore, 
these lines were determined to be appropriate for comparison to WT Hsp104. 
 
Because we had observed that WT Hsp104 negatively impacted the eye, we chose to 
characterize two DPLDWB lines for any potential toxic effect.  We found that with either 
the strong gmr-Gal4 driver or weak 1xgr-Gal4 driver, two separate lines of DPLDWB had 
no effect on eye morphology (Fig I-8A).  This finding implies that substrate binding and 
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ATP hydrolysis are required for the toxic effect of WT Hsp104.  This strengthens our 
proposed toxicity mechanism of aberrant Hsp104-driven protein remodeling. 
 
We also tested DPLDWB Hsp104 
for ability to modulate MJD 
disease.  WT Hsp104 was able to 
suppress the toxicity of MJDtrQ78 
but exacerbated degeneration 
associated with MJDnQ78 (Fig 2-
2).  We therefore wanted to 
confirm that these effects are 
dependent on active remodeling 
by Hsp104. 
 
We first performed these 
experiments using the 1xgr-Gal4 
driver to match the conditions 
used for WT Hsp104.  We found 
that DPLDWB Hsp104 had a mild mitigating effect on the degeneration associated with 
both MJDtrQ78 and MJDnQ78 (Fig I-9A).  The finding that DPLDWB Hsp104 does not 
display the differential activities on the two disease proteins indicates that this feature of 
WT Hsp104 is indeed activity-dependent. 
 
Figure I-8  DPLDWB Hsp104 is non-toxic 
A. Eye images and retinal sections demonstrate that 
two DPLDWB Hsp104 lines, 2.1 and 9.1, had no impact 
on eye morphology with either strong gmr-Gal4 or weak 
1xgr-Gal4 drivers.  This is in contrast to the toxic effect 
of comparable expression levels of WT Hsp104, which 
produced eye degeneration and retinal disorganization 
(see Fig 2-1). 
B. Western immunoblots demonstrate relative protein 
levels for each DPLDWB Hsp104 line.  All lines had 
similar expression levels, which were between the levels 
of weak WT Hsp104 line 2.1 and strong WT Hsp104 line 
6.1. 
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The effect of DPLDWB was also examined with the stronger gmr-Gal4 driver.  In this 
condition, neither DPLDWB line had any effect on severity of toxicity of either disease 
protein (Fig I-9B).  We were therefore reassured that the inactive DPLDWB Hsp104 is 
indeed inactive, and confirmed that modulation of disease is dependent on the active 
substrate binding and ATP hydrolysis of WT Hsp104. 
 
A503V 
 
Previous research in the Shorter lab has indicated that A503V Hsp104 exhibits 
enhanced anti-amyloid capacity compared to WT Hsp104.  However, it has been 
documented that the A503V mutant is difficult to purify because of some initial toxicity 
during bacterial expression.  Because this Hsp104 variant has a mutation in the middle 
domain, we have hypothesized that this mutation destabilizes the protein such that it is 
difficult to express high levels of the protein.  However, the A503V Hsp104 mutant 
Figure I-9  DPLDWB Hsp104 is 
inactive 
A. Using the 1xgr-Gal4 driver, 
MJDtrQ78 and MJDnQ78 have 
mild toxicity and co-expression 
of DPLDWB Hsp104 has a mildly 
mitigating effect.  Unlike WT 
Hsp104, DPLDWB Hsp104 does 
not show differential effects on 
the two disease proteins. 
B. Eye images and paraffin 
sections confirm that DPLDWB 
Hsp104 is unable to modulate 
disease using the gmr-Gal4 
driver.  Both DPLDWB Hsp104 
lines have no effect on the 
severity of degeneration or 
retinal impairment caused by 
MJDtrQ78 or MJDnQ78.  Again, 
DPLDWB Hsp104 does not 
show differential effects on the 
two disease proteins.  (Note that 
Control and DPLDWB 2.1 lines 
are duplicated from Fig 2-8.) 
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recovers from this initial difficulty and is obtainable with a longer growth time.  Once it 
has been purified, the A503V mutant has generally enhanced activity (antagonizing 
amyloidogenesis, ATP hydrolysis, etc.), so we wanted to test its efficacy in vivo.  We 
were prepared for the possibility of toxicity on its own due to this observation from the 
bacterial system, and therefore thought that the GeneSwitch system might be an ideal 
setting for this Hsp104 mutant. 
 
Multiple independent A503V Hsp104 lines were obtained.  The transgenes were mapped 
and balanced: 
 
Table I-6  A503V Hsp104 lines 
Line: Chromosome: Description 
17.1 2 Lethal; dead larvae and dead pupae 
18.2 2 Lethal; dead larvae and dead pupae 
20.2 X Unknown; no offspring from cross 
 
To characterize expression level, the Hsp104 gene was expressed in the eye by the 
1xgr-Gal4 driver.  All lines proved to be lethal in this system, with flies dying in either the 
larval or pupal stage.  More lines were created in addition to those listed above, but the 
lines were not robust and have been lost.  One slightly milder line had viable larvae and 
lethality was only seen in pupae, and from this, one female fly eclosed.  This fly had a 
decimated eye that was very small and lacked pigment entirely (Fig I-11), thus 
confirming the extreme toxicity of A503V Hsp104.  If this is due to an enhancemet of 
activity compared to WT Hsp104 or a separate effect (e.g., due to protein instability) is 
still unknown. 
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We had anticipated that A503V Hsp104 might be damaging on its own, so we used it in 
the GeneSwitch setting to control expression by drug application.  We constitutively 
expressed MJDtrQ78 by direct activation by gmr and used the gmr-GS driver to control 
expression of UAS-transgenes.  We found that WT Hsp104 was effective at suppressing 
progressive degeneration, but DPLDWB Hsp104 and Hsp70 had no protective effect in 
this sequential expression system (Fig 2-10).   
 
We were hoping that the toxicity observed for A503V Hsp104 would be avoided by the 
controlled expression of gmr-GS, and addionally that the enhanced activity of A503V 
Hsp104 would result in a stronger rescue than that observed for WT Hsp104.  However, 
we found that the burst of A503V Hsp104 appeared to make MJDtrQ78 degeneration 
worse when turned on early (Fig I-11A) or late (Fig I-11B).  This is an initial observation 
that requires more replicates and quantification, but we noticed a disruption to the retinal 
shape as well as the tissue loss and wispy appearance of surviving retinal cells in the 
A503V Hsp104-treated retinas.  We cannot rule out the possibility that this toxicity is due 
to A503V Hsp104 expression on its own.  The expression levels of this mutant might be 
tweaked to minimize disruption (akin to using the 1xgr-Gal4 driver for WT Hsp104), but 
Figure I-10  A503V Hsp104 is highly toxic 
Only one female fly eclosed from the mildest A503V Hsp104 line driven by 
1xgr-Gal4.  The eye was severely compromised, displaying a very reduced 
size, no pigment, and development of necrotic patches on the external eye.  
This confirms that even when lethality is escaped, the A503V Hsp104 
protein is damaging. 
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our results in this experiment have led us to eliminate the A503V Hsp104 mutant from 
further experiments. 
 
A. gmr-MJDtrQ78 caused 
degeneration of the retina; gmr-
GS expression of the indicated 
Hsp104 transgene was 
activated at d1 and severity of 
MJDtrQ78-induced degen-
eration was evaluated at d7.  
WT Hsp104 prevented tissue 
loss, but expression of A503V 
Hsp104 did not.  In fact, it 
appears that MJDtrQ78 toxicity 
may be enhanced by A503V 
Hsp104. 
B. Results were nearly identical 
when the Hsp104 transgenes were turned on later, at d3.  Again, MJDtrQ78 toxicity seems to be 
enhanced by A503V Hsp104 co-expression, but more replicates are need for quantification. 
Note that Control and WT Hsp104 images duplicated from Fig 2-10. 
 
Conclusions and Future Directions 
 
Our inactive mutant, DPLDWB Hsp104, was indeed found to be inactive.  The mutant 
Hsp104 had no negative impact on the eye, unlike equivalent levels of WT Hsp104.  
DPLDWB Hsp104 was also unable to modulate MJD-associated degeneration. 
 
Other inactive Hsp104 mutants might be used to probe the mechanism of WT Hsp104 
further.  For example, the mutation of the two Walker B sites (DWB) creates the Hsp104 
“trap mutant”, which is known to bind substrate but not release it (Bosl et al., 2005).  
Therefore, comparing DWB and DPLDWB Hsp104 might distinguish any off-target 
negative interactions with substrate that are due to incomplete or partial translocation. 
Figure I-11  A503V Hsp104 
worsens MJD toxicity 
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The A503V Hsp104 mutant was extremely toxic on its own, and may be enhancing MJD 
degeneration when temporally controlled by the gmr-GS system.  This mutant may 
improve following further optimization, but we will not pursue it.  We may need to 
develop other activity-enhanced mutants that do not show the negative effect.  Screens 
are ongoing in the Shorter lab to identify optimized Hsp104 variants. 
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Overall conclusions: Expressing Hsp104 in the fly  
 
There is still a lot to understand about Hsp104 expression in an animal system, and 
therapeutic application of Hsp104 for protein aggregation disease is not yet feasible.  We 
observed unanticipated toxicity when WT Hsp104 was expressed in multiple Drosophila 
systems.  Loss of Hsp104 activity through the inactivating DPLDWB mutations 
eliminates this negative outcome, indicating that the mechanism of toxicity is dependent 
on activity, possibly because Hsp104 drives indiscriminate aggregation of endogenous 
proteins.  Exploration of further Hsp104 mutants may yield further insight into this 
undesirable side effect of Hsp104 expression and may suggest ways to minimize the 
damaging effects.  Moreover, development of substrate-optimized Hsp104 mutants may 
eliminate off-target interactions altogether.  Our results also indicate that Hsp104 may be 
most toxic during a sensitive developmental stage.  Taken together, the use of 
GeneSwitch technology to selectively activate a controlled burst of Hsp104 expression is 
probably the best paradigm to study Hsp104, as it eliminates the negative effect of 
Hsp104 alone, and it most accurately replicates a disease-relevant application.  
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APPENDIX II : BIOCHEMICAL STUDIES 
 
DEVELOPING NOVEL ANTAGONISTS OF Aβ42 AMYLOIDOGENESIS 
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Background 
 
Alzheimer’s Disease (AD) is a devastating disorder that robs individuals of their cognitive 
abilities by impairing memory, thinking, and behavior through the progressive 
development of dementia (ADI, 2009, Thies and Bleiler, 2011).  It places an enormous 
burden on patients and families, as well as on economic and social resources, and is 
increasing in prevalence as our population ages (Thies and Bleiler, 2011).  AD patients 
have striking neuropathology in their central nervous system upon autopsy, with large 
neuritic plaques comprised of the Aβ42 peptide are observed in the extracellular space 
of the brain (ADI, 2009, Thies and Bleiler, 2011). 
 
Aβ42 is a short peptide of 42 amino acids that is released by proteolytic cleavage from 
the membrane-bound Amyloid Precursor Protein.  The Aβ42 peptide is extremely 
hydrophobic, and as such, is extremely aggregation-prone (Forman et al., 2004).  
Specifically, the peptide forms linear fibrils that adopt the stereotypical amyloid fold.  
Many proteins are known to access the amyloid conformation, which is defined as a 
cross-β structure in which β-sheets form perpendicular to the fiber axis (Jimenez et al., 
2002, Luhrs et al., 2005).  It is an extremely stable conformation that is resistant to heat 
denaturation, detergents, and proteases (Westermark et al., 2005, Chiti and Dobson, 
2006).  Aβ42 fibrils then form lateral interactions to create the large amyloid plaques 
observed in AD.  Because of the strength of the intermolecular contacts of the cross-β 
conformation, these plaques are thought to be intractable. 
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Moreover, prior to amyloid fibril formation, monomers first access soluble oligomeric 
assemblies (Kayed et al., 2003).  These may be even more toxic than fibrils, and some 
have proposed that fibrils are a protective mechanism to sequester the toxic soluble 
species (Dobson, 2003, Kayed et al., 2003, Douglas et al., 2008, Wolfe and Cyr, 2011).  
In fact, symptoms of neurodegenerative disease often appear before the accumulation of 
high amyloid load (Hardy and Selkoe, 2002, Caughey and Lansbury, 2003).  Further, 
plaques may serve as a reservoir for release of toxic oligomers (Koffie et al., 2009).  
Therefore, elimination of both mature amyloid fibrils and pre-amyloid oligomers would be 
ideal, as both protein accumulations are associated with disease development. 
 
As such, a treatment is needed to directly combat amyloidogenesis of Aβ42.  The 
development of an anti-amyloid treatment may have farther-reaching implications, as AD 
is also characterized by formation of amyloid inclusions of the tau protein in intracellular 
neurofibrillary tangles (Forman et al., 2004).  Moreover, many other neurodegenerative 
diseases are characterized by underlying protein pathology, and despite vastly different 
primary sequences, the proteins implicated often access the amyloid conformation 
(Forman et al., 2004).  Our hope is that agents to directly target amyloid fibrils will have 
widespread application to the varied collection of devastating neurodegenerative 
diseases. 
 
Here, we present three novel therapies to combat Aβ42 amyloidogenesis: in Part 1, the 
yeast disaggregase Hsp104; in Part 2, small molecule analogs of DAPH-1; and in Part 3, 
arylamide foldamers.  
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PART 1.  Tailoring Hsp104 for Aβ42 
 
Despite the remarkable stability of the cross-β fold, a yeast chaperone called Hsp104 
actively disassembles amyloid fibrils (Shorter and Lindquist, 2004, 2006, 2008, DeSantis 
et al., 2012).  Hsp104 is a heat shock protein that greatly improves survival following 
environmental stress by resolubilizing the proteins that become denatured and 
aggregate during stress (Sanchez and Lindquist, 1990, Sanchez et al., 1992, Parsell et 
al., 1994, Glover and Lindquist, 1998).  But in addition to reversing disordered 
aggregates, Hsp104 also controls the disassembly and dissemination of amyloid fibrils 
critical to beneficial yeast prion states (Chernoff et al., 1995, Shorter and Lindquist, 
2008).  In yeast, certain proteins act as prions; they are regulated by sequestration 
within self-replicating amyloid fibrils, thus reducing the available population of soluble 
protein without affecting transcription or translation.  Hsp104 is essential for restoring the 
sequestered protein monomers to their soluble and active state (Chernoff et al., 1995, 
Shorter and Lindquist, 2004, 2006, 2008). 
 
But how does Hsp104 tackle the extremely stable intermolecular connections found 
within amyloid fibrils?  The active Hsp104 protein is a ring-type hexamer made of six 104 
kDa monomers, each containing two substrate binding loops that project into the central 
channel within two nucleotide binding domains (NBDs) (Fig II-1A) (Wendler et al., 2007, 
Wendler et al., 2009).  The disaggregase acts as a molecular machine that couples ATP 
hydrolysis in each NBD to large structural shifts that ratchet the substrate binding loops 
and thus pull the substrate through the central channel (Lum et al., 2004, Lum et al., 
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2008).  Thus, Hsp104 pries protein monomers away from the protein aggregate, and 
after passing through the Hsp104 channel, the substrate is released and the 
resolubilized protein may adopt its native fold and resume normal physiological function 
(Fig II-1A). 
 
Because of this unparalleled 
ability to dismantle amyloid, 
Hsp104 is very promising in 
attacking amyloids associated 
with human disease.  
Preliminary results from our lab 
suggest that Hsp104 does 
indeed have strong efficacy in 
antagonizing various disease-
associated amyloid fibrils 
(DeSantis et al., 2012), but 
Aβ42 was particularly resistant to Hsp104 remodeling.  My first aim was to isolate 
conditions that would improve Hsp104 interactions with Aβ42 to allow evaluation of 
Hsp104 as a potential therapeutic.  In these experiments, it was critical to compare wild-
type (WT) Hsp104 to an ATPase Dead Hsp104 variant (K218T:K620T) that has a 
mutation in the conserved Walker A motif in each NBD and thus cannot bind or 
hydrolyze ATP.  This variant will therefore not be able to actively remodel substrates and 
Figure II-1  Hsp104 structure and function 
A.  Representation of Hsp104.  The Hsp104 protein (green) 
assembles into a three-tiered ring-shaped hexamer. Each 
monomer contains two conserved substrate-binding loops 
that project tyrosines into the central channel (yellow Y) and 
two ATP hydrolysis sites (yellow star), one in each NBD.  
Hsp104 remodels disordered aggregates, in collaboration 
with Hsp70/40, and amyloid fibrils by prying monomers from 
the aggregate and translocating through the central channel. 
B.  Amino acids Tyrosine and Phenylalanine. 
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will separate true activity-dependent interactions with Aβ42 from non-specific effects of 
incubating fibrils with a foreign protein. 
 
Additionally, Aβ42 fibrils may be so difficult to reverse because of the extremely 
hydrophobic nature of the Aβ42 peptide.  Thus, my second aim was to test Hsp104 
variants with mutations to the substrate-contacting residues of Hsp104 to make them 
more hydrophobic.  Thus, the substrate-binding loops may be more similar to Aβ42 and 
may have improved efficacy in contacting and subsequently dismantling Aβ42 fibrils.  
The conserved substrate-interacting motif GYVG is found in WT Hsp104 (KYKG in 
NBD1), and the tyrosine residue (Y) has previously been determined to make contact 
with the substrate (Lum et al., 2004, Lum et al., 2008).  One can envision that Y has 
resulted from evolutionary pressures because the phenyl ring is able to strengthen 
protein interactions and the polar hydroxyl group has the widest ability to interact with 
diverse substrate residues.  Therefore, by replacing the Y with phenylalanine (F), we 
would maintain the phenyl ring but would eliminate the polar group and increase 
hydrophobicity (Fig II-1B).  We examined the Y→F mutation in each NBD to determine if 
this did indeed increase efficacy of Hsp104. 
 
Aβ42 fibrils are reversed by Hsp104 
 
Previous results from our lab demonstrated that Hsp104 had minimal interaction with 
Aβ42 fibrils, so we needed to optimize reaction conditions.  We found that addition of the 
organic solvent dimethyl sulfoxide (DMSO) to the reaction actually uncovered the anti-
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Aβ42 activity of Hsp104.  To quantify these interactions, we incubated pre-formed Aβ42 
amyloid fibrils with Hsp104 overnight (16 h) and then measured how much amyloid 
material remained by using the amyloid-binding dye Thioflavin-T (ThT) (10 µM; excitation 
450 nm, emission 482 nm).   
 
In buffer alone (KHMD: 150 mM KCl, 40 mM Hepes-KOH pH 7.4, 20 mM MgCl2, 1mM 
DTT; 5 mM ATP; and ATP Regenerating System: 10 mM creatine phosphate, 0.02 
mg/ml creatine kinase), incubation with WT Hsp104 did seem to reduce the presence of 
pre-formed Aβ42 amyloid fibrils to about 80%, but the inactive ATPase Dead Hsp104 
actually reduced amyloid presence to a greater extent (Fig II-2A, left).   
 
In the presence of 10% DMSO, the same reaction yielded vastly different results.  
Addition of 10% DMSO to the reaction did not change the overall levels of untreated 
Aβ42 fibrils, suggesting that DMSO is not altering the beginning fibril population.  Rather, 
DMSO unmasks the activity of WT Hsp104, showing amyloid levels being reduced to 
about 10% of the starting amount (Fig II-2A, right).  Further, the presence of DMSO does 
not affect ATPase Dead Hsp104, and in fact, the inactive Hsp104 has less effect on 
Aβ42 fibrils than in buffer alone (Fig II-2A, right).  Thus, we conclude that DMSO is 
allowing us to distinguish active remodeling of Aβ42 amyloid fibrils by WT Hsp104. 
 
We wanted to determine the concentration DMSO concentration required to observe this 
effect, so the reactions were repeated with increasing concentrations of DMSO (0 – 10% 
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total volume).  We observed that at least 7% DMSO was required to uncover Aβ42 fibril 
disassembly by Hsp104 (Fig II-2B). 
  
B. At least 6% DMSO is 
required to observe Hsp104 remodeling of Aβ42 fibrils.  Pre-formed Aβ42 fibrils (0.5 µM) were 
incubated with WT or ATPase Dead Hsp104 (2 µM) for 16 h at 37ºC and evaluated by amyloid-
binding dye ThT.  The reaction was performed in buffer with the addition of 0–10% DMSO.  As 
DMSO concentration increases, WT Hsp104 activity was uncovered while the passive effect of 
ATPase Dead Hsp104 is minimized.  n≥2, Mean±SEM 
 
Our interpretation of these results is that DMSO is not affecting the nature of fibrils on 
their own, but rather is allowing us to observe the true remodeling potential of Hsp104.  
Because Aβ42 is so hydrophobic, we hypothesize that the peptides that are freed from 
the fibrils by Hsp104 are immediately re-joining a fibril structure, which is why we do not 
observe strong disaggregation by WT Hsp104 in buffer alone.  Our hypothesis is that 
with > 7% DMSO present, the released Aβ42 peptides remain solubilized after Hsp104 
Figure II-2  WT Hsp104 
reverses pre-formed Aβ42 
fibrils 
A. DMSO uncovers the 
active remodeling of Aβ42 
fibrils by Hsp104.  Pre-
formed Aβ42 fibrils (0.5 µM) 
were incubated with WT or 
ATPase Dead Hsp104 (2 
µM) for 16 h at 37ºC and 
evaluated by amyloid-
binding dye ThT.  The 
reaction was performed in 
either buffer alone (KHMD) 
or in buffer with the addition 
of 10% DMSO.  In buffer 
alone, WT Hsp104 did not 
resolubilize Aβ42 from fibrils 
when compared to the 
inactive ATPase Dead 
Hsp104.  In the presence of 
10% DMSO, WT Hsp104 
activity was apparent when 
compared to ATPase Dead 
Hsp104.  n≥2, Mean±SEM 
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release, thus allowing us to gauge Hsp104 activity.  However, other interpretations are 
possible, such as the possibility that DMSO increases the ATPase rate or solubility of 
Hsp104.  Moreover, this experiment highlights the importance of having a negative 
control.  An ATPase Dead Hsp104 is crucial to distinguish active Hsp104 remodeling 
from non-specific bulk protein effects.  
 
We alternatively found that increasing Hsp104 concentration in strong excess to Aβ42 
fibrils also allowed distinction between WT and ATPase Dead Hsp104.  As the molar 
excess of WT Hsp104 increased from 4× to 36×, WT Hsp104 activity improved but the 
effect of ATPase Dead Hsp104 was unchanged (Figure II-3).  The EC50 of WT Hsp104 
was 5.7 µM with the maximal effect at 17.6 µM (57% fibrils remaining).  Thus, achieving 
higher concentrations of Hsp104 uncovers WT Hsp104 activity just as addition of DMSO 
does, perhaps because increased availability allows Hsp104 to tackle the Aβ42 fibrils 
before remodeled monomers rejoin the aggregate. 
Pre-formed Aβ42 fibrils (0.5 
µM) were incubated for 16 h 
at 37ºC with increasing 
concentrations of either WT 
or ATPase Dead Hsp104 (2–
18 µM).  As WT Hsp104 
concentration increased, so 
did the elimination of amyloid 
content of the Aβ42 fibrils.  In 
contrast, the effect of 
ATPase Dead Hsp104 did not change with increasing concentration.  The line of best fit for WT 
Hsp104 was y = 0.0032x2 – 0.0988x + 1.318 (R2 = 0.99726) (EC50 = 5.744 µM; Maximal activity = 
17.626 µM; Maximal disassembly = 0.5707) and the line of best fit for ATPase Dead Hsp104 was 
y = -0.0032x + 0.8708.  n≥3, Mean±SEM 
 
Figure II-3  High levels of 
Hsp104 are required to 
disassemble Aβ42 fibrils 
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Hsp104 can be optimized for Aβ42 
 
Once we had established that Hsp104 was able to reverse Aβ42 fibrils, we sought to 
enhance its efficacy by introducing mutations to the substrate-binding loops of Hsp104.  
We mutated the substrate-contacting residues Y257 and Y662 to F in order to make 
them more hydrophobic and encourage interaction with the very hydrophobic Aβ42 
peptide. 
 
Again, overnight incubation of Aβ42 fibrils with WT Hsp104, but not ATPase Dead 
Hsp104, reduced amyloid content as measured by ThT.  Mutation of the substrate-
binding loop in NBD1 (Y257F) or NBD2 (Y662F) alone did not enhance activity of 
Hsp104 in dismantling Aβ42 amyloid fibrils (Fig II-4).  However, when these mutations 
were combined (Y257F:Y662F) such that every substrate-contacting residue was the 
hydrophobic amino acid F, Hsp104 reversed amyloid fibrils completely, such that there 
was no amyloid present (Fig II-4). 
 
 
 
Figure II-4  An Hsp104 variant has 
enhanced activity against Aβ42 
fibrils 
Y257F:Y662F Hsp104 has enhanced 
disaggregation activity of Aβ42 fibrils.  
Pre-formed Aβ42 fibrils (0.5 µM) were 
incubated for 16 h at 37ºC with the 
indicated Hsp104 variant (2 µM) in 
KHMD with 10% DMSO.  Mutation of 
the substrate-contacting residues in 
each NBD had little effect on their 
own, but combined increased 
disaggregation activity to completely 
eliminate amyloid fibril content.  n≥2, 
Mean±SEM 
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We also examined Y257F:Y662F Hsp104 for activity against another substrate to 
determine whether enhanced activity was specific to Aβ42.  We examined the ability of 
Hsp104 variants to reactivate chemically denatured firefly luciferase.  Because this 
substrate forms a non-amyloid (disordered) aggregate, coordinating chaperones Hsp70 
and Hsp40 were required for Hsp104 function.  WT Hsp104 reactivated about 12% of 
the denatured luciferase, Y257F:Y662F had less activity, reactivating about 8%, and 
ATPase Dead Hsp104 was completely inactive (Fig II-5).  This suggests that 
Y257F:Y662F Hsp104 is 
indeed specialized for activity 
against Aβ42 as a substrate 
and is not simply exhibiting 
increased remodeling 
activity. 
 
Conclusions and Future Directions 
 
Despite initial indications that Hsp104 was unable to interact with Aβ42, we were able to 
identify two separate conditions to unmask its unique disaggregase activity.  We found 
that addition of 10% DMSO facilitated striking elimination of Aβ42 fibrils by WT Hsp104 
Figure II-5  The Aβ42-optimized Hsp104 variant is less effective against aggregated 
luciferase 
Y257F:Y662F Hsp104 does not have enhanced disaggregation activity of aggregated luciferase.  
Chemically denatured firefly luciferase aggregates (500 nM) were incubated for 1.5 h at 25ºC 
with Hsp70/Hsp40 (1 µM) and an Hsp104 variant (6 µM).  The resulting products were tested for 
ability to catalyze a luminescence reaction, indicating reactivated luciferase, and compared to 
non-denatured luciferase to estimate the percentage of proteins reactivated from the aggregate.  
WT Hsp104 was more effective at restoring luciferase function than Y257F:Y662F Hsp104, and 
the ATPase Dead variant was completely inactive.  n=2, Mean±SEM 
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and minimized the apparent bulk protein effect of ATPase Dead Hsp104.  Alternatively, 
we found that very high levels of WT Hsp104 compared to Aβ42 (36-fold excess) 
allowed Hsp104 to reverse fibrils.  The effect of ATPase Dead Hsp104 does not change 
with increased concentration, but does appear to reduce ThT reactivity consistently, to 
about 80% of untreated fibrils.  Therefore, we used the DMSO condition to pursue 
analysis of substrate-optimized Hsp104 variants. 
 
Because of the extreme hydrophobic character of Aβ42, we mutated the substrate-
contacting residues on the binding loops of Hsp104 from Y to F.  We found that 
Y257F:Y662F Hsp104 did indeed have enhanced ability to eliminate Aβ42 fibrils, and in 
fact completely eliminated amyloid content.  This enhancement of activity was specific 
for Aβ42 as a substrate.  Testing this variant in a biological system (e.g., Drosophila) 
would ultimately determine if Y257F:Y662F Hsp104 is more promising against Aβ42 
therapeutically. 
 
The ThT results obtained here are promising, but more experiments are needed to fully 
characterize the effect of Hsp104 on Aβ42 fibrils.  Sedimentation analysis would 
determine whether Aβ42 is being truly resolubilized or redirected into non-amyloid 
aggregates, and electron microscopy (EM) images would also be helpful in determining 
the nature of remodeled Aβ42.  To add physiological relevance, the toxicity of untreated 
Aβ42 to cultured neuroblastoma cells (e.g., SH-SY5Y) could be compared to the Aβ42 
fibrils treated with Hsp104 to establish whether Hsp104 treatment is reducing the toxicity 
of these fibrils. 
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The Aβ42 peptide is a cleavage product that has no known normal function.  Thus, 
elimination of Aβ42 following disassembly of fibrils would be ideal for this substrate.  
Therefore, it would be useful to also test the HAP mutant of Hsp104, which has three 
mutations (G739–K741 to IGF) that allow it to associate with the bacterial proteolytic 
chamber ClpP (Tessarz et al., 2008).  Thus, when HAP remodels a substrate, it feeds 
the protein into ClpP for proteolysis rather than releasing the protein into a soluble state.  
The HAP/ClpP system would be a useful tool for evaluating the improved efficacy of the 
Y257F:Y662F mutations since the successfully remodeled substrates would be 
eliminated from the reaction and cannot reform into fibrils with time.  Examination of 
Aβ42 elimination rates would give quantifiable data regarding relative potency of Hsp104 
variants. 
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PART 2.  Developing small molecules for Aβ42 
 
Background 
 
Small molecules are appealing as a potential treatment for Aβ42 because of the relative 
size in comparison to an amyloid fibril, allowing the molecule to intercalate within the 
tight intermolecular contacts and break apart the associations.  Additionally, a small 
molecule can be optimized for a specific substrate to enhance potency. 
 
A screen of bioactive small molecules previously uncovered 4,5-dianilinopthalimide 
(DAPH-1) as a potent inhibitor of Aβ42 amyloidogenesis (Blanchard et al., 2004).  Our 
lab has developed analogs based on this structure, with organic synthesis performed by 
Professor Stephen Buchwald (MIT Chemistry).  We designed molecules to probe the 
necessity of each component group (aniline rings vs pthalimide) in anti-Aβ42 function as 
well as exploring the parameters required of small constituents added to the aniline rings 
(Fig II-6). 
 
We employed these molecules in various assays to understand how DAPH molecules 
interfere with various steps of the Aβ42 amyloidogenesis pathway.  We were interested 
in probing the role of these molecules in preventing and reversing fibril formation, ability 
to affect oligomerization, and the effect of DAPH treatment on toxicity of the Aβ42 
conformers. 
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Figure II-6  Structures of DAPH analogs 
The DAPH-1 structure was modified in this series of analogs.  The collection includes molecules 
deficient in aniline rings, either lacking rings (DAPH-6) or tethered to the scaffold (SA), and a 
molecule with a bulky group added to pthalimide (DAPH-2) to determine which component 
groups are critical in the observed anti-amyloid function of DAPH-1.  A water-soluble analog 
(DAPH-14) was also created.  Small functional groups were added to the aniline rings to 
determine what properties might enhance efficacy of the rings in interfering with Aβ42 amyloid 
formation.  Groups examined were fluorine (DAPH-7) and NO2 (DAPH-10), as well as methoxy 
(DAPH-12) and a methyl group (DAPH-22).  DAPH-12 was further probed by examination of 
modifications to this molecule: replacing methoxy with ethoxy (DAPH-12a), a methyl group 
added onto the pthalimide (DAPH-12b), or the creation of CF3 on the aniline rings (DAPH-12c). 
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Initial results: DAPHs antagonize Aβ42 fibrils 
 
Initial DAPH experiments were conducted in our lab by Huan Wang.  First, a small 
screen was performed to determine which component groups with the DAPH molecule 
contributed to the inhibitory property observed for Aβ42 amyloid formation.  As with 
previous studies, DAPH-1 suppressed Aβ42 fibril formation by ThT and this effect was 
more pronounced as the concentration of the small molecule was increased (Fig II-7A).  
DAPH analogs lacking aniline rings (DAPH-6) and with tethered rings (SA) were 
ineffective at inhibiting fibrillization, suggesting that the aniline rings are critical for a 
productive interaction with Aβ42, and these rings must be mobile.  Moreover, Huan 
Figure II-7  Prevention of Aβ42 
fibrillization by DAPHs 
A.  DAPH analogs require flexible 
aniline rings to prevent Aβ42 fibril 
formation.  DAPH molecules (10 µM 
or 40 µM, or equivalent volume 
DMSO as a vehicle control) were 
added prior to fibrillization of Aβ42 
(10 µM), shaking at 700 rpm at 37ºC 
for 24 h.  Analogs deficient in aniline 
rings (DAPH-6 and SA) do not 
suppress Aβ42 fibrillization, but the 
addition of small hydrocarbon groups 
to the aniline rings (DAPH-12 and 
DAPH-22) improve inhibitory potency 
compared to that of DAPH-1. n=4, 
Mean±SEM 
B.  Successful DAPHs eliminate the 
appearance of Aβ42 fibrils.  
Fibrillization reactions in the presence 
of each small molecule as in A were 
negatively stained and viewed by EM.  
Aβ42 alone forms a dense network of 
fibrils, and DAPH analogs showing 
efficacy in suppressing 
amyloidogenesis by ThT (A) also 
prevented the visual development of 
fibrils.  Scale bar = 0.5 µm 
Experiments by Huan Wang. 
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found that addition of small hydrocarbon groups onto the aniline rings (DAPH-12 and 
DAPH-22) enhanced the efficacy in preventing Aβ42 fibril formation, with lower 
concentration of these analogs showing as much potency as the higher concentration of 
DAPH-1 (Fig II-7A).  EM images confirmed that the analogs suppressing amyloid 
formation by ThT indeed prevented fibril development (Fig II-7B). 
 
Huan also examined the ability of the panel of DAPH analogs to antagonize pre-formed 
Aβ42 fibrils.  Results were consistent with those seen in prevention of fibrillization.  
DAPH molecules required flexible aniline rings to exhibit potency in reversing Aβ42 
fibrils, and again, DAPH-12 and DAPH-22 showed enhanced activity (Fig II-8A and 8B).   
Figure II-8  Reversal of Aβ42 
fibrils by DAPHs 
A.  DAPH analogs require flexible 
aniline rings to reverse Aβ42 fibril 
formation.  DAPH molecules (10 µM 
or 40 µM, or equivalent volume 
DMSO as a vehicle control) were 
added to preformed fibrils of Aβ42 
(10 µM) and incubated at 37ºC for 1 
h.  Analogs deficient in aniline rings 
(DAPH-6 and SA) do not reverse 
Aβ42 amyloid fibrils, but the 
addition of small hydrocarbon 
groups to the aniline rings (DAPH-
12 and DAPH-22) improve potency 
compared to that of DAPH-1. n≥3, 
Mean±SEM 
B.  Successful DAPHs eliminate the 
presence of Aβ42 fibrils.  Pre-
formed fibrils were incubated each 
small molecule as in A, and were 
negatively stained and viewed by 
EM.  Aβ42 alone maintained fibril 
integrity, and DAPH analogs 
showing efficacy in eliminating 
Aβ42 fibrils by ThT (A) also 
reversed the visual appearance of 
fibrils.  Scale bar = 0.5 µm 
Experiments by Huan Wang. 
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In addition to preventing and reversing Aβ42 fibrils, successful DAPH analogs also 
affected the templating property of amyloid, as measured by the ability to seed 
fibrillization of Aβ42 monomers.  Huan observed that Aβ42 assemblies formed in the 
presence of DAPH do not seed fibrillization of monomers, indicating that these 
conformers formed in the presence of DAPHs are non-amyloid.  She also found that 
Aβ42 fibrils disassembled by DAPHs no longer serve as a template in seeding reactions, 
indicating large structural reorganizations by the small molecules.  Therefore, it is 
obvious that DAPH molecules are dramatically interfering with the highly stable amyloid 
contacts and remodel the structures to eliminate the pernicious conformation. 
 
After probing the mechanism of which components of the DAPH molecules interact with 
Aβ42 fibrils, we sought to examine the interaction between DAPH-1 and oligomers, and 
further, to examine if treatment with DAPH analogs eliminates the cytotoxicity associated 
with Aβ42 fibrils. 
 
DAPH-1 redirects Aβ42 oligomerization 
 
We have established that DAPH-1 can prevent and reverse Aβ42 fibrils by remodeling 
the structure of these assemblies.  We next wanted to probe how DAPH-1 might affect 
the pre-amyloid oligomerization of Aβ42.  
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Jake Lazarus developed a protocol to promote Aβ42 oligomerization over fibril formation.  
He found that an intermediate agitation speed served to encourage the formation of 
oligomers and delay the conversion to fibrils (Fig II-9).  We therefore used this procedure 
for all oligomer studies. 
 
In order to evaluate the effect of DAPH-1 on Aβ42 oligomer formation, we sought to 
visualize the appearance of discrete oligomeric species on a semi-native gel.  We 
formed oligomers either alone or in equimolar DAPH-1 and then examined consecutive 
time points of the soluble populations to visualize the time course of oligomerization.  
Untreated Aβ42 started as low molecular weight (MW) oligomers but quickly 
accumulated into high MW oligomers before forming large insoluble amyloid fibrils that 
were unable to enter the gel (Fig II-10, vehicle).  We found that DAPH-1 accelerated the 
loss of soluble populations of Aβ42, redirecting oligomers into insoluble non-amyloid 
accumulations (Fig II-10).  Note that the formation of high MW oligomers was completely 
prevented by DAPH-1 treatment.  
 
Figure II-9  Aβ42 oligomer 
preparation 
Aβ42 amyloid formation was 
monitored ThT.  Aβ42 was 
dissolved in HFIP, speed-
vacuumed to dryness, and 
resuspended in buffer.  Agitation of 
Aβ42 at 300 rpm or 1000 rpm at 
37ºC promotes the rapid formation 
of fibrils, but agitation at 500 rpm 
favors the formation of oligomers.  
The reactivity with amyloid-binding 
dye ThT begins to increase after 2 
h, suggesting the enrichment of 
pre-amyloid oligomeric forms at 
earlier time points. 
Experiment by Jake Lazarus. 
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Equimolar DAPH-1 prevents Aβ42 
oligomer formation. The 
oligomerization reaction was 
performed by agitating Aβ42 (100 
µM) in the presence of DAPH-1 
(100 µM) or equivalent volume 
DMSO (vehicle) at 500 rpm.  The 
reaction products were filtered 
through a 0.22 µm filter to collect 
the soluble species at indicated 
time points and then the oligomers 
were exposed to 2% SDS, and, 
without boiling the samples, were 
resolved on a 10–20% Tris-tricine 
gel at 4ºC.  The peptides were detected by Western blot using the α-Aβ 6E10 antibody.  The 
progression of Aβ42 alone shows the transition from low MW oligomers to high MW oligomers to 
insoluble fibrils unable to enter the gel.  The presence of DAPH-1 prevents the formation of high 
MW oligomers and redirects Aβ42 into insoluble aggregates that are non-amyloid in nature. 
 
We next examined the time course of Aβ42 oligomerization by dot blot using 
conformation-specific antibodies.  The oligomerization reaction was performed either 
alone or in equimolar DAPH-1 and then spotted unfiltered to view the total population or 
0.22 µm filtered to view only the soluble species.  Each reaction was spotted in serial 
dilutions to highlight subtle differences between treatments.  The α-Aβ 6E10 antibody 
showed that total levels of Aβ42 were consistent among the treatments, but highlighted 
that DAPH-1 accelerated the loss of soluble Aβ42 (Fig II-11A).  The A11 antibody that 
recognizes a generic oligomer conformation did not have strong reactivity, but 
differences were apparent in the highest concentration dilution, again showing that the 
oligomeric structure was prevented by DAPH-1 (Fig II-11B).  Another conformation-
specific antibody, NAB61, which reacts with the structure of Aβ oligomers and some Aβ 
fibrils that correspond to brain pathology, showed that DAPH-1 dramatically eliminated 
the development of pathologic conformations by Aβ42 (Fig II-11C).  These results 
Figure II-10  DAPH-1 intereferes 
with Aβ42 oligomerization 
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demonstrate that DAPH-1 accelerates the loss of soluble Aβ42 oligomeric populations 
into less pathological forms. 
 
 
 
Aβ42 oligomers, which are strongly associated with cytotoxicity, are structurally altered 
by DAPH-1 treatment.  Semi-native gel allowed visualization of distinct oligomeric bands, 
and DAPH-1 dramatically reduced the amount of soluble oligomers formed and 
completely eliminated the formation of high MW oligomers.  Therefore, DAPH-1 
Figure II-11  DAPHs redirect 
Aβ42 oligomers 
A–C.  DAPH-1 redirects Aβ42 
oligomers into insoluble 
accumulations.  Aβ42 
oligomerization was performed 
as in Fig II-10 in the presence 
of equimolar DAPH-1 (100 µM 
each) and spotted in serial 
dilutions on a nitrocellulose 
membrane.  Samples were 
passed through a 0.22 µm filter 
to separate the soluble species 
from the total sample.  
Antibodies used were: (A) Anti-
Aβ 6E10 antibody to probe for 
total Aβ levels; (B) Anti-
oligomer A11 antibody to probe 
for oligomeric structure; and (C) 
Anti-Aβ “pathologic 
conformation” NAB61 antibody 
(specific to oligomers and 
certain fibril strains) to probe for 
structures associated with brain 
pathology.  DAPH-1 
accelerates the loss of soluble 
Aβ42 samples (6E10) and 
reduces the presence of 
oligomers (A11) and structures 
associated with brain pathology 
(NAB61). 
144 
 
redirected oligomers from the amyloid pathway into alternate, insoluble structures.  Dot 
blot confirmed this accelerated formation of insoluble material and further demonstrated 
that this corresponded to a loss of pathological material.  Therefore, although DAPH-1 is 
driving off-pathway aggregation, this conformation may be more tolerable in a biological 
system than amyloid inclusions. 
 
We have established that DAPH molecules structurally alter both Aβ42 fibrils and 
oligomers, and next wanted to determine if these alterations reduce toxicity of these 
conformers. 
 
DAPH treatment reduces toxicity of Aβ42 fibrils 
 
Again, we sought to use a panel of DAPH analog molecules to probe the efficacy of 
DAPHs to disassemble Aβ42 fibrils, but the purpose of these experiments was to 
examine whether remodeling by DAPHs corresponded to reduced cytotoxicity of the 
fibrils.  We tested DAPH-1, known Aβ42-optimized structures DAPH-12 and DAPH-22, 
as well as an array of other analogs for potentially enhanced activity in disassembling 
pre-formed Aβ42 fibrils.  Immediately following the disassembly reaction, the molecule-
treated reaction products were applied to cultured SH-SY5Y neuroblastoma cells to 
monitor cell survival and therefore gauge toxicity. 
 
Again, we observed that DAPH-1 had the ability to reverse pre-formed Aβ42 fibrils by 
reducing amyloid content to 54% by ThT, and that DAPH-12 and DAPH-22 showed 
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enhanced disaggregation activity (47% and 36%, respectively) (Fig 12A).  The other 
molecules tested had various degrees of success in antagonizing fibrils, with DAPH-12c 
showing the most potent effect, reducing amyloid presence more than DAPH-1, to 35% 
(Fig II-12A).  It is interesting to note that while DAPH-12, containing the added methoxy 
groups, showed improved efficacy against Aβ42 fibrils, the expansion to ethoxy in 
DAPH-12a eliminated function altogether (88% fibrils remaining) (Fig II-12A).  Thus, 
addition of a small hydrocarbon chain to the aniline rings of DAPH is beneficial, but the 
chain must not exceed a certain length. 
 
The Aβ42 fibrils treated by DAPHs were added extracellularly to cultured SH-SY5Y 
neuroblastoma cells to mimic the toxic extracellular plaques that occur in AD.  Untreated 
Aβ42 fibrils (buffer) did cause toxicity, resulting in the death of 35% of the cultured cells, 
as measured by MTT assay to assess mitochondrial viability (Fig II-12B).  The DAPH 
molecules showing greatest ability to reduce toxicity were DAPH-1 (24%), DAPH-12 
(21%), DAPH-22 (13%), and DAPH-12c (15%) (Fig II-12B).  Because the efficiency of 
each DAPH to eliminate amyloid content of the fibrils corresponded so well to conferring 
protection against toxicity, we performed a correlation to compare these two measures.  
Indeed, reversal of cross-β structure by a DAPH molecule correlated well with 
elimination of fiber toxicity, with a correlation coefficient of 0.889 (Fig II-12C). 
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A.  Certain DAPHs 
reduce fibrillar content 
of Aβ42 fibrils, as 
measured by ThT.  Pre-
formed Aβ42 fibrils (10 
µM) were treated with 
the indicated DAPH 
molecule (40 µM) for 2 h 
at 37ºC.  As before, 
DAPH-1 eliminated 46% 
of the cross-β 
conformation of the 
fibrils, and DAPH-12, 
DAPH-22, and DAPH-
12c showed enhanced 
anti-amyloid activity.  
n≥5, Mean±SEM 
B.  Fibrils treated by 
certain DAPHs have 
reduced toxicity.  The 
reaction products from 
A were applied to 
cultured SH-SY5Y 
neuroblastoma cells 
(10,000 cells/well, 
undifferentiated) such 
that half the media was 
replaced (5 µM final 
concentration of Aβ42).  
After 4 h treatment, cell 
survival was measured 
by the MTT assay, 
which uses a dye to 
measure mitochondrial 
viability.  Treatments 
were normalized to 
treatment by small 
molecule alone and 
then compared to Triton 
X-100 detergent to 
determine relative toxicity.  Untreated Aβ42 fibrils were toxic to 35% of cells, but this was reduced 
by pre-treatment with DAPH-1 or successful DAPH analogs (-12, -22, and -12c).  n≥4, 
Mean±SEM 
C.  Correlation between efficacy in eliminating amyloid and impact on toxicity for each DAPH 
molecule.  The correlation coefficient was 0.889, indicating a strong association between DAPH-
driven elimination of cross-β conformation and resulting cytotoxicity of the treated Aβ42 fibrils. 
Figure II-12  DAPH 
remodeling corre-
sponds to reduced 
toxicity 
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We have shown that DAPH analogs showing success in combating the amyloid structure 
of Aβ42 fibrils also reduces the toxicity of those fibrils.  We were also able to draw some 
conclusions about structural alterations that improve the anti-Aβ42 activity of DAPH-1. 
Previous results have demonstrated that the aniline rings are critical for function, and 
further, we found that addition of small hydrophobic groups to these rings may enhance 
the ability of DAPH to interact productively with Aβ42. Addition of methyl groups (DAPH-
22) improves efficacy, as does methoxy (DAPH-12), but interestingly, addition of ethoxy 
groups (DAPH-12a) abolishes all functionality.  Therefore, there is a size limitation of the 
groups or the constituent may block activity.   
 
It was unexpected that addition of a group to the pthalimide had an effect on the potency 
of the DAPH molecule, as we have shown that the aniline rings are the critical 
component in Aβ42 interactions.  We observed that the addition of a bulky group on the 
pthalimide did impair activity (DAPH-2, compared to DAPH-1) and that even a small 
addition of a methyl chain had an effect (DAPH-12b, compared to DAPH-12).  Therefore, 
the pthalimide may be influencing the potency of the rest of the molecule. 
 
It is harder to draw definitive conclusions about other constituent groups.  We found that 
NO2 groups  on the aniline rings (DAPH-10) had strongly decreased activity compared to 
DAPH-1.  The water-soluble analog DAPH-14 also showed impaired function.  
Interestingly, while addition of fluorine alone had a slightly inhibitory effect (DAPH-7), we 
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observed that CF3 (DAPH-12c) greatly potentiated anti-Aβ42 activity.  More molecules 
may be needed to clarify the contribution of these groups. 
 
Speculation on the mechanism of DAPH molecules 
 
The intermolecular contacts of the Aβ42 fibril have been well characterized, and many of 
the critical residues involved in fibrillization have been identified.  The adjacent amino 
acids F19 and F20 are part of the protofibril core that is critical for amyloidogenesis 
(Luhrs et al., 2005), and the repetition of the aromatic rings of the side chains was 
reminiscent of the arrangement of the aniline rings in the DAPH-1 molecule (Fig II-13A 
and II-13B).  Because of our findings that the aniline rings are critical to the anti-Aβ42 
function of DAPH molecules, we hypothesized that the aniline rings might be interfering 
with the Aβ42 fibril by disrupting interactions between the aromatic rings (Fig II-13B).  In 
this model, DAPH-1 intercalates the Aβ42 fibril and, through π - π stacking, disrupts the 
existing intermolecular contacts. 
 
 
Figure II-13  Model of DAPH 
with Aβ42 
A.  The DAPH-1 molecule has 
aromatic rings (circled in pink). 
B.  The Aβ42 peptide has 
adjacent aromatic amino acids 
(F19 and F20, circled in pink) 
that are critical to fibrillization, 
based on the structure from 
Luhrs et al., 2005.  Our 
hypothesis is that the DAPH-1 
molecule interacts with the 
Aβ42 fibril at these residues, 
and by π - π stacking, disrupts 
the existing fibril contacts.  
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To test the feasibility of this model, we collaborated with Professor Kim Sharp to create a 
motile representation of these molecules.  Dr. Sharp created movies showing the natural 
3-dimensional fluctuations of each molecule (Fig II-14A), and was then able to measure 
the pseudo-torsion angles adopted by the bonds at the base of the aromatic rings of 
interest (Fig II-14B).  Superficially, it does seem that the aniline rings of DAPH-1 are able 
to adopt angles that are complementary to the phenylalanines of the Aβ42 fibril, thus 
supporting our model that aromatic interactions between these molecules may interfere 
with the existing phenylalanine contacts within the fibril.  
A 
 
 
 
 
 
 
To experimentally test this interaction, we sought to use an Aβ42 fibril that did not have 
the adjacent FF motif.  Previous research had determined that replacement of both 
phenylalanines with isoleucines, F19I:F20I (FF→II Aβ42) still resulted in fibril formation 
Figure II-14  Motion 
models of DAPH 
and Aβ42 
A.  Modeling the 
motion of the 
aromatic rings in 
DAPH-1 and in Aβ42 
fibrils.  The molecular 
structures were 
animated to simulate 
the range of motion 
of each molecular 
bond in solution.  
B.  The frequency of 
time throughout the 
simulations that the 
aromatic rings spent 
at specific torsion 
angles was plotted in 
a histogram.  
Movies and analysis 
by Professor Kim 
Sharp 
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(Hilbich et al., 1992).  Additionally, the exchange of F19 for its binding partner across 
fibril strands G38, F19G:G38F (F↔G Aβ42) also maintained the capacity to form fibrils 
(Luhrs et al., 2005).  We had these two peptides synthesized in order to examine 
whether DAPH-1 could interfere with the intermolecular contacts formed by these fibrils 
lacking the FF motif. 
 
We found that FF→II Aβ42 was able to form fibrils with similar kinetics to WT Aβ42, but 
that under our conditions, F↔G Aβ42 did not (Fig II-15).  Rather than optimizing the 
reaction for both Aβ42 variants, we proceeded with experiments to determine if DAPH-1 
maintained anti-amyloid properties for the FF→II Aβ42 peptide that lacks the aromatic 
rings critical to our model. 
 
To determine if DAPH-1 interfered with FF→II Aβ42 fibrillization, we looked at amyloid 
assembly in the presence of increasing concentrations of DAPH-1.  DAPH-1 inhibited 
amyloid formation of FF→II Aβ42, at levels almost identical to WT Aβ42 (Fig II-16A).  
Moreover, DAPH-1 was as effective at disassembling pre-formed FF→II Aβ42 fibrils as 
Figure II-15  Aβ42 variant 
fibrillization 
Each variant of Aβ42 (10 µM) 
was agitated in the plate reader 
at 12.7 Hz at 37ºC for 20 h, 
and resulting fibril formation 
was monitored by ThT.  FF→II 
Aβ42 formed fibrils with similar 
kinetics and to a similar extent 
as WT Aβ42.  Our conditions 
did not result in F↔G Aβ42 
fibrillization.  n=3, Mean (SEM 
not included for simplicity) 
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pre-formed WT Aβ42 fibrils (Fig II-16B).  Taken together, these data suggest that DAPH-
1 activity does not depend on the adjacent aromatic residues at F19 and F20; it must 
antagonize Aβ42 amyloidogenesis in another manner. 
 
 
In conclusion, the interaction between DAPH-1 and Aβ42 does not depend on aromatic 
rings at F19 and F20.  Therefore, it is unlikely that DAPH-1 is breaking fibers apart at 
that location by means of aromatic ring interactions.  The exact mechanism remains 
under investigation in the Shorter lab. 
 
 
Figure II-16  DAPH-1 
prevents fibrillization of an 
Aβ42 variant  
A.  DAPH-1 prevents 
fibrillization of WT and FF→II 
Aβ42 fibrils as measured by 
ThT.  Aβ42 (10 µM) was 
incubated with increasing 
concentrations of DAPH-1 (0–
50 µM) with agitation of 700 
rpm at 37ºC for 16 h.  DAPH-
1 suppressed fibril formation 
for both forms of Aβ42, with 
similar sensitivity to 
increasing small molecule 
ratios. n=3, Mean±SEM 
B.  DAPH-1 reverses WT and 
FF→II Aβ42 fibrils. Pre-
formed Aβ42 fibrils (10 µM) 
were incubated with DAPH-1 
(10 µM or 40 µM) at 37ºC for 
2 h and the amyloid content 
remaining was examined by 
ThT.  Treatment with DAPH-1 
eliminated fibrils for both 
forms of Aβ42 to a similar 
extent.  n=3, Mean±SEM 
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Conclusions and Future Directions  
 
Our results have characterized DAPH-1 as a molecule that interferes with the 
development of Aβ42 fibrils and oligomers, and even possesses the ability to reverse 
pre-formed fibrils.  Further, we have identified modifications to the DAPH-1 structure that 
improve its activity as an Aβ42 antagonist.  We found that short hydrocarbon chains 
added to aniline rings are most effective but that the size of these groups must be within 
a size limitation.  We also established that successful remodeling of Aβ42 fibrils by 
DAPHs correlated with a reduction in the cytotoxicity of the fibril. 
 
The interaction between DAPHs and oligomers requires further characterization.  It will 
be of interest to determine if the DAPH analogs with improved efficacy against Aβ42 
fibrils will also have enhanced activity against oligomers.  Additionally, the toxicity of 
these forms is of great interest.  Previous studies have indicated that pre-amyloid 
oligomers are more cytotoxic than fully assembled fibrils (Kayed et al., 2003).  However, 
our initial experiments to evaluate oligomer toxicity in SH-SY5Y neuroblastoma cells 
indicated only minimal toxicity of oligomers.  The structures of our oligomers may be 
distinct from the oligomers from these studies, or an experimental parameter might need 
to optimized (such as differentiating the neuroblastoma cells).   
 
We examined a limited selection of DAPH analogs, so development of additional 
molecules may allow even further optimization against Aβ42.  We have developed some 
guidelines for successful additions to the aniline rings, the short hydrocarbons of DAPH-
12 and DAPH-22, but additional investigation into the CF3 group of DAPH-12c is 
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warranted.  Other issues must be considered if DAPHs are to be developed as an AD 
treatment, such as ensuring the molecule can cross the blood-brain barrier. 
 
Because DAPH-1 potently interfered with FF→II Aβ42 amyloidogenesis, our model of 
aromatic ring association between the aniline rings of DAPH-1 and the FF motif of Aβ42 
was determined to be incorrect.  Therefore, the mechanism of the interaction is still 
unknown.  The hairpin turn occurring at amino acids 26–30 is facilitated by a salt bridge 
between D23 and K28 may be point of entry for small molecules because it may be 
accessible to water molecules.  Mechanistic studies will be required to identify the 
point(s) of interaction between DAPH-1 and Aβ42 fibrils. 
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PART 3.  Using foldamers to antagonize Aβ42 amyloidogenesis 
 
Background 
 
Foldamers are protein mimics that do not have a canonical peptide backbone but are 
able to form secondary structures such as α-helices and β-sheets.  These molecules are 
critical for understanding the parameters of protein folding in terms of purely molecular 
features (e.g., hydrogen bonding and hydrophobic interactions) rather than features that 
may be peptide-specific (Goodman et al., 
2007, Zhang et al., 2012).  There are distinct 
classes of foldamers.  While the aliphatic 
foldamers have carbon chains that have 
variations to the natural α-peptide framework, 
there is also a class of aromatic foldamers, 
which include the arylamide foldamers, that 
contain aromatic rings within the repeating 
backbone motif (Fig II-17A) (Goodman et al., 
2007).  Despite having such a distinct 
configuration from the canonical α-peptide, 
aromatic foldamers are also able to adopt 
secondary folds such as the α-helix or β-sheet 
(Fig II-17B) (Gellman, 1998).  Additionally, 
Figure II-17  Foldamer framework 
(A)  The α-peptide is the canonical backbone 
used in natural peptides.  The arylamide 
foldamers employ aromatic rings as spacers 
within the backbone.   
(B)  The polymeric arylamide chain is able to 
adopt folds as an aliphatic chain would.  
Shown is a crude example of an arylamide 
foldamer stacking in the α-helix 
conformation. 
155 
 
foldamers are able to oligomerize to form even more complicated quaternary structures 
(Goodman et al., 2007).   
 
Because these foldamers are able to mimic protein structures, but are not susceptible to 
cellular proteolytic degradation pathways (Horne et al., 2009), these molecules may be 
an ideal treatment for interrupting protein aggregation associated with disease. 
 
Certain foldamers inhibit Aβ42 fibrillization 
 
The aim of these experiments was to establish the potential application of aromatic 
foldamers in combating Aβ42 amyloid formation.  We collaborated with Professor 
William DeGrado, who selected and supplied the panel of arylamide foldamers used 
here (Fig II-18).  The collection of molecules includes carbon side chain additions with 
various amine arrangements as well as intermittent addition of an ether group to the 
aromatic rings within the backbone. 
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Figure II-18  Collection of arylamide foldamers 
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We performed the 
Aβ42 fibrillization 
experiment in the 
presence of 
equimolar foldamer 
and monitored 
amyloid formation 
by ThT.  The 
foldamers had 
varying degrees of 
success in preventing Aβ42 fibril formation, with the impact ranging from no effect to 
almost complete inhibition (Fig II-19). 
 
From this collection, we have pulled out three foldamers to highlight the distinct 
interactions that these molecules may have with Aβ42 (Fig II-20).  Foldamer 344 (Fig II-
20, top panel) had no effect on Aβ42 fibrillization kinetics.  Foldamer 615 is particularly 
interesting because it did not suppress fibril formation and the final amyloid load is 
equivalent to untreated Aβ42, but the foldamer delayed the lag phase preceding fibril 
formation (Fig II-20, middle panel).  The precise mechanism of this interaction requires 
further characterization, but this finding may indicate that 615 is suppressing the 
oligomer formation that is required to initiate amyloid formation, but once an elongation-
competent structure is formed, the foldamer has no effect on rapid fibril polymerization.  
Figure II-19  Certain foldamers prevent Aβ42 fibrillization 
Foldamers have varying degrees of success in preventing Aβ42 
fibrillization.  Monomeric Aβ42 (10 µM) and the indicated foldamer (10 
µM) were agitated at 12.7 Hz at 37ºC for 4 h, with ThT monitoring fibril 
formation over time.  Certain foldamers had a strong inhibitory effect 
while other had no impact on amyloidogenesis.  n=6, Mean±SEM 
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Additionally, we identified Foldamer 334 
as a potent suppressor of Aβ42 fibril 
formation, which seems to completely 
inhibit amyloidogenesis (Fig II-20, bottom 
panel).  
 
While certain foldamers were capable of preventing Aβ42 fibrillization, all molecules 
tested were unable to reverse pre-formed fibrils (Fig II-21).  Even the potent inhibitor of 
amyloid formation, 334, had no effect on eliminating existing Aβ42 fibrils.  Therefore, 
foldamers must be interacting with Aβ42 along the amyloidogenesis pathway (e.g., 
capping fibril-templating structures) and have no ability to break apart the existing stable 
contacts common to the amyloid cross-β fold.  
No foldamer was able to 
eliminate existing amyloid fibrils.  
Pre-formed Aβ42 fibrils (10 µM) 
were treated with the indicated 
foldamer (10 µM) at 37ºC for 16 
h, with ThT monitoring changes in 
amyloid level.  Each treatment 
mirrored the untreated Aβ42 
group, with amyloid level slightly 
decreasing over time, but none 
demonstrating dramatic 
disassembly.  The Aβ42 alone condition did have a slight initial increase in amyloid levels, and all 
Figure II-20  Foldamers have distinct 
effects on Aβ42 
Foldamers may interact with Aβ42 at different 
stages of amyloidogenesis.  Graphs taken 
directly from Fig II-19.  Foldamer 344 had no 
effect on Aβ42 fibril formation.  615 extended 
the lag phase that precedes rapid elongation, 
suggesting an interaction with obligate pre-
amyloid oligomers.  334 was a very strong 
suppressor of amyloid formation. 
Figure II-21  Foldamers do not 
disassemble Aβ42 fibrils 
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of the foldamers prevented this, again consistent with previous results that the foldamers interfere 
with amyloid formation but are incapable of reversing the stable amyloid contacts once they exist. 
 
Conclusions and Future Directions 
 
These preliminary results suggest that foldamers are indeed a promising avenue to 
prevent Aβ42 fibril formation.  Further experiments are needed to characterize the 
inhibitory effect and determine how the foldamers interfere with amyloidogenesis.  The 
mechanism will be distinct from a small molecule, such as DAPH-1, which is able to 
break apart existing contacts in addition to preventing contact formation.  This is another 
caveat of developing foldamers as a therapeutic; it must be administered prior to 
development of amyloid load.  However, the idea that sequestration of toxic soluble 
species into fibrils is beneficial suggests that foldamers may be ideal to prevent growth 
of existing plaques without releasing toxic components by disassembling existing 
aggregates. 
 
Further collections of foldamers might be tested for potency in preventing Aβ42 fibril 
formation, with the successful structures determined here guiding selection of new 
molecules.  Moreover, a greater understanding of the foldamer state is needed to 
understand the interaction and predict successful analogs.  Some of these foldamers 
associate into oligomeric complexes, and this may be critical to anti-Aβ42 function.  
These issues, as well as determining ideal stoichiometry, are currently being 
investigated in the Shorter lab.  
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Overall conclusions: Developing novel antagonists of Aβ42 amyloidogenesis 
 
The novel treatments presented here introduce potential disease therapies that might be 
further developed to combat Aβ42 amyloid conformers.  Hsp104, DAPH analongs, and 
arylamide foldamers each present a separate mode of action, which, in turn, may each 
be well suited for a specific disease environment.  For example, our biochemical assays 
indicate that Hsp104 and successful DAPH analogs physically dismantle pre-formed 
Aβ42 fibrils, while successful foldamers could only prevent de novo amyloid formation.  
As such, foldamer application to an existing amyloid fibril population would be 
completely ineffective.  However, one caveat of reversing Aβ42 fibrils is the potential 
release of toxic species from sequestration within these aggregates (Hardy and Selkoe, 
2002, Koffie et al., 2009).  Therefore, a combinatorial therapy might allow synergistic 
synthesis of these distinct activities.  One can imagine that Hsp104 applied alongside 
small molecules or foldamers might be more effective at eliminating amyloid fibrils that 
Hsp104 alone because the Hsp104-remodeled Aβ42 monomers can be kept soluble by 
the other treatment molecules.  Moreover, it has been reported that amyloid fibrils 
formed in the presence of an inhibitory small molecule alter their intermolecular contacts 
such that the molecule’s target site is altered, creating drug-resistant strains (Roberts et 
al., 2009).  A combination of small molecules was able to overcome this imposed strain 
selection, but our hope is that even more diverse molecules may synergize further.   
 
The results presented here are mostly preliminary in nature, and further investigations 
will ultimately determine the potential of each of these treatment molecules in combating 
Aβ42 amyloidogenesis.    
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APPENDIX III : DETAILED METHODS 
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Fly Phenotype Analysis and Protein Techniques 
 
Eye Images 
 
1. Anaesthetize flies on CO2 pad.  To kill the fly, hold the fly still with a pair of 
forceps with your left hand, and with your right hand, jab the sharp end of another 
pair of forceps into the thorax.  It is especially effective to slightly open the 
forceps once inside the thorax. 
 
2. Place a drop of clear nail polish onto a slide.  Use the forceps to lift the fly by 
holding onto its legs and then gently place the fly into the drop.  It is best to put 
the legs and abdomen in the nail polish but leave the head outside of the drop; 
sometimes the drop will envelop the head if it is too close to the head or if it is 
watery nail polish. 
 
3. Wait for the nail polish to dry.  Use your forceps to arrange or tilt the head so that 
you have a flat view of the eye from above.  (The fly might move or you may 
need to readjust later, but arranging things now really saves time.) 
 
4. Take your slide to the Leica Z-16 apo zoom microscope.  Turn on the acquisition 
software LAS V3.8 (you can skip the motorfocus drive initialization step by 
selecting “cancel” and then “no”) and turn on the light source.  In the Process tab, 
select Z and then change setting to Transmitted Light Method 2. 
 
5. Go to the Browse Tab and add a new folder within your data folder.  [The icon 
has a folder with a subfolder and a plus sign to indicate addition of a new 
subfolder.]  Use the rename button at the bottom to name the new folder with the 
current date.  Then, select the new folder as the capture location in which new 
files will save.  [This icon has a red dot on top of the subfolder and a white check 
mark next to it.] 
 
6. In the Acquire Tab, make sure you are in the Z window and view the image of the 
fly.  It is easier to adjust the fly’s position and head angle by looking through the 
microscope lens and not by watching on the screen.  Center the fly so its eye is 
in the middle of the image. 
 
7. Using the outer wheel on the attachment console, make sure the zoom is set to 
maximum (114X) so all the images you take are equivalent. 
 
8. Use the inner wheel to control focal plane.   
 
a. In the image of the Z stack plane, click the left orange arrow so it turns 
black.  Move the wheel to adjust the focus to the lowest level (outer edge) 
of the eye.  Make sure the eye is positioned so that the whole outer edge 
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is close to being in focus; this will ensure a nice angle in your picture.  
Click the arrow so it turns orange again to lock in your setting. 
 
b. In the Z stack image, click the right orange arrow so it turns black.  Move 
the wheel to adjust the focus to the highest level of the eye (usually the 
top of the curve somewhere in the middle of the eye).  Click the arrow so 
it turns orange again to lock in your setting. 
 
9. Set the Z Step size to 15.  Your eye image should end up being around 10 steps 
to accommodate the entire eye.  You should adjust these settings if you’re taking 
pictures of something larger than a fly eye. 
 
10. Rename the image file name in Options.  I also make sure that “Create stack” 
and that “Align images before combining” are both checked. 
 
11. Hit the Acquire button and watch as the scope takes images at each Z step.  It 
usually takes a while for the software to create the Multi-Focus image. 
 
12. The software displays your image in the Browse tab when it is finished.  If you 
need to rename your file, you must do that within the data folder, as it will not let 
you within the Leica software. 
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Paraffin Sections 
 
Fixing heads 
 
1. Fill an eppendorf tube with about 1 ml of Bouin’s fixative solution (Sigma HT10-1-
32).  Label the tubes ahead of time with an experiment number to keep track of 
the genotype within that tube. 
 
2. Anaesthetize flies on CO2 pad.  Gently squeeze the thorax of the fly with forceps 
in your left hand.  The fly will extend its neck.  Use a razor blade with your right 
hand to sever the neck connection. 
 
a. Some people remove the proboscis, but I do not.  It is better to handle the 
heads as little as possible if there is a degenerative eye phenotype. 
 
3. Move the severed head into the eppendorf tube with your forceps.   
 
4. Repeat until you have at least three heads per genotype (but you probably want 
more if it is an important experimental condition!). 
 
5. Once you have all the heads floating in the Bouin’s solution, add a small square 
of KimWipe to hold the heads submerged under the surface of the liquid.  This is 
difficult and takes finesse.  Your square should be just thinner than the width of 
the opening of the eppendorf tube.  Hold it with your forceps and lower it 
perpendicularly to the surface of the liquid so that it enters in the middle of the 
tube.  Slide the KimWipe toward the tube wall and try to trap the heads between 
the KimWipe and the wall.  It may take several KimWipes to trap and hold all the 
heads beneath the surface. 
 
6. Put the eppendorf tubes in a rack on the Orbital Shaker and let them shake for 3 
days to 1 week.  (I have gone over a week’s incubation and the samples seemed 
fine, but I try not to make it a habit.  Usually, I monitor the tubes daily and wait 
until the heads sink to the bottom.) 
 
7. Make Leaching Buffer 
 Stock For 1 L 
 50 mM Tris 1 M Tris, pH 8.0 50 ml 
 150 mM NaCl powder 8.7g 
 water  to 1 L 
 
8. Cut lens paper into sixths:  Make two vertical cuts to divide it into thirds and then 
a horizontal cut to separate each of those in half. 
 
9. Set up a workspace in the hood.  Place a pipette tip box lid on an angle by 
putting one end on a tip grid insert and leaving the other on the flat surface.  Fill a 
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beaker with a level of Leaching Buffer that will cover your samples (usually 
around 200 ml depending on the number).  Gather embedding cassettes and 
label them with your experiment number.  Find a new plastic transfer pipette 
(dropper). 
 
10. Place a square of lens paper into the angled tip box lid and use the dropper to 
dampen the square with Leaching Buffer. 
 
11. Carefully remove the KimWipe bits from the eppendorf tube and make sure all 
the heads stay behind in the Bouin’s solution.  Suck the heads into the dropper 
and then expel them onto the square of lens paper. 
 
12. Use the dropper to carefully rinse the lens paper to remove a lot of the Bouin’s 
solution.  Let it flow down the angled surface and repeat until the paper is only a 
faint yellow. 
 
13. Make sure the heads are in the center of the lens paper square.  Use forceps to 
fold the lens paper into a C-fold in both directions, making a little packet to 
contain the heads.  Fold the right edge so it creates a crease about a third of the 
width of the paper and so that it covers the heads in the center of the square.  
Then, fold the left edge on top of that so the left flap overlaps the right flap.  This 
will create a fold ‘barrier’ on both sides to hold the heads into the middle.  Then, 
take the top edge and fold it down in the same manner so it creates a fold a third 
of the way from the top, and fold the bottom up to overlap and complete the final 
fold to hold the heads within the packet. 
 
14. Once the packet is folded, you can use the dropper to squeeze streams of 
Leaching Buffer onto it to clear the rest of the Bouin’s solution away. 
 
15. Place the lens paper packet into the embedding cassette with the appropriate 
label.  Drop it into the beaker containing Leaching Buffer. 
 
16. When all heads have been moved into cassettes, move the Leaching Buffer onto 
the Orbital Shaker for 6 hours to overnight. 
 
17. If you cannot proceed with the paraffin embedding procedure, you may store the 
leached samples in 70% EtOH in the fridge.  They should last indefinitely in this 
condition, but try not to leave them for too long. 
 
Embedding and Blocking Paraffin Sections 
 
1. Prepare the embedding machine.  All of the chemicals needed are stored in 
bottles near the machine with the number for each bucket it should go in.  Simply 
pour the chemical into the indicated bucket.  The solutions should be clear and 
166 
 
you need about 1 L to fully submerge your samples, so you may need to refresh 
the supplies occasionally. 
 
1 Histoclear  Do not put samples in this! 
2 (Empty) 
3 70% EtOH 
4 80% EtOH 
5 95% EtOH (I) 
6 95% EtOH (II) 
7 100% EtOH (I) 
8 100% EtOH (II) 
9 Xylenes (I)  Toxic! Use a mask or pour in a hood 
10 Xylenes (II)  Toxic! Use a mask or pour in a hood 
11 Paraffin (I)  Heated bucket, do not remove 
12 Paraffin (II)  Heated bucket, do not remove 
 
You will need to rotate the machine by pressing the button on the keypad in order 
for the openings to line up with each bucket. 
 
Remember to turn on the exhaust fan above the machine once you have opened 
the Xylenes container! 
 
2. Lift the arm of the embedding machine out of its storage position in Histoclear.  
Let the Histoclear drip back into the bucket.  
 
3. After samples have been leached, put the cassettes into the appropriately sized 
basket and place the basket into the embedding machine arm. 
 
4. Run a program based on the length of time you want the process to take.  
Overnight runs should be Program A (17 hrs) and daytime runs should be 
Program D (6 hrs). 
 
  Program A:   Program D: 
 3 hr  30 min 70% EtOH 
 1 hr  30 min 80% EtOH 
 1 hr  30 min 95% EtOH (I) 
 2 hr  30 min 95% EtOH (II) 
 2 hr  30 min 100% EtOH (I) 
 2 hr  30 min 100% EtOH (II) 
 1 hr  30 min Xylenes (I) 
 1 hr  30 min Xylenes (II) 
 2 hr  1 hr  Paraffin (I) 
 2 hr  1 hr  Paraffin (II) 
  
Note:  I have started using Program D for daytime runs because I had an incident 
in which the arm did not progress properly and my samples were left dry 
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overnight and ruined.  I frequently check the progress of the arm throughout the 
daytime run. 
  
5. The arm will stay submerged in the final step of hot paraffin until you use the 
button on the keypad to raise the arm.  When you retrieve your cassettes, let 
them cool on a paper towel.  You can store them indefinitely now that they are 
paraffin-embedded. 
 
6. To block the heads, take the cassettes to the Histology Prep Centre machine.  
Turn on the cold plate (green switch on the left) and allow it start cooling down.  
Collect a number of metal cup molds and make sure they are clear of old 
paraffin, especially around the edges.  Label the colored rings ahead of time. 
 
7. Place your cassette onto the right portion of the hot plate and let the paraffin melt 
enough that you can lift the lens paper packet out of the cassette without forcing 
it.  (I do this to the right side so the melted paraffin doesn’t get onto the molds I’m 
using on the left side.) 
 
8. Carefully unfold the C-folds of the packet.  You may need to put it on the hot 
plate to make it more pliable. 
 
9. Use the foot petal to drip some paraffin into a metal cup mold.  Don’t fill the cup 
all the way.  Let it sit on the hot plate in front of the drip spout. 
 
10. Briefly heat up the lens paper at a point under the head you want to block in 
order to loosen it.  Use your forceps to scoop underneath the head to transfer it 
into the metal cup mold.  Do not lift the head by squeezing between the forceps. 
 
11. Position the magnifying glass so you can see well.  Position the head flat in the 
middle of the cup and then bring the metal cup mold forward so it is resting just 
off the hot plate.  The paraffin will start to turn white and harden from the bottom 
up, so you have limited time.  Reach your forceps under the proboscis and gently 
tilt the head upward so the proboscis moves from facing you to facing up, with 
the back of the head at the base of the cup and the neck stump toward you.  
Once it is in place, move the metal cup mold onto the cold plate to let it harden.  
If you are not pleased with the head placement or angle, you can place the cup 
back onto the hot plate and wait for the paraffin to melt to try again. 
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12. Place your labeled colored ring onto the top of the metal cup mold so that the 
tabs for the ring are perpendicular to the tabs on the cup.  This will give you a 
place to leverage when separating them later. 
 
13. Use the foot pedal to fill the cup + ring with paraffin to the top of the ring. 
 
14. Place the cup + ring on the cold plate and don’t move it while it hardens. 
 
15. When the top of the paraffin looks opaque and the outside of the ring feels cool, 
try separating the cup from the ring.  It should come easily; if you have to force it, 
you will often stretch or break the paraffin inside the ring and will have to redo it.  
Now your sample is perfectly positioned in the paraffin bulb attached to the 
colored ring and is ready to be cut. 
 
Cutting Paraffin-Embedded Heads 
 
1. Cool your paraffin-embedded samples attached to the colored ring by placing 
them in ice for at least 30 min. 
 
2. Turn on the microtome and check the settings are on 8 µm sections with 
continuous transition.  Turn on the water bath and heat to 38C. 
 
3. Use a razor blade to trim the blocks to a trapezoid shape around your fly head.  
This will allow the slices to form a ladder as they slices are cut.   Make small 
slices working from the outside in, or you might accidentally break off a chunk 
that contains the head. 
 
 
 
4. Put the block into the cutting stage and tighten the top screw as tight as you can.  
Orient the trapezoid so the small edge is toward the top. 
 
5. Unlock the hand wheel and rotate it so the sample moves toward the blade.  
Bring the stage in or out with the arrow buttons so that the surface of the sample 
just misses the blade. 
 
6. Use the continuous cutting option by pressing start and adjacent button on the 
console simultaneously.  I like a speed around 9.  The slices should start to 
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accumulate as a ribbon on the blade surface, with the ladder shape mentioned 
above.  Watch as the ribbon goes and guide it go straight with a paintbrush. 
 
a. If the sections have a cut or score through them, there may be something 
on the edge of the blade.  Use the large paintbrush to gently brush the 
front and back edges as well as the surface of the sample to clear any 
debris that might be damaging the sections. 
 
7. When the specimen is finished, you will see the head starting to disappear from 
your sections.  Hit the stop button on the console.  Carefully use two 
paintbrushes to lift either end of the ribbon off the blade surface and move it onto 
a napkin to the side.  You may trim off the ends that do not contain useful layers 
of the head:  the length of the ribbon should fit onto a slide. 
 
8. Repeat for two more samples of the same genotype.  I usually put three samples 
onto one slide. 
 
9. When you have your three ribbons, get a paintbrush tip wet in the water bath and 
use the droplet of water to adhere to the top of the ribbon.  Lift the ribbon and 
slowly move it over the water bath.  Make sure it stays untwisted and that the 
shiny side is facing down.  Lower it so that the far end of the ribbon touches the 
surface of the water, and then slowly lower the rest of the ribbon so it gradually 
rests on the water.  
 
10. Repeat for the other ribbons.  When you have all three floating, use the 
paintbrush to create currents between the ribbons to bring them closer together.  
Arrange them so they are fairly close and will fit on a slide. 
 
11. Take a pre-labeled Superfrost slide and put it perpendicularly into the water near 
the top of the aligned ribbons.  Angle the slide and slowly move it under the 
samples.  Lift the slide so the top of the ribbons stick to the top of the slide, and 
then keep lifting the slide so it comes out of the water and the ribbons stay on.  
You may need to adjust the angles of the ribbons with a wet paintbrush, but be 
careful not to let the ribbon go over the edge of the slide, as it will twist 
irretrievably. 
 
12. Allow the slide to drip dry in a gray plastic slide holder. 
 
13. After sectioning all the samples, dry the slides overnight by placing the slide 
holder horizontally into the baking oven in the ablation room.  Turn the oven on to 
the 42C mark and leave the samples overnight. 
 
14. In the morning, turn the oven up to 60C for 30 min. 
 
15. Let the slides cool on the bench for 30 min. 
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16. Dewax the samples by lowering the slide holder into a trough of Histoclear (I) for 
5 min in the Room 307 hood.  Move the holder into Histoclear (II) for another 5 
min. 
 
17. Clear the samples in Histoclear (III) to prepare the slides for mounting.  Take the 
slides out of the holder within the Histoclear (III) and let any excess Histoclear 
drip back into the trough.   
 
18. Squeeze a line of Cytoseal along the bottom edge of the slide.  Place a long 
cover slip at an angle along the bottom edge so it contacts the Cytoseal, and 
then slowly lower the angle so the cover slip covers the whole slide. 
 
19. Allow the slides to dry in the hood overnight. 
 
20. Use the Leica fluorescence microscope to image the samples.  Use the red 
fluorescence channel to view the autofluorescence of the tissue.  Find the 
appropriate section to image. 
 
a. Magnification: 20X objective with 1.6X 
optovar 
 
b. 16-shot acquisition with empirically 
determined exposure time 
 
c. Gain: 1.0X;  Saturation: 100X;  Levels: 
0 – 1.1 – 255 
 
d. Use the Focus tool [magnifying glass 
icon] to select a region of interest and 
use the hand wheel on the microscope 
to adjust the focal plane until it is clear 
on the screen. 
 
e. Hit Acquire. 
 
21. Process the image in Photoshop by changing to grayscale, inverting the colors, 
and then adjusting the levels.  Rotate and crop the image so the image is 
highlighting the retinal structure. 
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Western Blot 
 
Running the gel 
 
1. Collect heads by decapitating with a razor blade, and store them in an eppendorf 
tube in the -80C freezer until ready to use.  I take a minimum of 3 heads, but 
usually 10–15 heads per genotype.  Always be consistent within an experiment. 
 
2. Add sample buffer to the eppendorf with your heads, usually 15–25 µl for ideal 
coverage.  I varied the volume depending on number of heads, just be consistent 
within an experiment.  I started by using NuPage 4X LDS Sample Buffer (Cat # 
NP0007), but then switched to (and prefer!) Laemmli Sample Buffer (Cat # 161-
0737). 
 
a. For NuPage 4X LDS Sample Buffer, add 12.5 µl β-ME to 112.5 µl sample 
buffer, so final concentration is 10%.  Note:  This is 4X the concentration 
that should be used when running your sample. 
 
b. For Laemmli Sample Buffer, add 50 µl β-ME to 950 µl sample buffer, so 
final concentration is 5%.  Note:  This is 1X and can be loaded directly 
into the gel.   
 
3. Use a blue pestle to grind the heads in the tube. 
 
4. Boil samples at 99C for 3 min in heat block or Thermomixer.  Pre-heat the heat 
block so you don’t have to wait too long. 
 
5. Spin samples at 15,000 rpm for 3 min. 
 
6. Prepare a premade NuPage Novex 4-12% polyacrilimide bis-tris gel (Cat # 
NP0322 for 12 wells; Cat # NP0323 for 15 wells) gel.  Cut the gel out of its 
sealed pouch over the sink.  Remove the white sticker from the bottom of the gel 
case to reveal an open line.  Carefully remove the well dividers by gently pulling 
straight out.  Do not wiggle the divider or you may damage the wells!  Rinse the 
gel case and exposed wells with deionized water. 
 
7. Place the gel against a white electrode insertion panel.  Place either a second gel 
or place a buffer dam on the other side of the insert.  This should create a closed 
reservoir.  Lower the insert into a gel running box.  Place an expander piece in 
the back of the box and pull the handle so the expander presses tightly against 
the insert.  This creates a water-tight reservoir between the gel and the dam. 
 
8. Dilute 20X NuPage MES SDS Running Buffer (Cat # NP0002) to 1X by 
combining 100 ml with 1900 ml water. 
 
173 
 
9. Pour 1X NuPage MES SDS Running Buffer into the reservoir between the gel 
and the dam.  Also add running buffer to the surrounding area so it covers the 
open line on the gel case. 
 
a. I use a plastic transfer pipette to squeeze running buffer into the wells.  
You can see the preservative solution ripple out of the wells.  This is 
probably unnecessary, but I feel better about having clean wells. 
 
b. At the very least, check that the well dividers are intact and vertical.  
Move your head around to check the phase contrast of the gel with the 
running buffer to make sure the little divider tab hasn’t folded over to 
block one of the wells.  Use a pipette tip to straighten dividers if 
necessary. 
 
10. Designate a lane for the molecular weight ladder SeeBlue Plus2 Prestained 
Standard (1X) (Cat # LC5925).  Load 10 µl of the molecular weight ladder. 
 
11. Load 10 µl prepared sample into each well.  You can change this volume 
depending on your start volume.  Note:  It is better to load a designated amount 
from each tube rather than to take whatever volume is present in the tube 
because the volume can change during preparation of the sample.  Also try to 
load a full number of heads (for example, 8 µl of a 10 µl preparation made from 5 
heads would be equal to loading 4 heads). 
 
a. I like to put 1X Sample Buffer (e.g., Laemmli Buffer with β-ME but no 
heads) into any unused wells.  It helps the samples run straight without 
spreading into neighboring lanes. 
 
12. Run the samples for 15 min at 80 V. 
 
13. Increase the voltage to 150 V and run until the blue front line reaches the bottom 
of the gel (~45 min). 
 
Semi-Dry Transfer 
 
1. Make 2X transfer buffer with 10% MeOH.  Combine 200 ml NuPage 20X 
Transfer Buffer (Cat # NP0006-1) with 1600 ml water and 200 ml MeOH. 
 
2. Soak 2 thick filter papers in 2X transfer buffer with 10% MeOH. 
 
3. Cut a nitrocellulose membrane to the size of your gel.  Soak the membrane in 2X 
transfer buffer with 10% MeOH. 
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4. Turn off the gel-running box and remove the gel case.  Carefully crack the gel 
case with the metal spatula until the connection points are severed and you can 
lift one side of the case off the gel.  Use the spatula to cut off the well lane 
dividers and the thick part of the gel where it protrudes into the open line on the 
case.  Turn the gel upside down over a dish with 2X transfer buffer with 10% 
MeOH and gently separate one edge of the gel from the case until the gel falls 
into the transfer buffer. 
 
5. Disassemble the semi-dry transfer apparatus and wet-wipe the metal plates with 
2X transfer buffer with 10% MeOH. 
 
6. Place one of the thick filter papers onto the apparatus base.  I make sure the 
Chinese character is away from me and the transfer paper’s long edge is 
perpendicular to the long edge of the apparatus (vertical). 
 
7. Use the roller tool or a 15 ml Falcon tube to gently roll out bubbles. 
 
8. Place the nitrocellulose membrane onto the stack.  Again, use the roller or a tube 
to gently roll out bubbles. 
 
9. Carefully tilt the dish with the gel in it and float the gel onto the spatula and 
balance it so it doesn’t slide off.  Take your time on this step. 
 
10. Place the gel onto the nitrocellulose membrane and angle the spatula to allow 
the gel to slide onto the membrane.  Be careful to line it up well.  Use the roller or 
a tube to gently roll out bubbles (it will slide more than roll). 
 
11. Place the remaining filter paper onto the stack.  Roll out the bubbles. 
 
12. Wipe the excess liquid from the surrounding plate.  Place the spacer onto the 
prongs and expand to lock into place.  Put the lid firmly on top of that. 
 
13. Turn on the power source.  Run 20 V for 20 min (set for 400 mA). 
 
Immunoblotting procedure 
 
1. Place the membrane into a tip box containing PBS (Cat # P3813).  Allow the 
membrane to wash on an orbital shaker for 5 min. 
 
2. Ponceau stain the membrane to make sure all the protein transferred correctly 
and evenly.  Pour Ponceau S solution (Cat # P7170) into the tip box and incubate 
on the orbital shaker for 5 min. 
 
3. Rinse the membrane in PBS for a short time.  Monitor to make sure it doesn’t 
completely remove the Ponceau stain.  I usually shake a little in my hand just to 
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remove the unbound Ponceau S solution.  Place the membrane into a clear 
sheet protector pouch. 
 
a. Make a copy of the membrane with the black and white copy machine.  
This is great for your lab notebook. 
 
b. I used to scan a color photo of the staining, but I lost access to the 
scanner computer.  Now, I take a photo of the membrane with my camera 
phone and email it to myself.  You could use a regular camera, but I 
found this to be easier. 
 
4. Place the membrane back into the tip box and rinse with a fresh PBS wash for a 
short time. 
 
5. Remove the Ponceau stain with 0.1 M NaOH.  Rinse quickly and watch the 
Ponceau stream off the membrane; it is a lovely shade of lavender. 
 
a. Make 1 M NaOH stock. 
 Stock For 50 ml 
 NaOH powder 2 g 
 water   to 50 ml 
 
b. Dilute to working concentration of 0.1 M NaOH.  Add 5 ml 1 M NaOH 
stock to 45 ml water. 
 
6. Once there is no more Ponceau coming off the membrane and the membrane 
looks white again (about 10-15 seconds), pour off the solution. 
 
7. Rinse with 3 x 5 min PBS washes on the orbital shaker. 
 
8. Block the membrane in 5% milk in PBS.  I make this by weighing out 0.5 g milk 
(Cat # 170-6404) in a 15 ml Falcon tube and then pouring PBS to the 10 ml line.  
I am not overly cautious about exact amounts. 
 
9. Cut a hybridization bag (#403) into fourths so that each is about the size of your 
membrane.  Cut the edges so only one edge is still connected, and then carefully 
splay out the two sides of the bag.  Place the membrane onto one face and then 
fold the other face up so that it looks like a pouch around the membrane.  Use 
the Impulse Heat Sealer to seal two more edges (so only one edge remains 
open).  Pour in the 5% milk in PBS and then seal the final edge so it is enclosed 
within the pouch. 
 
10. Put the pouch face down the nutator and block for 30 min at RT. 
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11. Cut a corner off the pouch and pipette your primary antibody into the liquid 
through the opening.  Massage the antibody into the milk and then reseal that 
corner with the heat sealer. 
 
a. Note:  If you have a valuable antibody or a low dilution that would require 
you use too much for this method, you can also make an antibody 
solution in less volume (e.g., 2 µl antibody in 2 ml PBS).  Cut the pouch 
and put the membrane into a fresh pouch and add the antibody solution 
before sealing the final edge. 
 
12. Incubate with primary antibody overnight (unless otherwise noted) on the nutator 
in the cold room. 
 
13. Cut the pouch and put the membrane back into the tip box.  Rinse 3 x 5 min in 
PBS. 
 
14. Block the membrane in 5% milk in PBS for 30 min on the nutator at RT. 
 
15. Cut a corner off the pouch and pipette your HRP-conjugated secondary antibody 
into the liquid through the opening.  Massage the antibody into the milk and then 
reseal that corner with the heat sealer. 
 
16. Incubate with secondary overnight for 1 hr on the nutator at RT. 
 
17. Cut the pouch and put the membrane back into the tip box.  Rinse 3 x 5 min in 
PBS. 
 
18. Turn on the FujiFilm LAS3000 Imager and cool the camera. 
 
19. Prepare the HRP substrate to develop the membrane.  From the SuperSignal 
West Dura Extended Duration Substrate kit (Cat # 34075), add 1 ml A and 1 ml B 
to a 15 ml Falcon tube. 
 
20. Carefully transfer the membrane into an uncut hybridization bag by lowering it 
through the opening with forceps.  Place it as close to the middle as you can.  
Flatten the bag and squeeze any excess PBS off of the membrane so it is 
pressed against the two faces of the bag. 
 
21. Place the membrane into the machine and pour the HRP substrate solution into 
the bag.  Let it incubate a few minutes and allow the liquid to flow over the entire 
surface of the membrane by gently tilting the bag.  Squeeze the excess liquid 
toward the bottom of the bag so it isn’t pooled on top of the membrane. 
 
22. In the acquisition software, go to the Focusing tab to make sure the membrane is 
in the viewing window and adjust the focus if necessary. 
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23. In the Method/Tray Position tab, set the mode to Chemiluminescence.  I usually 
start by setting Exposure Type as Increment and the Exposure Time at 10 sec.  
This will take an update the image every 10 sec while keeping the intermediate 
images.  I usually start with the Sensitivity set to Super, but then adjust down if 
the signal is strong. 
 
24. Allow the images to accumulate until it is definitely oversaturated.  I save each 
image because I don’t know what will be useful later; I like to have light 
exposures all the way to really dark ones. 
 
25. Set the Method/Tray Position to Digitize/Epi and then change the Exposure Type 
from Increment to Precision and set the Exposure Time to 1/60 sec.  Make sure 
the Sensitivity is Standard or it will oversaturate. 
 
26. Save the image, as it will allow you to know where the ladder is on your blot 
when you look at the antibody placement. 
 
27. To compile the two images, I first export each file in ImageGauge as a TIF 8 bit 
file, and then open both with Photoshop.  I drag the Epi image of the ladder into 
the file containing the Chemiluminescent image, and hold shift when releasing.  
This will line them up perfectly.  Then I draw the ladder in a new layer and hide 
the actual image of the ladder. 
 
Table III-1  Antibodies used for Western immunoblot 
Name 1º/2º Catalog Number Dilution Incubation 
α-HA-HRP Both (rat) Roche 12013819001 1:500 2h at 4ºC 
α-myc 9E10 Mouse Santa Cruz sc40 1:500 O/N at 4ºC 
α-Hsp104 Rabbit Enzo Life Sciences ADI-SPA-1040 1:2000 O/N at 4ºC 
α-human-Hsp70 W27 Mouse  abcam ab3148 1:500 O/N at 4ºC 
α-tubulin-HRP 11H10 Both (mouse) Cell Signaling 9099 1:1000 O/N at 4ºC 
α-actin Rabbit abcam ab8227 1:2000 O/N at 4ºC 
α-rhodopsin Mouse DSHB 4C5 1:50 O/N at 4ºC 
Goat α-Mouse-HRP 2º Jackson ImmunoRes 115-035-146 1:2000 1h at RT 
Goat α-Rabbit-HRP 2º Millipore AP307P 1:5000 1h at RT 
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Cryosections and Immunohistochemistry 
 
Blocking heads 
 
1. Anaesthetize flies on CO2 pad.  With your left hand, squeeze the abdomen of the 
fly so its neck protrudes and with your right hand, use very sharp forceps to pull 
the neck at the base of the head.  The head should come off very cleanly with no 
distortions (compression or extension). 
 
2. Place a sheet of lab bench paper down to protect your bench.  Squeeze a large 
drop of Tissue Freezing Medium (TFM, red cap) into a round bottom well in a 
glass dish. 
 
3. Place the head into the well of TFM.  Swirl the head under the surface and to the 
bottom of the well.  Remove any small air bubbles still attached the head.  Be 
careful!  This is the longest step.  Carefully lift the antennae and remove the 
bubble from the divots below and stretch the proboscis to make sure no bubbles 
lurk at the base. 
 
4. Place more heads of the same genotype into the same well.  I usually collect 6 
heads per genotype. 
 
5. Let the heads sit for 10-15 minutes in the TFM. 
 
6. Prepare a strip of peel away plastic cup molds by placing a large drop of TFM 
into each cup.  Fill about halfway up the slanted surface, about to the notch on 
the side. 
 
7. Lift a head from the glass dish and place it into a cup (one head per cup).  Do not 
squeeze the head with your forceps; it is best to suspend the head in a droplet 
between the forcep tips. 
 
8. Swirl the head to the bottom of the cup and arrange it so the proboscis is facing 
up and the neck stump is toward you (will produce coronal sections).  Be certain 
the head is flat as it may shift when you move the cup around. 
 
9. Fill a plastic Tupperware dish with dry ice and pour ethanol on top.  Let the 
ethanol cool and bubble. 
 
10. Smoothly place the strip of plastic cup molds into the ethanol.  The edges of the 
TFM will start to freeze from the bottom up.  Once the TFM is completely hard 
and white, use a Sharpie to draw a line on the edge of the TFM block to indicate 
the bottom the sample (i.e., the edge toward which the neck stump points). 
 
11. Label a 50 ml Falcon tube with the genotype information and let it chill in dry ice. 
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12. Pull the strip of cups out of the ethanol and dab it onto the lab bench paper to 
remove some of the excess cold ethanol.  Squeeze the cup so the TFM block 
pops out into the Falcon tube. 
 
13. Store the Falcon tube in the -80C freezer indefinitely until you are ready to 
section the heads. 
 
a. You can also cut immediately!  This is preferable because the tubes can 
build up quickly and really crush your spirits. 
 
b. There is also an option to prepare all your heads directly onto the cutting 
stage chuck.  I attempted this with poor results, but this would be ideal.  
Basic idea:  Place a large drop of TFM onto the chuck and lower it into 
the ethanol/dry ice.  As it begins to freeze upward, place a smaller drop 
on top and put a head into it.  Orient the head and let it freeze in the 
ethanol.  Add another drop and place another head and orient it.  Let it 
freeze, and keep building upward to create a totem pole of heads in a 
vertical stack.  You can cut these immediately and they are all already 
aligned and positioned. 
 
 
Cutting cryosections 
 
1. Place the Falcon tube with your TFM blocks into the cryostat.  Allow the blocks to 
adjust to the temperature for about 30 minutes. 
 
2. Line up the blocks in the cryostat so the marks are all facing you.  Flip the blocks 
over and draw a mark on the top side of the block so you can tell which way is 
down when the block is facing up. 
 
3. With your right hand, firmly grip the top of a block with forceps.  (If you squeeze 
too tightly, the block will pop out, so keep it a little loose.)  With your left hand, 
squeeze a dollop of OCT onto the chuck.  Swiftly move the block onto the dollop 
on the chuck and press down firmly so the dollop squeezes out on both sides.  
Hold the block in place so the top is level; you have minimal time to adjust angles 
so immediately level it out.  The dollop will freeze pretty quickly and hold your 
block in place. 
 
4. Wait 20-30 minutes so the block is firmly frozen to the chuck.  Label slides (one 
slide per head) and leave them on the top of machine at room temperature. 
 
5. Place the chuck into the holding stage.  Position so the mark on the block is 
facing down. 
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6. Trim the specimen block into the trapezoid shape around the sample using a 
razor blade. 
 
7. Move the blade to the edge of the block using the in and out arrows ↑↓ on the 
keypad.  Also using the keypad, ensure that the section size is set to 12 µm. 
 
8. Rotate the handle on the right side of the machine away from you (a clockwise 
turn).  This will move the blade the set sectioning size. 
 
9. When a short ribbon strip lines up on the plate, press the room temperature slide 
to the sample ribbon and it will stick.  I put the ribbon perpendicular to the length 
of the slide.  Do not cut your ribbon long enough to reach from one edge to the 
other, you want a clear border on all sides of the samples. 
 
10. Check the sections in the ribbon in the microscope.  Make sure the samples are 
flat and don’t have bubbles on the tissue. 
 
a. I have a hard time with samples rolling up on themselves.  If you briefly 
heat the front edge of the sample block with your fingernail, it will usually 
cut smoother. 
 
b. If your samples roll up or go wrong in any way, stop the ribbon you are 
cutting, collect it, and start a new ribbon. 
 
11. Store the slides in the machine until you are finished cutting all samples. You can 
also store the slides in a slide box in the -80C freezer overnight. 
 
 
Immunostaining cryosections 
 
1. Warm up slides on slide warmer, set to 37C, for 30 min. 
 
2. Make fresh 0.5% paraformaldehyde solution (PFA).  Break a 20% stock 
paraformaldehyde ampule in the hood.  Add 1000 µl to 40 ml PBS. 
 
3. Prepare the slide-holding humidity chamber.  These are the shallow dishes 
covered in aluminum foil with serological pipettes taped in the bottom.  Rip paper 
towels in half longways and place them in the bottom of the dish.  Wet the paper 
towels in the sink and pour off any excess water.  You will place your slides on 
the raised pipette platform. 
 
181 
 
a. I find that 18 slides are about as much as I can handle (3 genotypes x 6 
samples each).  For this, I need one and a half humidity chambers, since 
I can fit 6 slides in a pipette column. 
 
4. Draw a circle around useful sections with the green pap pen.  Be sure the circle 
you draw will fit within your coverslip (I use the square ones).  I find that three 
ribbons gives about the right width. 
 
5. Put the slides in the prepared humidity chamber. 
 
6. Use a dropper to cover the circle area with 0.5% PFA.  Let the sections fix for 30 
min at RT. 
 
7. Dump the PFA back into the Falcon tube and dispose of it properly. 
 
8. Use a dropper to cover the circle area with PBS.  After a 5 min incubation time, 
dump the PBS into a waste container and dropper fresh PBS onto the circle.  Do 
a total of 3 washes, 5 min each. 
 
9. Prepare PBSG blocking solution.  100X stock solutions of each component have 
been made by Xiuyin. 
 
PBSG solution: 
 Stock For 40 ml 
 0.2% BSA 100X 400 µl 
 0.01% saponin 100X 400 µl 
 1% goat serum 100X 400 µl 
 PBS   40 ml 
 
 
10. Cover the circle area with PBSG and block for 1 hr at RT.  Store the PBSG at 4C 
overnight. 
 
11. Make 1º Ab solution in PBSG. 
 
a. You can put in two antibodies at once, as long as the antibodies are from 
different animals (e.g., one mouse, one rabbit).   
 
b. The concentration is usually 1:100.  For 18 slides, I put 13.5 µl primary 
antibody in 1350 µl PBSG. 
 
c. You usually have to preadsorb rabbit antibodies (see next section).  In 
this case, you are starting with a 1:25 dilution already, so I put 337.5 µl 
1:25 preadsorbed antibody in 1350 µl PBSG. 
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12. Spin the 1º Ab solution at 12,000 rpm for 5 min to settle any debris.  This will 
make the staining much cleaner. 
 
13. Pick up the first slide and dump the PBSG block off the slides and then use a 
kimwipe in the corner of the circle area to dry excess liquid off the sample.  Add 
70 µl of the 1º Ab to the circle and tilt to make sure the whole area is covered.  
Place the slide back into the chamber and proceed to the next slide. 
 
14. Incubate the antibody overnight in the cold room.  Label the tray so no one 
bumps it or moves it! 
 
15. Do 3 PBSG washes (from PBSG stored in fridge overnight), 1 min each. 
 
16. Make 2º Ab solution in PBSG. 
 
a. If you used two primary antibodies from different animals, you must 
choose secondary antibodies with different AlexaFluor attachment colors 
(e.g., goat-anti-mouse-594 and goat-anti-rabbit-488). 
 
b. Again, the concentration is usually 1:100, so I put 13.5 µl secondary 
antibody in 1350 µl PBSG. 
 
17. Spin the 2º Ab solution at 12,000 rpm for 5 min. 
 
18. Dump off the PBSG rinse and use a kimwipe to dry the area, as before.  Add 70 
µl of the 2º Ab to the circle and tilt to make sure the whole area is covered. 
 
19. Incubate the antibody for 1 hr at RT. 
 
20. Do 3 PBS washes, 5 min each. 
 
21. Make the Hoechst stain by diluting the stock solution 1:1000 in PBS (10 µl in 10 
ml).  The Hoechst 33342 stock (Cat# H3570) is in the fridge next to Xiuyin. 
 
22. After the final PBS wash, dump off the solution and dry with a kimwipe.  Dropper 
the Hoechst onto the circle area and make sure the entire area is covered.  
Incubate for 10 min. 
 
23. Do 3 PBS washes, 5 min each. 
 
24. Seal with a square coverslip.  Place the coverslip on a small stack of paper 
towels.  Put a generous drop of Vecatashield (Cat # H-1000) onto the coverslip.  
Lower the slide face-down onto the drop so the Vectashield spreads out to cover 
all the specimen area.  Use clear nail polish around the edges of the coverslip to 
seal the entire area. 
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25. Store the slides in a slidebox at 4C to preserve the signal. 
 
Preadsorbing an antibody 
 
1. Collect larvae from a vial or bottle.  I use 5905 flies – you must use a line that 
doesn’t have whatever your antibody will be detecting!  I collect 20 wandering 
larvae that seem large but not yet hardened.  (I use 20 larvae to preadsorb 20 µl 
of antibody, so you can adjust as needed.)  I put the larvae in an eppendorf tube 
as I collect. 
 
2. I usually do a quick wash in PBS to remove residual fly food on the larvae.  I use 
a transfer pipette to add and remove liquid a few times and then spin the tube at 
15,000 rpm for 3 min to settle the larvae.  Use a pipette to remove all of the 
liquid. 
 
3. Make a 4% PFA solution by adding 2 ml of the 20% ampule stock to 8 ml PBS.  
Use a transfer pipette to add about 1 ml to the eppendorf tube. 
 
4. To fix the larvae, you need to physically tear apart the bodies.  The best way to 
do this is to use the transfer pipette to move the PFA and larvae into a round 
bottom glass dish.  Use two pairs of forceps to hold each larva with one forcep 
and tear it apart with the other.  It is hard for the forceps to reach into the bottom 
of an eppendorf tube, so it is definitely worth the effort to move it to the glass 
dish.  After all larvae are torn apart, move the liquid and debris back into the 
eppendorf tube. 
 
5. Place the eppendorf tube on the nutator at room temperature and allow the 
larvae to fix for 1 hr. 
 
6. Spin the tube at 15,000 rpm for 3 min.  Remove the liquid from the settled debris.   
 
7. Wash 3 times in PBS.  Add about 1 ml of PBS and nutate for 5 min, and then 
spin again at 15,000 rpm for 3 min to remove the liquid. 
 
8. Calculate how much antibody you want to preadsorb such that the final antibody 
concentration is diluted 1:25.  For 20 larvae, I add 20 µl antibody to 480 µl PBS.  
Add this to the larvae debris and nutate at 4C overnight. 
 
9. Spin the tube at 15,000 rpm for 3 min.  Collect the supernatant containing the 
antibody and save it in a fresh tube. 
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Table III-2  Antibodies used for immunohistochemistry 
Name 1º/2º Catalog Number Dilution Incubation 
Main Antibodies: 
α-HA 5B1D10 Mouse Invitrogen 32-6700 1:100 1h at RT 
α-myc 9E10 Mouse Santa Cruz sc-40 1:100 1h at RT 
α-Hsp104 Rabbit (preadsorbed) 
Enzo Life Sciences 
ADI-SPA-1040 1:100 1h at RT 
α-Hsp70 Rabbit (preadsorbed) 
Enzo Life Sciences 
ADI-SPA-812 1:100 1h at RT 
α-Hsc70/Hsp70 Mouse Enzo Life Sciences ADI-SPA-822 1:100 1h at RT 
AlexaFluor 594  
Goat α-Mouse IgG 2º 
Life Technologies 
A-11032 1:100 1h at RT 
AlexaFluor 488  
Goat α-Rabbit IgG 2º 
Life Technologies 
A-11008 1:100 1h at RT 
Confirmation Antibodies: 
α-HA Y11 Rabbit (preadsorbed) 
Santa Cruz 
sc-805 1:100 1h at RT 
α-myc A14 Rabbit (preadsorbed) 
Santa Cruz 
sc-789 1:100 1h at RT 
α-human-Hsp70 W27 Mouse Santa Cruz sc-24 1:100 1h at RT 
AlexaFluor 594  
Goat α-Rabbit IgG 2º 
Life Technologies 
A-11037 1:100 1h at RT 
AlexaFluor 488  
Goat α-Mouse IgG 2º 
Life Technologies 
A-11029 1:100 1h at RT 
Also used: 
Hoechst dye n/a Molecular Probes 33342 1:1000 10m at RT 
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Pseudopupil 
 
1. Anaesthetize flies on CO2 pad.  Hold the fly body with forceps in your left hand 
and use a razor blade to sever the neck. 
 
2. Squeeze a line of Vaseline onto a microscope slide. 
 
3. Hold the proboscis of the fly head to transfer the head onto the Vaseline line.  
Lower the head at an angle so one eye is resting on the glass of the slide and the 
other eye is propped on the line of Vaseline.  This will allow the light to shine 
directly through the raised eye.  (Do not get Vaseline on the eye!  It will blur the 
image.)   
 
4. I usually prepare 5 heads at a time on one line of Vaseline.  Image the 
pseudopupil within 10-15 min of preparation. 
 
 
 
5. Go to the microscope.  Place a drop of immersion oil onto each head. 
 
6. Adjust the microscope settings: 
 
a. 20X objective, 1.6X optical zoom 
 
b. No fluorescent filter (C1) 
 
c. Max voltage on lamp = 12V 
 
d. Filters OFF, including GF switch 
 
7. Looking through the eyepiece at a blank part of the slide, adjust the settings: 
 
a. Focus the condenser so you get a small octagon of light 
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b. Close aperture iris as much as possible 
 
8. Using the microscope light bulb (you do not need the fluorescence light source!), 
center a head within the field of view and adjust the plane so the pseudopupil is 
in focus.  It will look very small!  It takes a long time to adjust to seeing and 
distinguishing the small spots. 
 
9. Count the number of photoreceptor cells per ommatidial cluster.  This takes 
practice, so start with control genotypes that should have 7 photoreceptors per 
ommatidia to get used to what you’re looking for. 
 
a. Photoreceptor cells undergoing degeneration can be very difficult to 
quantify.  The lighted spot may be missing altogether, in which case it is 
easy to know it is missing.  But most often, the light becomes very blurry 
and is not exactly a discrete spot but is not exactly missing either.  You 
need to make a judgment call about how blurry the edges need to be to 
quantify it as an intact cell.  You must be consistent!  I find it helpful to do 
as many genotypes as you can at once so you are more consistent in 
your designations. 
 
b. If you are worried about bias in designating blurry photoreceptor spots 
within an ommatidium, blind yourself to the genotype.  Write the genotype 
on the bottom of each vial when you put the flies in.  Scramble the vials 
around and then randomly number them.  Collect data with reference to 
the random number.  After collecting the data, turn each vial over to see 
which number corresponds to which genotype. 
 
10. Count 10 ommatidia per eye, and examine 10 eyes per genotype.  This will give 
sufficient data points for the spreadsheet analysis. 
 
11. Try to take pictures.  This is exceedingly difficult as it is hard to get multiple 
ommatidia into one plane of focus.  You need 4-7 ommatidia in view, and the 
ideal set up is as a daisy pattern (one in the middle with the others surrounding 
that one in a circle; see below). 
 
12. Camera settings must be adjusted: 
 
a. Levels:  50 – 1.6 – 255 
 
b. 36-shot resolution (may have to use 16-shot if the image looks wavy) 
 
13. Crop the image and clean it up in Photoshop. 
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Original:           Adjusted levels: 
         
 
14. Analyze the data in the Excel spreadsheet template pseudopupil.xls 
 
a. The spreadsheet was created by a previous lab member.  It can be found 
on the Bonini Lab Server, in the BONINI LAB – PROTOCOLS folder. 
 
b. Each row indicates one eye.  Enter the number of ommatidia that 
displayed 7 photoreceptor cells, 6, etc.  You should have 10 ommatidial 
counts for each row, so the total will read 10 after you have entered your 
data. 
 
c. The spreadsheet will automatically calculate the mean and standard 
deviation or standard error.  Use Prism for statistics. 
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SDD-AGE and Western Blot Aggregate Analysis 
 
Preparation before starting  
 
1. Collect heads and store in an eppendorf tube in the -80C freezer until ready to 
process all genotypes.  I use 5 heads per genotype. 
 
2. Prepare all the solutions before beginning the protocol. 
 
3. Make Lysis Buffer.  I make a 100 ml stock containing Tris, NaCl, and water.  I 
store this indefinitely, and I make 10 ml batches fresh each time I use it, to which 
I add the β-ME and a Roche Complete Mini EDTA-free Protease Inhibitor 
Cocktail Tablet (Cat # 04693159001). 
 
 Stock For 100 ml 
 100 mM Tris 1 M Tris, pH 7.5 10 ml 
 50 mM NaCl 5 M 1 ml 
 10 mM β-ME (fresh) 14.3 M add 7 µl to 10 ml 
 protease inhibitors (fresh) tablet add 1 tablet to 10 ml 
 water  89 ml 
 
4. Make 4X Sample Buffer.  It is difficult to get these components into solution, so 
add ingredients in the order listed to the right. 
 
 Stock For 25 ml order: 
 2X TAE 50X 1 ml 3 
 20% glycerol 100% 5 ml 4 
 8% SDS powder 2 g 2 
 bromophenol blue powder 0.0125 g 5 
 water  17 ml 1 
 
a. Make sure each component is fully mixed in before adding the next.  You 
will need to nutate thoroughly after adding SDS.  Additionally, once 
complete, I leave it on the nutator overnight before using. 
 
b. The SDS will fall out of solution if left for a long time.  If there is any 
precipitate, make fresh Sample Buffer.  You can store the Sample Buffer 
on the nutator instead of on the shelf to extend use. 
 
5. Make TAE Buffers. 
 
a. 1X TAE.  [For making the agarose gel.] 
 
 Stock For 1 L 
 1X TAE 50X 20 ml 
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 water  980 ml 
 
b. 1X TAE with 10% SDS.  [For making the agarose gel.] 
 
 Stock For 50 ml 
 1X TAE (made above) 45 ml 
 10% SDS powder 5 g 
 
c. 1X TAE with 0.1% SDS.  [For running the agarose gel.] 
 
 Stock For 1 L 
 1X TAE 50X 20 ml 
 0.1% SDS powder 1 g 
 water  980 ml 
 
 
Preparation of lysate 
 
1. Collect some liquid nitrogen in a dewar. 
 
2. Add 25 µl of Lysis Buffer (prepared fresh) for 5 heads.  From this, I usually end 
up collecting 20-21 µl of lysate at the end. 
 
3. Grind the heads with a blue pestle.  It is easier to do if you use the special 
eppendorf tubes that fit the blue pestles.  Thoroughly crush the heads, and then 
take care to leave as much of the Lysis Buffer in the tube when you remove the 
pestle.  I usually rotate the pestle at the dry top part of the tube to remove all 
residual liquid. 
 
a. I grind the heads in all tubes before moving on to the next step. 
 
4. Use long forceps to lower each eppendorf tube into the liquid nitrogen.  Wait a 
few seconds for the liquid to completely freeze. 
 
5. Let the tubes thaw on ice.   
 
a. I use the thawing time to label eppendorf tubes for the final lysate you 
collect at the end. 
 
6. Grind again with a new blue pestle.  (This should release contents from the cells 
that were broken open during the freezing process.)  Again, take care to leave as 
much liquid behind as possible. 
 
7. Spin the lysates for 3 min at 15,000 rpm. 
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8. Collect 20 µl supernatant into a new tube labeled lysate. 
 
a. You can prepare a lot of lysates at once and store them in the -80C 
freezer until ready for use. 
 
b. If continuing with SDD-AGE/Western immediately, go ahead and divide 
the lysate into two tubes:  10 µl for SDD-AGE and 5 µl for Western blot.  
(Note: This is not the exact volume I used for all my experiments, but it is 
what I would recommend going forward.)` 
 
 
SDD-AGE and Western blot 
 
1. This protocol is adapted from Halfmann and Lindquist, J Vis Exp, 2008.  
http://www.ncbi.nlm.nih.gov/pubmed/19066511  
 
2. Make 1.5% agarose gel containing 0.1% SDS. 
 
 Stock For 70 ml 
 1.5% agarose powder 1.05 g 
 1X TAE stock 70 ml 
 
Swirl.  Microwave for 1 min, 30 sec.  Swirl.  To this, add: 
 
 0.1% SDS  1X TAE with 10% SDS (100X) 700 µl 
 
3. Place in a mold and use the 8 well insert to clear the bubbles away.  Insert one or 
two 15 well inserts (I like to do two rows in one gel to speed up processing).  Let 
the agarose cool and harden on the benchtop. 
 
4. Separate lysates: 5 µl aliquot for Western blot; 10 µl aliquot for SDD-AGE. 
 
5. Add 3.33 µl of 4X homemade Sample Buffer to 10 µl SDD-AGE sample.  Pipette 
up and down to mix. 
 
6. Remove agarose gel from the mold and insert it into the running apparatus.  
Submerge the gel in 1X TAE with 0.1% SDS.  Make sure the gel is positioned so 
that the protein will run toward the red + pole. 
 
7. Load SDD-AGE samples into the wells.  Put 1X Sample Buffer (diluted in Lysis 
Buffer) into the empty wells so it will run evenly.  I also load the SeeBlue Plus2 
protein ladder, but one with larger molecular weight markers might be more 
appropriate. 
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8. Run SDD-AGE samples in the agarose gel at 18 V for 4 hours.  The published 
protocol recommends 3 V per cm of agarose gel width, and the mini-gel mold is 6 
cm across. 
 
9. Prepare NuPage LDS Sample Buffer by adding 10% β-ME.  Add 1.667 µl of 4X 
NuPage Sample Buffer with β-ME to 5 µl Western sample.   
 
10. Boil samples for 3 min, spin at 15,000 rpm for 3 min. 
 
11. Load Western samples into the wells of a pre-cast 4-12% Bis-Tris gel.  Run the 
gel as described in the Western blot section. 
 
12. Transfer protein from Bis-Tris gel onto a nitrocellulose membrane using semi-dry 
transfer at 20 V for 20 min.  You should be able to complete the Western blot 
procedures before the SDD-AGE gel finishes the 4 h run. 
 
13. Transfer protein from SDD-AGE agarose gel onto a nitrocellulose membrane 
using downward capillary transfer overnight. 
 
a. Make 1X TBS (Cat # T6664-10PAK). 
 
b. Cut 5 square 3 MM CHR Whatman papers, 20 x 20 cm (Cat # 3030-861), 
into fourths.  Leave these squares dry. 
 
c. Cut 1 square 3 MM CHR Whatman paper, 20 x 20 cm, into fourths.  Pre-
wet these squares in 1X TBS. 
 
d. Cut 1 long 3 MM CHR Whatman paper, 18 x 34 cm (Cat # 3030-221), in 
half long-ways.  Pre-wet this “wick” in 1X TBS. 
 
e. Stack the following components in a glass dish: 
 
i. 4 paper towels, folded in half 
ii. 20 square sheets of dry Whatman paper 
iii. 2 square sheets of wet Whatman paper 
iv. Nitrocellulose membrane 
v. Agarose gel 
vi. Place two strips of parafilm on either side of the agarose gel to 
prevent the TBS from flowing around instead of through the gel. 
vii. 2 square sheets of wet Whatman paper 
viii. 1 long “wick” sheet of wet Whatman paper 
ix. Carefully place the gel casting tray directly on top of the agarose 
gel. 
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x. Carefully center a 1 L bottle full of liquid on top of the gel casting 
tray to apply pressure to the gel.  Check back to make sure things 
are balanced evenly before leaving it overnight. 
xi. Pour TBS into pipette tip boxes on either side of the stack and 
lower the ends of the “wick” paper into the reservoirs. 
 
f. See schematic below: 
 
 
 
 
14. After you have all the protein safely transferred onto nitrocellulose membranes 
(SDD-AGE + capillary transfer; Western + semi-dry transfer), proceed with 
Ponceau S staining and antibody probing, as described in the Western blot 
section. 
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DNA Techniques 
 
PCR to genotype recombinant flies 
 
Isolation of genomic DNA 
 
1. Make Squash Buffer: 
 Stock For 50 ml 
 10 mM Tris-HCl 1 M, pH 8.0 500 µl 
 1 mM EDTA 0.5 M 100 µl 
 25 mM NaCl 5 M 250 µl 
 water  49 ml 
 
On ice, make fresh: 
  Stock For 2 ml 
 Squash Buffer (above) 2 ml 
 20 µl/ml Proteinase K 20 mg/ml 40 µl 
 0.1 mg/ml RNase 5 mg/ml 40 µl 
 
2. Anaesthetize flies on CO2 pad.  Collect 10 flies of one genotype in an eppendorf 
tube. 
 
3. Add 300 µl Squash Buffer + PK + RNase.  Grind flies with a blue pestle. 
 
4. Transfer fly lysate to a pcr strip of small tubes.  Run MCSQUASH program: 
 
MCSQUASH 
   (Lid = 105.0ºC) 
1 37.0ºC 40:00 
2 95.0ºC 05:00 
3 4.0ºC  hold  (transfer to ice when finished) 
 
5. Transfer fly lysate back to an eppendorf tube.  Add 300 µl phenol-chloroform pH 
8.0-8.5 (Sigma P3803-100ML) to the tube.  When drawing the 300 µl from the 
stock bottle, be sure to put your tip at the bottom of the bottle to ensure you don’t 
draw the top storage layer of Tris. 
 
6. Spin the eppendorf tubes in a microcentrifuge at 8,000 rpm for 10 min.  The 
phase separation will be evident, with a thick liquid at the bottom, the fly bodies in 
the middle, and a clear liquid supernatant at the top. 
 
7. Collect 200 µl of the supernatant into a new tube.  I do not risk getting more than 
that volume for fear of accidentally collecting some liquid from the other layer. 
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8. Add 1/10 volume (20 µl) of NaOAc 3 M, pH 5.2 to the tube. 
 
9. Add 2X volume (440 µl) of 100% EtOh to the tube. 
 
10. Mix with pipette or by flicking.  Spin the tubes at 12,000 rpm for 10 min. 
 
11. Carefully pipette away the supernatant.  Wash the pellet with 1 ml 70% EtOH 
(made with MilliQ water to maintain purity!).  Spin the tubes at 12,000 rpm for 2 
min. 
 
12. Carefully pipette away the supernatant.  Use a 2 µl pipette to fully remove all 
residual liquid.  Be thorough in this step.  Once all liquid has been removed, let 
the pellet air dry for 5 min. 
 
13. Resuspend the pellet in 20 µl TE Buffer, pH 8.0-8.5. 
 
 Stock For 50 ml 
 10 mM Tris-HCl 1 M, pH 8.0 500 µl 
 1 mM EDTA 0.5 M 100 µl 
 water  49 ml 
 
14. Store in -20C freezer. 
 
 
PCR amplification of genomic DNA 
 
1. Use the Taq 2X Master Mix kit. 
 
a. Know the features of your transgenic insert.  The Hsp104 gene has 2727 
bases (< 3 kb) with GC content of 61.97. 
 
b. Use the Standard Buffer for 50-65% GC content. 
 
2. Determine which primers to use.  (See my “Protocols” binder for information 
about where these primers align with the DNA.) 
 
a. To amplify a UAS-transgene insert, use:  
 
pUAST-5’b 5’- AGCAACCAAGTAAATCAACTGC -3’ 
pUAST-3’b 5’- TTCATCAGTTCCATAGGTTGG -3’ 
 
b. To amplify a Gal4 insert, use: 
 
NB 1224 5’- GTCTTCTATCGAACAAGCATGCGA -3’ 
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NB 1225 5’- TGACCTTTGTTACTACTCTCTTCC -3’ 
 
3. Set up mix in a pcr strip tube: 
 
   Desired concentrations:      Volume added: 
200 nM primer   1 µl 1/10 primer mix 
< 1,000 ng DNA (1 µl)  1 µl genomic DNA 
1X Master Mix   12.5 µl 2X Master Mix 
MilliQ water to 25 µl   10.5 µl MilliQ water 
 
a. Be sure to include positive and negative controls to know that your PCR 
reaction is working properly. 
 
4. Run the PCR amplification reaction in the thermocycler.  Check your polymerase 
enzyme for optimal running temperature and the size of your gene will inform the 
time required at each step. 
 
a. For a UAS-transgene insert: 
 
MCPCRUAS 
   (Lid = 105.0ºC) 
1 94.0ºC 02:00 
2 94.0ºC 00:30 
3 55.0ºC 00:30 
4 68.0ºC 01:30 
5 Repeat 2–4 x 30 
6 68.0ºC 05:00 
7 10.0ºC hold 
 
b. For the Gal4 insert: 
 
MCPCRGAL 
   (Lid = 105.0ºC) 
1 94.0ºC 02:00 
2 94.0ºC 00:15 
3 56.0ºC 00:20 
4 72.0ºC 00:30 
5 Repeat 2–4 x 29 
6 72.0ºC 05:00 
7 10.0ºC hold 
 
5. Collect the PCR reaction products and check the size of the amplified insert by 
agarose gel.  You can store the reaction products at -20C. 
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Running DNA on an agarose gel 
 
1. Run these things on a gel.  Hsp104 product should run at 2.8 kbp and Gal4 
product should be ~420 bp. 
 
2. Make a 1.5% agarose gel in 1X TAE buffer. 
 
 Stock For 70 ml 
 1.5% agarose powder 1 g 
 1X TAE stock 70 ml 
 
a. Microwave 1 min.  Swirl.  Microwave another 1 min. 
 
b. Add 7 µl of 10,000X SYBR safe DNA stain to the flask. 
 
c. Pour the liquid into the plastic mold.  Insert a well-divider comb. 
 
d. Let the gel polymerize on the benchtop. 
 
3. Place the gel mold into the running apparatus.  The DNA runs toward the red + 
pole, so make sure the wells are toward the black – end (with plenty of space for 
the DNA to resolve on its way to the + end). 
 
 
 
4. Submerge the gel in the running apparatus in 1X TAE. 
 
5. Prepare samples by adding 5X Blue Juice to samples: 
 
8 µl PCR product 
2 µl 5X Blue Juice 
 
Note:  I got Blue Juice from Alondra and don’t know what is 
actually in it. 
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6. Load 1 µl of 1 kb + Ladder into one of the lanes.  Load 5 µl of the PCR product 
sample into each other lane. 
 
7. Run the gel at 100 V for 15+ min. 
 
8. View DNA bands in the UV imager in the fly stock room.  Alter the exposure time 
with the +/- buttons on the screen and zoom by hand on top of the machine. 
 
a. Print the photo on the attached paper roll. 
 
b. Save the image to the Untitled Folder on the Desktop.  You can retrieve 
the images with a USB flash drive. 
 
 
Purifying PCR products 
 
1. Use the QIAquick PCR purification kit. 
 
2. Add 5 volumes of Buffer PB to 1 volume of PCR sample and mix. 
 
50 µl PCR sample 
250 µl Buffer PB 
 
3. Load sample onto a QIAquick column.  Centrifuge at 13,000 rpm for 1 min.  
Discard flow-through. 
 
4. Wash the column with 750 µl Buffer PE.  Centrifuge at 13,000 rpm for 1 min.  
Discard flow-through.  Centrifuge column for an additional 1 min. 
 
5. Place column in a clean eppendorf tube.  Add 30 µl Buffer EB to the center of the 
membrane.  Let stand for 1 min.  Centrifuge at 13,000 rpm for 1 min. 
 
6. Check concentration and purity on the NanoDrop. 
 
  
198 
 
Site-directed mutagenesis 
 
1. Select plasmid and design primers to introduce the desired mutation. 
 
2. Use the QuikChange Lightning Kit to introduce mutations.  See kit for details on 
reaction preparation and cycle guidelines. 
 
3. Set up reaction in a pcr strip tube: 
 
5 µl  10X Reaction Buffer 
1 µl  DNA template (1/10) 10-100 ng 
1 µl  primer 1  125 ng 
1 µl  primer 2  125 ng 
1 µl  dNTP mix 
1.5 µl  QuikSolution reagent 
39.5 µl MilliQ water 
 
Pipette up and down to mix. 
 
+ 1 µl  QCL enzyme 
 
Pipette up and down to mix. 
 
4. Run the reaction in the thermocycler.  Use MCQUIKCH program.  The elongation 
step (#4) requires 30 sec/kb of DNA.  The Hsp104 plasmid is 12 kb, so I used 6 
min. 
 
MCQUIKCH 
   (Lid = 105.0ºC) 
1 95.0ºC 02:00 
2 95.0ºC 00:20 
3 60.0ºC 00:10 
4 68.0ºC 06:00 
5 Repeat 2–4 x 17 
6 68.0ºC 05:00 
7 4.0ºC  hold 
 
5. Digest the parental plasmid by adding 2 µl Dpn1 enzyme.  Incubate the reaction 
at 37C for 5 min. 
 
6. Check concentration and purity on the NanoDrop. 
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Mini-Prep and Midi-Prep 
 
Transformation into bacteria 
 
1. Select plasmid.  Transform the plasmid into XL10-Gold cells (or another 
appropriate cell type).  Thaw the cells on ice. 
 
2. Add 2 µl β-ME provided with the cells to a 45 µl aliquot of cells.  Swirl and 
incubate on ice for 10 min. 
 
3. Add 2 µl plasmid to the cells.  Swirl and incubate on ice for 30 min. 
 
4. Heat the tubes in a 42C water bath for 30 sec.  Incubate on ice for 2 min. 
 
5. Add 500 µl warm LB.  Shake cells in the thermocycler at 37C for 1 hr. 
 
6. Plate the media onto an agar plate containing ampicillin (Cell Center).  Spread 
the liquid with an L-shaped spreader. 
 
7. Invert the plate and incubate at 37C overnight. 
 
a. You may store the plates in the refrigerator for up to a week.  Wrap the 
edges with parafilm and store inverted. 
 
Mini-Prep 
 
1. Select a single colony from the overnight plate by touching the plate with a non-
filtered pipette tip.  Drop the tip into a 15 ml Falcon tube containing 5 ml of LB + 
100 µg/ml ampicillin. 
 
a. Shake the tubes at 37C overnight. 
 
2. Spin the Falcon tubes in the large centrifuge at 3500 rpm for 5 min.  Pour off the 
supernatant.  A small residual volume will remain; resuspend the pellet in this (~ 
1 ml).  Transfer the resuspended cells to an eppendorf tube. 
 
3. Spin the eppendorf tubes in the microcentrifuge at 8,000 rpm for 3 min. 
 
4. Follow kit protocol: 
 
a. Resuspend the pellet in 250 µl Buffer P1 (in the fridge). 
 
b. Add 250 µl Buffer P2 and invert tube to mix. 
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c. Add 350 µl Buffer N3 and invert tube to mix. 
 
d. Spin the tube at 13,000 rpm for 10 min. 
 
e. Load supernatant into the QIAprep spin column. 
 
f. Spin at 13,000 rpm for 1 min.  Discard the flow-through. 
 
g. Apply 500 µl Buffer PB to the column. 
 
h. Spin at 13,000 rpm for 1 min.  Discard the flow-through. 
 
i. Apply 750 µl Buffer PE to the column. 
 
j. Spin at 13,000 rpm for 1 min.  Discard the flow-through.  Spin again at 
13,000 rpm for 1 min to dry the column. 
 
k. Put the column into a clean eppendorf tube.  Add 50 µl Buffer EB to the 
center of the membrane and let it stand for 1 min.  Spin at 13,000 rpm for 
1 min to collect the DNA. 
 
5. Check concentration and purity on the NanoDrop. 
 
Midi-Prep 
 
1. Select a single colony from the overnight plate by touching the plate with a non-
filtered pipette tip.  Drop the tip into a 15 ml Falcon tube containing 5 ml of LB + 
100 µg/ml ampicillin. 
 
a. Shake the tubes at 37C for 8 h.  
 
2. Dilute the culture 1/500 into LB + 100 µg/ml ampicillin.  Add 50 µl culture to 25 ml 
LB in a 50 ml Falcon tube.  
 
a. Shake the tubes at 37C overnight. 
 
3. Spin the Falcon tubes in the large centrifuge at 4,000 rpm for 20 min at 4C. 
 
a. You can freeze the cell pellet at -20C at this step, but I don’t. 
 
4. Follow the kit protocol: 
 
a. Resuspend the pellet in 4 ml Buffer P1 (fridge). 
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b. Add 4 ml Buffer P2.  Invert to mix.  Let sit for 5 min. 
 
c. Add 4 ml chilled Buffer P3.  Invert to mix.  Incubate on ice for 15 min. 
 
d. Centrifuge in a round-bottom tube at 13,000 rpm for 30 min at 4C in the 
Beckman Coulter Avanti Centrifuge J-25I (rotor JA-25.50) near the 
Pohlschröder lab.  Collect the supernatant. 
 
e. Centrifuge the supernatant in a fresh round-bottom tube at 13,000 rpm for 
15 min at 4C. 
 
f. Equilibrate a QIAGEN-tip 100.  Apply 4 ml Buffer QBT and allow to drip 
through by gravity flow. 
 
g. Apply the supernatant from the last spin to the QIAGEN-tip. 
 
h. Wash the QIAGEN-tip with 10 ml Buffer QC.  Repeat.  (2 x 10 ml) 
 
i. Elute DNA with 5 ml Buffer QF. 
 
j. Precipitate DNA by adding 3.5 ml isopropanol.  Mix well.  Spin at 4,000 
rpm for 75 min at 4C in the large centrifuge.  Carefully remove and 
discard the supernatant. 
 
k. Wash the DNA pellet with 2 ml 70% EtOH.  Spin at 4,000 rpm for 75 min 
at 4C.  Carefully remove and discard the supernatant. 
 
l. Let the pellet air dry for 10 min.  Redissolve the DNA in 200 µl TE Buffer, 
pH 8.0. 
 
5. Check concentration and purity on the NanoDrop. 
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Restriction Digest and Ligation 
 
Restriction enzyme digestion of DNA plasmid 
 
1. Select plasmid.  Determine which restriction enzymes are needed.  Look up 
which buffer is ideal for those two enzymes. 
 
a. Mine are XhoI and XbaI.  For this, I could use either NEBuffer 4 or 
Promega Buffer D.  I located Promega Buffer D, so I used that one. 
 
2. Set up reaction in an eppendorf tube, aiming for 10 µl. 
 
1 µl  10X Buffer – Promega Buffer D 
6 µl  MilliQ water 
2 µl  DNA plasmid (~1,000 ng) 
0.5 µl  enzyme XhoI 
0.5 µl  enzyme XbaI 
0.1 µl  100X BSA (supplement 100 µg/ml) 
 
3. Incubate for 1 h at 37C. 
 
4. Prepare the 1.5% agarose gel in 1X TAE Buffer.  (see previous section) 
 
5. Add 5X Blue Juice to each sample.   
 
10 µl reaction product 
2.5 µl 5X Blue Juice 
 
6. Load samples and 1 µl ladder.  Run at 100 V for 15+ min. 
 
7. You should see two distinct bands representing the plasmid empty vector and the 
excised gene insert. 
 
a. If you start with 1,000 ng of pUAST-Hsp104 plasmid, you should be left 
with ~ 800 ng backbone and ~200 ng gene insert. 
 
DNA gel extraction 
 
1. Wearing special UV goggles, view the gel containing your excited gene insert on 
a UV light box.  Use a sharp razor blade to carefully cut a rectangle out of the gel 
containing your desired fragment. 
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2. Weigh the gel slice in an eppendorf tube.  Subtract the mass of an empty tube to 
determine how much the gel slice weighs. 
 
3. Use the QIAquick Gel Extraction Kit. 
 
a. Add 3 volumes Buffer QG to 1 volume gel (100 mg ≈ 100 µl). 
 
b. Incubate at 50C for 10 min, or until gel has dissolved completely.  Vortex 
every 2-3 min to help dissolve the gel. 
 
c. Add 1 gel volume isopropanol.  Mix. 
 
d. Apply sample to QIAquick spin column.  Spin at 13,000 rpm for 1 min.  
Discard the flow-through. 
 
e. To wash, add 750 µl Buffer PE to the column.  Spin at 13,000 rpm for 1 
min.  Discard the flow-through.  Spin again at 13,000 rpm for another 1 
min. 
 
f. Place column into clean eppendorf tube.  Add 30 µl Buffer EB to the 
center of the membrane.  Let stand for 1 min.  Spin at 13,000 rpm for 1 
min. 
 
4. Check 1 µl of product on a DNA agarose gel. 
 
DNA plasmid ligation 
 
1. Use the NEB Quick Ligation Kit. 
 
2. Collect the linearized DNA fragments you want to ligate.  Set up the reaction: 
 
a. Combine 50 ng of plasmid vector with 3-fold molar excess of gene insert. 
 
b. Adjust volume to 10 µl with MilliQ water. 
 
c. Add 10 µl 2X Quick Ligation Buffer.  Mix. 
 
d. Add 1 µl Quick T4 DNA Ligase.  Mix. 
 
e. Spin briefly to bring all liquid to the bottom. 
 
f. Incubate at room temperature for 5 min. 
 
g. Chill on ice. 
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3. Transform the ligated plasmid or store the reaction product at -20C. 
 
4. Mini-prep several (~ 5) colonies that result from this transformation. 
 
5. Run the DNA from these mini-preps on an agarose gel to ensure that each is the 
correct size and is correctly ligated.  Also check concentration and purity of each 
on the NanoDrop. 
 
6. Select a plasmid from this and mini/midi-prep it.  Send this for sequence 
confirmation. 
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DNA Sequencing 
 
1. Select plasmid and determine concentration. 
 
2. Design sequencing primer oligos. 
 
a. To sequence a UAS-transgene insert, use: 
 
pUAST-5’a 5’- GCAACTACTGAAATCTGCCAAG -3’ 
pUAST-3’a 5’- TGTCCAATTATGTCACACCACA -3’ 
 
3. Fill out submission form for NAPCore at CHOP. 
 
4. Prepare samples.  9 µl is required, but I always prepare 18 µl so they can re-run 
the reaction if it doesn’t resolve well. 
 
4 µl Plasmid to be sequenced (1 µg; 4 x 250 ng/µl) 
6 µl Primer oligo (3.2 pmol) 
8 µl MilliQ water 
 
5. Drop off samples in Room 906B in the Abramson Building at CHOP. 
 
6. Use MacVector (program) or EMBOSS Needle (website) 
http://www.ebi.ac.uk/Tools/psa/emboss_needle/ to align the sequences with the 
plasmid. 
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